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“R e s u l t s !  W h y ,  m a n ,  I  h a v e  g o t t e n  a  l o t  o f  r e s u l t s .  I  
k n o w  s e v e r a l  t h o u s a n d  t h i n g s  t h a t  w o n t  w o r k ”
- Thomas Edison
Steroid hormones and their analogues can be used as growth promoters in cattle. 
The use of these substances is banned in the EU, and hence each member state 
must ensure that cattle are not being dosed with these drugs. This study focuses 
on the immunochemical detection of three steroidal growth promoters, 
ethynylestradiol (EE), diethylstilbestrol (DES) and trenbolone (TR).
Polyclonal antibodies were raised against EE and TR. The anti-TR antibodies 
were applied to two competitive ELISA formats, producing assays as sensitive as 
other reported systems while needing very little pre-treatm ent of the bile 
samples. The anti-EE antibodies were also applied to these ELISA  systems and 
also used to develop a biosensor-based assay using a BIAcore 3000®. These 
assays allowed the detection of EE at low ng ml"1 quantities in bovine bile.
As an alternative antibody supply the production o f scFv antibody fragments was 
investigated. Two naive phage display libraries, one murine and one human, 
were panned for the presence o f binding fragments specific for the target steroid 
molecules. A number o f  pre-immunised libraries were also constructed and 
selected against the antigens o f interest. None of the approaches provided 
specific clones that could be used as immunoreagents in analysis.
An investigation into the reduction of the incubation time required to perform a 
competitive ELISA was carried out. This method was shown to be effective for 
some of the polyclonal antibodies tested. The successful assays w ere applied to a 
prototype rapid ELISA machine. The ability o f this device to detect low 
quantities o f steroids in both a single and mixed sample was studied. A 
preliminary, prototype assay for the detection o f two separate steroid growth 
promoters in a single sample was shown.
A bstract
X V  il l
C h a p t e r  1  
I n t r o d u c t i o n
1.1 The Immune System
All living entities in nature must have the ability to protect themselves from 
elements in the environment that could cause them harm such as viruses, 
bacteria, fungi and parasites. It is the function of the immune system to protect 
against these foreign invaders by preventing them from multiplying and causing 
serious damage to the host. The immune system is made up of many different 
parts but it is usually separated into two functional divisions, innate and acquired 
immunity. These two parts have distinct functions and yet they are 
interdependent, complementing the tasks o f each other, to provide effective 
protection from disease, (Davey, 1992).
1.1.1 Innate Immunity
Innate immunity operates non-specifically during the early phases of an immune 
response and it is sometimes referred to as natural immunity (Elgert, 1996). It is 
the body's first line o f defence and some of the components it includes are the 
skin, the cough reflex, fever, inflammation response and phagocytic cells 
(Benjamini et a l ,  2000). It can be found at differing levels o f sophistication in 
vertebrates, such as mammals, reptiles and cartilaginous fish, and in some 
invertebrates, such as arthropods, earthworms and sponges.
The innate response is the primary immune response to any infection. It can 
respond rapidly and deal w ith an invading pathogen many days before the 
acquired immune response can begin to stage a response. This is one o f the 
reasons w hy the two systems work so well together. The cells o f the innate 
immune system, such as macrophages and neutrophils, have evolved receptors 
that can recognise common bacterial surface components. W hen these receptors 
are bound the cell is triggered to engulf and degrade the bacterial cell and also to 
release inter-cellular messengers called cytokines (Janeway et al., 1999).
The innate system is relatively non-specific and this is typified by the response of 
some o f the physiological and chemical barriers to infection. These barriers, such 
as hydrolytic enzymes in saliva, are not directed against any one type o f invader 
but will break down any substrates they encounter. If  a microorganism penetrates 
the barriers it is then attacked by the cellular defences, which can either engulf 
the invader and destroy it or kill it extracellularly. Some phagocytic cells contain
'enzyme-rich' lysosomes and produce peroxide or superoxide radicals to aid in 
the destruction o f infectious cells once they have been phagocytosed. 
N atural-killer cells will recognise cells that do not express a 'self-protein' on its 
surface called major histocompatibility com plex I (MHC I) and may destroy 
them by releasing cytotoxic agents (Benjamini et al., 2000). In some diseased 
cells M HC I is downregulated when compared to normal cells. This allows the 
natural-killer cells to recognise the altered cell and destroy it. Some cytotoxic 
agents can cause pores in the cell membrane o f the target, while others can enter 
the cell and cause programmed cell death or apotosis. Another component o f the 
immune system, called complement, can also destroy invaders by enhancing the 
pathogen's uptake by phagocytic cells or by initiating the com plem ent cascade, 
which will lyse the cell. Complement can also be used as part of the adaptive 
system.
1.1.2 Adaptive Immunity
Adaptive im m unity is a more specialised form o f immunity that is only found in 
vertebrates, which develops during the lifetime o f the organism (Benjamini et al., 
2000). The one aspect that differentiates the adaptive from  the innate systems is 
the specificity that the adaptive immune system shows towards the targets. Each 
cell involved in the adaptive or acquired immune response has a specific receptor 
that w ill bind to a single epitope. It is specific and so time is required for the 
response to assert itself. In this lag period the innate system engages and destroys 
the foreign cell if  possible. This system can be further divided into cell-mediated 
and humoral immunity
1.1.2.1 Cell-Mediated Immunity
Acquired immunity mediated by the T lymphocyte or T-cell is called cell- 
mediated or cellular im munity (Elgert, 1996). T-cells are lymphocytes that 
mature in the thymus and once they are mature they m igrate to the peripheral 
lymphoid tissues such as the lymph nodes and the spleen. It is in these peripheral 
lymphoid tissues that the T-cells encounter and respond to foreign antigens.
The ability o f the T-cell to recognise an antigen comes from its T-cell receptor 
(TCR). This specific receptor is acquired during the maturation of the cell and 
each cell has specificity for a single epitope or antigen structure. There are two
main types o f T-cells, the cytotoxic T-cells (Tc) and helper T-cells (Th). To 
enable the T-cells to be activated they must have an antigen presented to them; 
they cannot interact with the antigen unless it is associated with the MHC 
proteins. W hen the antigen is degraded in some cells, the com ponent epitopes are 
associated with the self-protein M HC I or II and expressed on the surface of the 
cell.
Th cells recognise the MHC II and epitope complex and release a set of chemical 
signals know n as cytokines. A subset of the Th cells, Th-1, secrete interleukin 2 
(IL-2), interferon gamma (IFN-y) and tumour necrosis factor beta (TNF-P) and 
these in turn activate Tc cells (Male et al., 1996). While Th-1 cells can activate 
B-cells this function is usually carried out by the Th-2 cells. Th-2 cells secrete 
IL-4 and IL-5, which activate the B-cells.
Tc cells recognise antigen epitopes in conjunction with M HC I proteins, which 
are found on virtually all normal nucleated cells. The Tc cells bind to cells 
expressing the M HC I and an antigen recognised by its TCR. W hen bound the Tc 
cells are able to deliver a lethal blow by releasing perforin to lyse the cells 
(Benjamini et al., 2000). By destroying the host cell the pathogen is then released 
and is susceptible to attack by circulating antigens.
1.1.2.2 H um ora l Im m un ity
The hum oral immune response is mediated by serum antibodies that are secreted 
by the B-lym phocytes or B-cells. These cells are so called because they were 
found to be produced by the Bursa of Fabricus in birds. In experiments where 
this organ was removed from a bird, the creature was unable to m ount a normal 
antibody response to an antigen. In mammals the B-cells are linked to gut 
associated lymphoid tissues, the fetal liver and, after birth, the bone marrow 
(Eales, 1997). The B-cells have a structure similar to the TCR on their surface. 
Each mature B-cell bears antigen specific receptors that have a structure and 
specificity identical to the antibody later synthesized by that B-cell.
To activate these cells the antigens must be presented to them just as in the case 
of T-cells. The cells that present these epitopes on their surface in conjunction 
with M HC II are called antigen presenting cells (APC) and include macrophages, 
dendritic cells and other B-cells. The recognition and subsequent binding to the
specific epitope will activate the cell and initiate its clonal expansion. The 
immune system is genetically able to produce a vast array o f receptors specific 
for an estim ated 1010 different epitopes (structure recognised by receptor). Only a 
small num ber o f cells expressing each specificity are maintained. Large numbers 
of a single specificity are only produced after the original cell has been activated 
(Bales, 1997).
Once an epitope has been presented to the B-cells and clonal expansion has 
occurred the immune system can produce cells and antibodies specifically able to 
recognise that epitope. The epitope may be a surface protein o f a bacteria or a 
coat protein o f  a virus or any structure that was presented to the B-cells. The cells 
resulting from the clonal expansion differentiate into effector and memory cells. 
M ost of the B-cells, after contact with the epitope or antigen, will differentiate 
into plasm a cells that synthesise and secrete proteins called antibodies. These 
antibodies have the ability to bind to the same epitope as the parent cell. The 
antibodies are then able to bind to the same pathogen that activated the original 
B-cell and enhance its destruction by cell lysis through com plement or by 
phagocytosis. The secreting B-cells have a short lifespan of 5-8 days but can 
produce large amounts o f antibody during this time. The memory cells give the 
im mune system the ability to respond to the same invader much more quickly if 
it is encountered for a second or subsequent time. They have much longer life­
spans and stay with the host for a life-time (Janeway et a l,  1999).
T-cells do not produce antibodies but they aid the B-cells in this function by 
providing grow th factors and cytokines and they are also involved in the 
regulation o f the immune response through the release o f the cytokines (Elgert, 
1996).
1.1.3 Im m unogenicity
In order for the immune system to produce antibodies against a particular invader 
the pathogen must possess the following characteristics of foreignness, high 
molecular weight, chemical com plexity and degradability (Eales, 1997).
An immune system does not mount an immune response to proteins that it 
recognises as 'self. These antigens would cause an immune response in another 
species but not in the species of origin, e.g. a rabbit albumin would not elicit an 
im mune response in rabbits but antibodies would be produced if a goat were
exposed. The more foreign the molecule is the greater the immunogenicity will 
be. The size and weight of the molecule also has some bearing on the immune 
response to it. Any compounds with weights less than 1,000 Da, such as the 
steroids investigated in this thesis, are not immunogenic and need to be altered 
and linked to larger carriers to increase their immunogenicity (Lieberman et al., 
1959). Compounds that have a molecular weight between 1 and 6 kD a may or 
may not elicit an immune response and those larger than 6 kDa are generally 
immunogenic (Benjamini eta l., 2000).
A certain degree of physiochemical com plexity is required in an immunogen to 
elicit an immune response. Homopolymers, long chains o f a single repeating 
unit, tend not to be immunogenic even if they have large molecular weights. If 
these structures are altered and smaller compounds are added to the structure this 
w ill enhance the immunogenic nature of the molecule allowing the generation of 
antibodies directed against both the large polym er and the sm aller hapten. By 
increasing the chem ical complexity of a compound its ability to raise an immune 
response can be enhanced (Janeway et al., 1999).
To stimulate an immune response many antigens m ust be degraded so that they 
can be presented by antigen-presenting cells (Elgert, 1996). I f  the antigen 
presenting cells cannot easily degrade a compound the epitopes o f the antigen are 
then not available to the immune system as a target. Peptides com posed o f D- 
amino acids have been shown not to be immunogenic and they are resistant to 
enzymatic degradation, while the same L-isomers are susceptible and are 
immunogenic (Benjamini et al., 2000).
Others issues that relate to the production o f an immune response are practical in 
nature and cover such topics as the dose, form and route o f administration 
(Janeway et al., 1999). The amount o f immunogen given in a dose is important 
as too little w ill not cause a response and too much may induce tolerance. In 
general, if the immunogen is particulate and denatured, it will be more 
im munogenic than soluble and native forms. An immunogen may be mixed with 
an adjuvant before immunisation. Adjuvants are mixtures that will enhance the 
animal's response to the immunisation. M any o f these mixtures contain oil and 
water, which delay the release of the antigen and cause it to deposit locally at the 
site o f injection. They can also contain some treated bacterial or viral antigen,
which can stim ulate macrophages and enhance the local im mune response such 
as inflammation.
There are a number o f routes that can be used to immunise an animal and some 
of these are considered to be more effective than others. It is generally found that 
subcutaneous injection is more effective than the intraperitoneal route, both of 
which provide better immune responses than intravenous or intragastric 
immunisation.
Repeated boosts are also required to obtain a strong immune response. A single 
dose will invoke the primary im mune response and is know n as priming the 
immune response. Further immunisations evoke increasingly intense responses 
leading to a heightened state o f immunity called hyperimmunisation.
1.1.4 A n tibody  S tru c tu re
Antibodies are glycoproteins belonging to the immunoglobulin supergene family 
(Davey, 1992). This gene family contains genes located on many parts o f the 
genome and has many proteins involved in the immune system (Roitt, 2001). 
There are five isotypes called classes of immunoglobulin, nam ely IgA, IgD, IgE, 
IgG and IgM. Each isotype possesses similar structural components as typified 
by the immunoglobulin G structure, (Figure 1.1). The amount of carbohydrate 
can vary widely between different immunoglobulin from 2-3% in IgG to 14% in 
IgD. The carbohydrate chain is usually covalently linked to the constant region 
of the heavy chain, (Figure 1.1) through asparagine residues, although serine or 
threonine residues can also be utilised. The carbohydrate moiety seems to have 
three different functions; to aid the secretion o f the antibody from antibody 
synthesising plasm a cells, to enhance the solubility o f the antibody and to protect 
the molecule from degradation (Davis, 1994).
The basic im munoglobulin structure consists of four peptide chains linked with 
inter-chain disulphide bonds. These chains are separated into two heavy chains 
and two light chains. The constant regions o f their heavy chains differentiate the 
isotypes of the immunoglobulins (Eales, 1997). These constant regions are given 
the designations Ca for IgA, Cg for IgD, Ce for IgE, Cy for IgG and for IgM. 
The light chains that are linked to the heavy chains can be either kappa, LK or 
lambda, L \, but in any one immunoglobulin only one type is present. No natural
antibodies have both kappa and lambda light chains, although antibodies can now 
be engineered with one chain o f each.
The variable regions of the antibody determine its specificity for binding of an 
epitope. W ithin the variable regions there are hypcrvariable regions called 
complementarity-determining regions (CDRs). It is at these points that most of 
the binding to the epitopes occurs. The CDRs are separated in the linear amino 
acid structure o f the variable fragment but in the folded form o f the peptide these 
areas come close to each other to form a pocket for the binding o f the antigen. To 
maintain the epitope in this binding site the fit must be very close and cover a 
large region as the forces that control the binding are weak, non-covalent forces. 
The constant or Fc portion of the Ig structure carries out the biological functions 
of the antibodies. These functions include
• Neutralisation o f toxins
• Im m obilisation o f micro-organisms
•  Neutralisation of viral activities
•  Agglutination o f micro-organisms particles
• Binding and precipitation of foreign particles
• Activating serum com plem ent for lysis or phagocytosis
• Crossing the placental barrier to provide the foetus with immunity
The Fc region contains constant regions from only the heavy chains. 
Immunoglobulins have five different sequences in the constant region and these 
give each class o f Ig a different biological function.
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Figure 1.1 : Structure o f Immunoglobulin G (IgG) molecule. The structure 
contains two identical light chains (~25kDa) and two heavy chains (~50kDa). 
The heavy chain consists o f five distinct domains usually known as the variable 
region, (Vh)  the constant regions I, 2 and 3, (Ch)  and the hinge region 
represented by a grey line between Cul and Ch2. The light chain has two 
domains consisting o f the variable and the constant regions. The two heavy 
chains are held together by two disulphide bonds between their hinge regions 
(orange lines). The light chains attach to the heavy chains through a single 
disulphide bridge between the Cl and the Cul domains. The Cl , Vl , Cul and Vh 
domains all contain intrachain disulphide bridges that give them their globular 
structure and these four domains make up the antigen-binding fragment (Fab) o f  
the IgG. The antibody-binding site is coded for by the complementarity 
determining regions (CDR) at the end of both the heavy and the light chains. 
These are highly variable regions that confer the antigen specificity to the 
molecule. The Fc region of the molecule contains the Ch2 and Cu3 domains.
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Figure 1.2 : Structure o f immunoglobulin IgG and its various smaller fragments 
that can be used to bind antigen. The pepsin enzyme degrades the IgG molecule 
below the inter heavy chain disulphide bridges giving the F(ab) 2  fragment and 
various Fc sub fragments. The F(ab) 2  fragment contains two antigen binding 
fragments linked by the disulphide bridges, while the Fab fragment has only one 
antigen binding fragment. Papain degrades the molecule just above the inter 
heavy chain disulphide link leaving 3 fragments, two Fab fragments and a Fc 
portion. A Fv molecule contains just the variable domains of the heavy and the 
light chains and a scFv (single chain Fv) contains the same domains stabilised 
by a peptide linker. An Fd fragment contains the varaible and ChI domains of 
the heavy chain. The smallest segment o f the antibody that contains its binding 
properties is the CDR fragment. These are the actual peptides that are involved 
in the interaction with the antigen. They must, however, have a framework to 
allow them to bind specifically.
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The diversity of each antibody molecule is coded for in the variable fragments of 
the heavy and light chains. It would be impractical for the germline DNA of an 
animal to hold separate coding sequences for each antigen specificity that it may 
require during its lifetime. To avoid this huge number of genes a smaller number 
of genes are joined together to form the functional protein. The three groups of 
genes coding for the heavy chain, the k light chain and the X light chain are 
located on 3 different chromosomes in both the mouse and the human genomes 
(Eales, 1997).
Three separate gene segments known as VH (variable), DH (diversity), and JH 
(joining) code for the variable region of a heavy chain immunoglobulin 
molecule. These then join to a Ch gene to form the complete heavy chain for the 
immunoglobulin. There are 5 classes of Ch genes coding for the constant region 
for each of the distinct immunoglobulin isotypes. The light chains use both Vl 
and Jl to code for their variable segment and these are different from the V and J 
genes used by the heavy chain. There are a number of different versions of each 
of these genes in the germline and they are rearranged during the differentiation 
of the B-cell to provide a single VDJh and a VJl construct, both of which will 
now appear next to the genes coding for their respective constant regions 
(Zaleski et al., 1983). The genes are then translated into mRNA and the non­
coding DNA is spliced out and the resulting genes transcribe the functional 
heavy and light chains of the immunoglobulin (Figure 1.3).
Further diversity can be generated in the areas where the gene segments join. The 
positions where the gene segments are fused together are not constant and so 
imprecise DNA recombination can lead to changes in the amino acids at these 
sites. Bases can be inserted, deleted, copied or altered at the sites of combination 
and these can be part of the hypervariable regions that produce the antigen- 
binding site leading to greater diversity in the immunoglobulin specificity 
(Tonegawa, 1983).
Point mutations occur at a much higher frequency in the V(D)J gene structure 
than normal. This is termed somatic hypermutation and it allows the secondary 
and further immune responses to produce antibodies with increased affinity for
1.1.5 Generation of Antibody Diversity
the antigen of interest. In the primary response the antibodies produced are 
usually of low affinity and are close to germline sequence but as the response 
matures the amino acid sequence diverges from the germline. This gives the 
immune system the ability to provide more active and specific antibodies as it 
encounters an antigen more than once.
Somatic gene conversion is a mechanism that is used in some animals, such as 
birds and rabbits to create diverse antibody repertoires (not used in the human or 
murine systems). This inserts sequences from pseudogenes, located near the VDJ 
gene segments, into the variable fragment of the antibody. This occurs in the 
DNA sequence itself after the VDJ recombination and before the gene is 
translated. Many species rely on this and somatic hypcrmutation to generate their 
diverse primary Ig repertoire. This allows animals that have limited numbers of 
antibody genes to still create vast antibody repertoires (Elgcrt, 1996).
In essence, the antibody repertoire is a function of
• the multiple inherited genes that make up the variable regions of both the 
heavy and light chains,
• rearrangement of the V, D and J gene segments in different combinations and 
the random association of the different heavy and light chains,
• diversity at the junction points between V, D and J genes,
• somatic hypermutation,
• somatic gene conversion, (Benjamini el al., 2000).
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Figure 1.3 : Genetic rearrangement o f the human heavy chain to give the 
completed protein. Each o f the segments that make up the variable domain has a 
number o f  different variances, i.e. Vh has 50 sequences, Du has 20 and Ju has 6. 
Each one o f these segments can recombine with any o f  the others leading to 
great variety in the transcripted sequence. The variable sequence can be linked 
to one o f the constant regions to produce a specific class o f antibody with distinct 
functions. The variable region can be grafted onto a different constant region to 
produce an antibody with the same specificity but different biological properties.
1.2 Production of Antibodies
A number of methods can be employed for the production of antibodies. Some 
factors should be considered before antibody production commences including 
the immunogen, the type of antibody required and its final application. Antibody 
generation may require the production of either polyclonal, monoclonal or 
recombinant antibodies.
1.2.1 Immunogen
As previously mentioned antigens must have a number of features before they 
are able to elicit an immune response. These include a critical size, chemical 
complexity, foreignness and degradability. Many small haptens, including steroid 
hormones, do not have these traits. To overcome this problem it is possible to 
link the small molecule to a larger one and immunise with this new conjugate 
(Erlanger, 1980). By linking the hapten to a carrier it has a significantly larger 
size, greater chemical complexity, a greater degree of foreignness to its host and 
it is now susceptible to enzymatic degradation.
The small molecules studied in this thesis are synthetic steroid hormones having 
molecular weights of less than 300Da. To produce an immunogen these 
compounds must be linked to a carrier molecule. To do this a chemical handle is 
introduced to the molecule. This allows any chemical linkage to be carried out 
through a position that does not involve an active group of the steroid and so the 
linkage will not mask an area of the molecule that may be required for 
recognition during immunisation. The derivatised molecule, or hapten, is then 
chemically linked to a carrier, usually a protein but carbohydrates can also be 
used.
The chemical handle that is introduced usually contains a chain of molecules. 
This chain introduces a distance between the hapten and the carrier molecule 
permitting the epitopes of the target to lie away from the carrier itself. In this way 
the steroid is not hidden or masked by the much larger carrier protein and the 
immune system is able to mount a response against it. This chain of molecules is 
often referred to as the bridge or linker region. It is possible that the immune 
system will produce antibodies specific for this region and so in an attempt to 
minimise this response the linker cannot be too long or too complex. If the bridge
is chemically quite simple it is less likely to be immunogenic. One method to 
avoid any cross reactivity in the final antibody application is to use a different 
bridge in the conjugates used in the assays than the one used in the immunogen. 
In addition, if the immunoassays used a format where there was no need for a 
conjugate this problem of bridge recognition would be avoided.
The site of the linkage is also important as any antibody specificity is directed at 
the portion of the hapten that is most sterically accessible. This is known as 
Landsteiner's principle (Wild and Davies, 1994). If a compound is linked at a 
position next to a unique immunogenic site very little, if any, of the antibodies 
produced will be directed against it.
1.2.2 Polyclonal Antibodies
Polyclonal antibodies have been used successfully in research and clinical 
applications for many years. When an antigen is introduced to an immune system 
immunoglobulins specific for that antigen are produced. The immune system is 
then exposed to the antigen a number of times through booster injections until 
the amount of antibody in the serum reaches an acceptable level for use as an 
analytical or clinical reagent. The amount of antibody in serum is called the titre. 
The antibodies contained in polyclonal sera are not all of the same specificity or 
affinity and they react to different epitopes on the immunogen (Dankwardt, 
2000). This is the reason for the name polyclonal as the antibodies arise from a 
number of different B-cells or clones.
The choice of animal for use in this procedure is important and the decision is 
based on a number of parameters. The facilities available for holding the animals 
must be adequate to house the species of choice. The animal must be easy to 
handle, produce the required amount of antibody, be able to mount a response to 
the immunogen and be able to do it with the amount of immunogen available. 
Some genetically in-bred strains are available for rodent and rabbits species and 
these can provide a more predictable immune response to a foreign antigen 
(Knott etal., 1997).
Polyclonal antibodies combine the advantage of a simple production technique 
producing large amounts of antibody with the disadvantages of animal usage and 
a poly-specific reagent (Knott et al, 1997).
1.2.3 Monoclonal Antibodies
The next step in the development of antibodies for use as reagents was the 
production of a homogeneous antibody preparation. This was made possible by 
the discovery that B-cells could be fused with myeloma cells to produce 
immortal cell lines that could secrete antibodies (Kohler and Milstein, 1975). The 
resulting hybridoma had two important traits that allowed it to be used as a 
source of monoclonal antibodies. It was immortal and therefore could be 
subjected to selection cloning and grown in culture and each hybridoma only 
secreted antibody of a single specificity (Dankwardt, 2000). The process for the 
production of the hybridoma and the selection of the relevant clones is outlined 
in Figure 1.4.
An animal, usually a rodent (mouse), is immunised with the antigen of interest. 
When the antibody titre is high enough the mouse is sacrificed and the spleen is 
removed. The lymphocytes are flushed from the spleen and fused with myeloma 
cells using polyethylene glycol (PEG). PEG is used as it forces the cells in 
solution close to each other and promotes membrane bridging, cell fusion and the 
transfer of nuclei (Hurrell, 1985). The resulting cells are grown in a media 
containing hypoxanthine, aminopterin and thymidine, (HAT). The aminopterin 
blocks the main synthetic pathway for nucleic acids and cells must use the 
alternative pathway utilising the enzyme hypoxanthine guanine phosphoribosyl 
transferase (HGPRT) to survive. The myeloma cells are altered so that they do 
not contain this pathway and the unfused spleen cells are unable to grow in 
culture and die within a few days. Hence, after a number of days the only cells 
growing in culture will be the fused cells or hybridomas combining the 
immortality of the myeloma cell line and the HGPRT enzyme from the spleen 
cells.
These hybridomas must then be screened to detect the cells that are producing 
antibody with the required specificity. The isolation of the antibody-producing 
cells is carried out using a procedure known as limiting dilution. This involves 
the dilution of the culture containing the cells and splitting it into smaller 
aliquots, ideally containing a single cell in each. The resulting culture will have 
cells with a single specificity derived from the original cell. These cultures are 
tested by checking the culture supernatants for antibodies that recognise the
antigen of interest. Once a particular culture is shown to be positive it is cloned 
out again, (diluted and split), and this process continues until the culture is totally 
monoclonal, i.e. all cells present are identical and secreting the same antibody 
(Goding, 1983).
The monoclonal cell line can then be used to produce limitless amounts of the 
antibody and the cell line can be stored under liquid nitrogen for use at a later 
stage. Monoclonal antibodies can be produced in vivo by injected the hybridomas 
into a mouse peritoneal cavity where they will be produced in a fluid called 
ascites (Knott et al„ 1997). This fluid can be drained either continuously or 
terminally, depending on mouse strain, to provide an antibody containing 
solution. At the present time many researchers wish to use fewer animals in their 
work and so the production of monoclonal antibodies in vitro is used in many 
cases. Large-scale cell culture facilities can produce gram quantities of antibody 
within a few weeks and the downstream processing is simple and reagents of 
high purity are achieved (Wild and Davies, 1994).
The advantages of monoclonal antibody production include the limitless supply, 
the singular specificity and the use of fewer animals than polyclonal antibody 
production. However, there are some disadvantages. Monoclonal antibodies tend 
to have lower affinities for the target antigen than the corresponding polyclonal 
antibodies. This is the main factor affecting sensitivity in competitive assay 
formats and so it may cause lower sensitivities in these assays. In addition, the 
fact that a monoclonal antibody is only reactive to one epitope may cause 
problems if the target has more than one iso form and the total amount of the 
protein is being assayed (Wild and Davies, 1994). In this case a polyclonal 
antibody that can recognise all isoforms may provide a more appropriate reagent.
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Figure 1.4 : Flow diagram o f  the production o f monoclonal antibodies. The 
spleenocytes are fused  with myeloma cells using PEG resulting in the production 
o f  hybrid cells (hybridomas) that are H G P R T. The hybridomas are grown in 
media so that only immortal HGPRT* cells stirvive. The antibody-secreting cells 
are cloned out to give a  monoclonal source and the antibodies are purified and 
characterised.
The production of recombinant antibodies uses molecular biology techniques to 
isolate, and so immortalise, the genes coding for antibodies of interest and 
express them using one of the expression systems available (Marks et al., 1991). 
It is these genes that are manipulated and screened to find the antibody that will 
bind to the target antigen. This technique intends to isolate all the genes coding 
for the variable fragments of the antibodies, express them and select from them 
antibodies with the required specificity (Lu and Sloan, 1999).
Recombinant antibodies can be produced from any source once the antibody 
genetics of the host species is known. As discussed in section 1.1.4 antibodies 
have their major variations in the variable sections of their structure but each end 
of this fragment are relatively conserved. Primers can be designed that anneal to 
these conserved areas (Wind et al., 1997). These primers will amplify the 
variable fragments regardless of their sequence between the primers. In most 
cases a single set of primers will not bind to many of the variable sequences due 
to slight base pair differences. Usually sets of these primers are designed and 
used in multiplex polymerase chain reactions (PCR).
Once these fragments have been amplified the genes can be expressed in a 
number of different ways. They can be expressed separately and allowed to 
combine in solution (Fv), linked together by a peptide chain and expressed 
(scFv), grafted onto a short framework of one heavy and one light constant 
region (Fab) or they can be grafted into an intact antibody gene, (Figure 1.2). 
Using this technology human antibodies can be constructed with a binding site 
derived from a murine source and so avoiding the problem of human anti-mouse 
antibodies (HAMA) if the antibodies are to be administered to humans (Maynard 
and Georgiou, 2000). The small scFvs can be linked together to provide 
diabodies, triabodies or tetrabodies with the same or sometimes different 
specificities (Todorovska et al., 2001).
The primers for the heavy and the light chain will be different and they will also 
change depending on the host species and source of the DNA. The DNA can be 
derived from hybridomas secreting an antibody of interest, the spleens of animals 
immunised with the target antigen (pre-immunised) or cells from a host that has 
not been immunised at all (naive). Once the variable sequences, both heavy and
1.2.4 Recombinant antibodies
light, have been amplified they can be used to construct a library of antigen 
binders (Figure 1.5). It is expressed proteins from this library that are screened to 
find the gene sequence with the required specificity.
Pre-immunised libraries have the advantage that the immune system has been 
exposed to the antigen. This implies that the cells of the immune system will 
contain more B-cells producing antibodies specific for the antigen of interest. 
When the mRNA is extracted from the cells, usually splenocytes, they should 
contain a higher proportion of sequences specific for the immunogen. This will 
make the isolation of the required antibody gene sequence easier as the library 
has already been pre-enriched with the required binders.
The naïve library system does not have this pre-enrichment but it does potentially 
have a great many more specificities. By creating a library from the naive 
antibody repertoire, it should have a vast diversity of clones each expressing a 
different target specificity. In theory, a large enough library could negate the 
need for the production of the pre-immunised libraries. If the large naïve library 
contained so many specificities it is highly likely to have clones that can bind to 
almost any target, the only difficulty remaining would be the selection of the 
correct clone (Vaughan et al., 1996).
These libraries can be expressed in a number of different systems. These include 
bacterial, yeast, insect and mammalian cells as well as in transgenic plants 
(Longstaff et al., 1998). The choice of expression system will depend on the 
attributes that are required from the final antibody or antibody fragment. Some of 
these systems do not allow glycosylation of the proteins and this may affect the 
function of any complete antibody. The folding of the proteins may not also be 
optimal in some of the systems.
A bacterial expression system is utilised in this study due to its ease of use, its 
low cost and the simplicity of the required manipulations (Charlton et al., 2001). 
The antibody fragments that will be developed are scFv's. These are fragments 
containing the variable heavy and light chains linked together by a short peptide 
(Figure 1.2). The bacterial system does not allow for glycosylation but this small 
antibody fragment does not require this modification as it is a binding fragment 
and is not required for any other function. It may be fused genetically to other 
proteins to allow for easy detection or purification but usually the addition of the
carbohydrate moiety is not required for the binding of the fragment to the target 
or other required functions (Muller et al., 1999).
The cytosol of the bacterial cell does not encourage the correct folding of 
proteins due to its reducing nature and so many recombinant proteins produced 
there require re-folding before use (George, 1997). An alternative strategy would 
be to direct the protein to the periplasmic space of the cell using a genetic leader 
sequence. This has an oxidising environment and contains molecules 
(chaperonins) that aid in the re-folding of proteins. Using these methods it is 
possible to produce large quantities of functional proteins from bacterial cultures.
Source of antibody genetic 
sequences -
naive or immunised mice,
I
Transform vector 
into £  coli cells
I
Phage displaying 
scFv fragment
Phagemid ( ]
Bacteriophage
Figure 1.5 : Schematic representation o f the production o f a phage display 
library.
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This technology allows mimicking of key features of in vivo antibody production 
and the antigen-driven maturation processes by the expression of large libraries 
of antibody fragments on the surface of filamentous bacteriophage 
(Berdichevsky et al, 1999). Three advances that have led to the development of 
phage display technology are
• the ability to produce functional antibody fragments in bacterial culture
• the isolation of the genes coding for the variable domains of both the heavy 
and light antibody chains
• and the ability to express antibody fragments as fusion proteins on the surface 
of filamentous bacteriophage (Chiswell and McCafferty, 1992; Berdichevsky 
etal., 1999).
This final point is the reason why the large libraries constructed through 
recombinant means can be easily screened. By expressing the antibody fragment 
as part of the surface protein pill the phage particles themselves can be used as 
the immune reagent and subjected to immunoaffinity selection (McCafferty et al., 
1990). The genes for the antibody fragment may be cloned into either a phage or 
a phagemid vector. The phage vectors have been in the main superseded by the 
phagemid vectors, the phage vectors being difficult to maintain and manipulate 
(George, 1997).
The phagemid vector is one that has both a phage and a bacterial origin of 
replication. This allows it to be maintained in bacterial cells such as E. coli and 
yet the proteins can be packaged and expressed by helper bacteriophage infecting 
the cell.
Once the library has been constructed and ligated into the phagemid vectors, it is 
then transformed into the host cells. These cells can be grown and stocks of the 
library are made. The size of the library is estimated by counting the number of 
host cells harbouring the phagemid. The cells can then be infected with helper 
phage, which provides the necessary proteins to produce phage particles 
containing the DNA from the phagemid. These phage particles express the fusion 
protein encoded on the phagemid on their surface and they are released into the 
supernatant of the bacterial culture.
1.2.4.1 Phage Display Technology
The phage are collected and subjected to what is termed biopanning. This can 
take on many forms and it is discussed in detail in Section 6.1.5. It is a process 
whereby the phage are allowed to bind to a target antigen and the phage that bind 
are re-infected into bacterial cells and amplified (Figure 1.6). This is akin to the 
affinity maturation seen in the selection of antibodies in vivo. The biopanning 
can be repeated a number of times to enhance the population of binders. 
Individual clones can then be isolated on agar plates. These can be grown under 
different conditions to induce the production of soluble antibody fragments. 
Some systems require the transferring the phagemid to a different bacterial strain 
or even splicing the antibody coding genes into a specialised expression vector to 
allow the soluble production of the antibody fragments. The route to soluble 
antibody production will depend on the system in use.
Once the proteins have been produced they must be purified and possibly 
concentrated. A number of different tags can be engineered into the phagemid 
vector to allow for easy purification and detection of the recombinant protein. 
These included the c-myc tag that is recognised by the monoclonal antibody 
9E10 (Vaughan et a l, 1996), the FLAG tag, a polyhistidine label (Krebber et al., 
1997) and a cellulose binding domain (Berdichevsky et al., 1999). The labels are 
all short polypeptide sequences that are detectable by commercially available 
antibodies allowing for immunodetection and affinity purification. The 
polyhistidine tag can also be used to purify the proteins by immobilised metal 
affinity chromatography (IMAC) (McCafferty et al, 1994; Casey et a l, 1995).
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Figure 1.6 : Schematic representation o f the biopanning process fo r  the selection 
o f phage displaying the antibody fragment, e.g. scFv, o f  the required specificity. 
Phage libraries can be subjected to numerous rounds o f  panning to select clones 
with specificity fo r  the target anitgen. The specific phage are captured on a solid 
support and eluted from  it once the non-specific phage have been washed away. 
The specific phage were then re-infected into E. coli cells for further rounds o f  
selection.
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Hormones, neurotransmitters and local mediators are the three functional groups 
of first biochemical messengers. The word hormone was introduced in 1905 by 
Starling and it comes from the Greek meaning to excite or arouse (Hardie, 1991). 
This group of biochemical messengers are probably the group most familiar to 
the general public through their varied and widespread use in medicine and also 
through their abuse in sports.
Hormones are produced and secreted by the cells of the endocrine system and 
travel in the bloodstream to their target cells (Hardie, 1991). This mode of action 
differentiates hormones from other classes of first messengers, such as 
neurotransmitters and local mediators. A neurotransmitter originates in the nerve 
terminal of a neurone and interacts directly with a target cell whereas a local 
mediator is produced by a cell and moves to a target cell via the extracellular 
fluid. Hormones are the only messengers that use the circulatory system to travel 
and interact with cells quite distant to their site of origin. Hormones are secreted 
by endocrine glands and these include the pituitary, thyroid, liver, pancreas, 
ovaries and testes. The hormones themselves are divided into subcategories, the 
steroid, thyroid and peptide hormones.
1.3.1 The Peptide Hormones
Peptide hormones can have one or two chains and anything from three to 199 
amino acid residues. Table 1.1 shows the peptide hormones and describes their 
structure. The peptide hormones are first synthesized as large peptides called pro­
hormones, which are subsequently cleaved to give the active form of the protein. 
The glycoproteins as shown in the Table 1.1 all have an identical a  chains but 
the have very distinct (3 chains, which give the hormones their biological activity. 
The carbohydrate molecule helps both the folding of the two chains and the 
stabilisation of the molecule to increase its circulating half-life.
1.3 The Hormones
Table 1.1 : The peptide hormones, (adapted fromKhanna and Waisman, 1988).
Hormone Structure Site of Origin
Adrenocorticotropin (ACTH) 139 amino acids (aa) Anterior Pituitary
a-Melanocyte stimulating 
Hormone (MSH)
13 aa
3-Endorphin 31aa
Thyroid stimulating hormone 
(TSH)
Glycoprotein : a  chain 92 aa 
3 chain 112aa
Follicle stimulating hormone 
(FSH)
Glycoprotein : a  chain 92 aa 
3 chain 118aa
Luteinizing hormone (LH) Glycoprotein : a  chain 92 aa 
3 chain 115aa
Anterior Pituitary
Somatotropin (growth hormone) 191aa
Prolactin 199aa
Vasopressin 9aa Posterior Pituitary
Oxytocin 9aa
Thyrotropin releasing hormone 3aa Hypothalamus
Somatostatin 14aa
Insulin 51aa Pancreas
Glucagon 29aa
Parathyroid hormones 84aa Parathyroid
Calcitonin 32aa Thyroid
Gastrin 17 or 34aa Gastro-intestinal
Cholecystokinin 33 or 39aa tract
Secretin 28aa
Chorionic gonadotropin (hCG) Glycoprotein : a  chain 92aa 
3 chain 142aa
Placenta
Epidermal growth factor 53aa Unknown
Nerve growth factor 118aa Submaxillary glands
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1.3.2 The Thyroid Hormones
The main hormones contained within the division of the thyroid hormones are 
thyroxine, (T4, 3,5,3',5’-tetraiodothyronine), 3,5,3'-triiodothyronine, (T3), 3,3,5'- 
triiodothyronine (rT3, reverse T3) and 3,3'-diiodothyronine, (3 ,3 '-T2). Of the 
compounds listed, T4 and T3 are active whereas rT3 and 3,3'-T2 are inactive, 
(Khanna and Waisman, 1988). The thyroid hormones have very wide and varied 
effects on the body including stimulation of carbohydrate, lipid and skin 
metabolism, changes in muscle and heart activity, and developmental regulation 
of the brain, muscle and bone. This variety of effects is produced by the fact that 
each cell reacts differently to the hormone stimulation depending on cell type and 
developmental stage. Even though the effects are diverse they all appear to be 
mediated by an interaction between the hormone and a nuclear receptor. The 
different consequences arise through the subsequent binding of the hormone- 
receptor complex to genes to activate or inactivate them. In different cell types 
different genes will be affected allowing the small number of thyroid hormones 
to have their multiple effects (Khanna and Waisman, 1988).
1.3.3 The Steroid Hormones
The third and final grouping of hormones are the steroids. They are the group 
involved in this research project. Table 1.2 outlines the main classes of steroid 
hormones. The steroid hormones share a basic sterane structure and the 
differences in the function of the molecules occurs with the functional groups 
linked to this 4-ring nucleus (Figure 1.7).
As can be seen from the Table 1.2 the hormones' effects can range from 
carbohydrate metabolism to maturation and they also affect a wide variety of 
different organs. All steroid hormones have a common parent molecule, 
cholesterol. Cholesterol is a 27-carbon molecule with the basic four-ring 
structure that all steroids possess and a long side chain at the 17 position. The 
structure of cholesterol and the steps involved in producing the other steroids is 
shown in Figure 1.8.
Steroid hormones themselves have a huge variety of effects and some of these 
have been manipulated using dosages of natural or synthetic analogues of the 
hormones. One of the most common uses of these hormones is in the
contraceptive pill. There are two types of pill, one is the progesterone only pill 
and the other is the combined pill. The combined pill contains both a progestin 
and an oestrogen. Two of the commonly used oestrogen analogues are mestranol 
and ethynyl estradiol, (EE). EE is also used as a growth promoter in animals and 
is one of the focus compounds of this project.
X)
Table 1.2 : The origin, targets and functions of steroid hormones, (after 
Malkinson, 1975).
Hormone
8 j ■.. . „ ■ esMI
Endocrine 
Gland !
Target Tissue Physiological
Response
Glucocorticoid.
cortisol
Adrenal
Cortex
General Metabolism of 
carbohydrates, proteins 
and lipids; mediation of 
inflammatory response
Mineralocorticoids:
aldosterones,
deoxycorticosterone
Adrenal
Cortex
Kidney, parotid 
gland, sweat and 
salivary glands, 
gastrointestinal 
tract
Regulates
transepithelial sodium 
transport
Oestrogens: 
estradiol, estrone
Ovary
(follicle)
Breast, uterus, 
vagina 
Bone, brain
Maturation and normal 
cyclic function 
Development of 
secondary sex 
characteristics
Androgens:
testosterone,
dihydrotestosterone
Testis,
adrenal
cortex
Prostate gland, 
seminal vessicle
Bone, brain, hair 
bulb
Maturation and normal 
function
Development of 
secondary sex 
characteristics
Progestin:
progesterone
Ovary
(Corpus
luteum)
Uterine
endometrium
Preparation for zygote 
implantation
12
Figure 1 .7; Sterane nucleus common to all steroids. The carbon molecules and 
rings are numbered according to standard steroidal nomenclature, (Power and 
Fottrell, 1993).
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OH
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Pregnenolone
CH2OH
C = 0
Cortisol (Glucocorticoid)
Estradiol (Estrogen) Aldosterone (Mineralocorticoid)
Progesterone (Progestin)
Figure 1.8 : Routes o f  biosynthesis o f some o f  the important steroid hormones 
from the parent compound cholesterol. (Each arrow may contain multiple steps.) 
(Adapted from Malkinson, 1975 and Paterson, 1983)
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The muscles of male animals are generally larger than the corresponding muscles 
in female animals and the inevitable question arose as to why this should occur. 
Many experiments have been carried out to determine the cause of these 
differences. It was found to involve the sex hormones and the associated sex 
organs (Lawrie, 1985). It was noticed that castrated animals had a reduced 
efficiency of weight gain when compared to whole animals. This implied that the 
sex organs had an effect on muscle growth through their biochemical 
messengers, the sex hormones.
The anabolic or protein-accreting effects of the gonadal hormones are eliminated 
during the process of castration. To investigate this effect the diets of castrated 
animals were supplemented with hormones and this counteracted the effects of 
the sex organ removal. This effect of extra weight gain is very desirable in meat- 
producing cattle as less feed is used and the animals can be slaughtered earlier 
leading to lower production costs. It has also been shown that the administration 
of both an estrogen and androgen is required for maximum growth response and 
that females respond better to the administration of androgens, showing a marked 
improvement in their rate of weight gain (Lawrie, 1985).
At first when the natural hormones were administered to the animals the 
beneficial effects were not the only changes noticed. The administering of these 
compounds, which are by definition linked to the sexual characteristics, also 
caused changes in the secondary sex characteristics. To avoid the side effects the 
steroids were chemically modified to produce analogues, which still possessed 
the desired metabolic functions but also minimised the side effects.
Growth promoters were seen as a way of increasing the meat producers’ profit 
margin. They have been used since the 1970’s when their anabolic effects were 
proven. It was suggested that the consumer also benefits from the use of the 
hormones. With the use of hormones the animal feed is converted to muscle at a 
higher rate and so the meat produced by these treated animals is leaner and this is 
in much demand by the public (Meyer, 2001). The saving to the producer is 
brought about by the ability to slaughter the animals earlier so saving on feeding 
and housing costs. The use of hormones as growth promoters is still widespread 
in the U.S. where the use of six steroids are permitted as growth promoters,
1.3.3.1 Use of Steroid Hormones as Growth Promoters
whereas all non-therapeutic uses of hormones in cattle has been banned 
completely in the European Union since the late 1980's, (EU Directive 
81/602/EC). The EU is not convinced that the use of steroid growth promoters in 
meat-producing animals is safe for the consumer.
The method of administration of the commercial preparation is by means of an 
implanted pellet under the skin of the backside of the carflap. This implant 
slowly dissipates over time releasing hormones into the animals system. None of 
the hormones, except for one of the permitted US steroids, melengestrol, are 
given as feed supplements (Penner, 1992). The level of hormone does not remain 
constant but falls as the pellet gets older. The life of the pellet is calculated to be 
the length of time it remains excreting hormones at a level to have a beneficial 
effect on the feed conversion efficiency. Hormones are implanted in both sheep 
and cattle but swine are not normally subjected to this treatment (Penner, 1992).
1.3.3.2 The Need fo r  Monitoring o f Steroid Levels in Food
This question of the need to monitor levels of steroids in foods is a very complex 
and important one. The human endocrine system is a complex, very delicately 
balanced system. This is illustrated quite clearly from the effect that small 
amounts of hormones in the contraceptive pill have. These small amounts almost 
completely block (98%) a woman’s ability to conceive by altering the normal 
functioning of the menstrual cycle. With this in mind the reasons for monitoring 
the levels of these endocrine-disrupting chemicals are clear. It is also possible for 
some of the steroid analogues to have other detrimental characteristics, for 
example DES and estradiol are listed as carcinogens (Opinion of SCVPH, 2002). 
The food we ingest should be tested to ensure that both the levels of any 
hormones, either legal or illegal, are not at levels that would cause health 
problems. Hormone measurements are also used to time the menstrual cycle of 
animals and any external hormones may interfere with the readings and so cause 
problems. However, breeding cattle should never be subjected to steroid growth 
promoters.
The use of these hormones in animals that are destined for slaughter is of concern 
if we do not know the consequences of the particular dosages and their respective 
residues. We may find the residues of these hormones and their metabolites in 
both the meat products and milk products derived from treated animals. When
tolerances of these compounds have been established it must proved extensively 
that these levels in ingested foods or that continual consumption of these tainted 
products could not cause any effect on the human system. To facilitate the 
enforcement of the EU directives banning the use of these hormones each 
member state must put in place proper testing regimes and reference laboratories. 
These requirements are set out in the directives 85/358/EEC, 86/469/EEC and 
96/23/EC.
Hormones are still in use in some parts of the world as growth promoters and yet 
are banned within the EU. Some authorities, such as the American FDA, allow 
some growth promoters as they have concluded that the residue amounts in meat 
from these treatments would most likely not cause any effects. The American 
authorities allow the use of a small number of steroidal hormones as growth 
promoters, namely estradiol, testosterone, progesterone, trenbolone acetate and 
zeranol. The first three of these hormones are naturally occurring in animals and 
humans whereas the other two are synthetically produced and are never found 
naturally. The U.S. FDA have concluded that there would be no physiological 
effect that could be expected in people consuming the meat from treated animals 
(Penner, 1992). This conclusion stems from studies which have shown that in the 
case of the natural hormones the amount consumed would be much less that 1% 
of the amount that a pre-pubital child would produce in a day. The FDA has even 
gone as far as to say that even if the hormones were mis-used the levels would 
not rise above the safe limits (Penner, 1992). The synthetic hormones required 
much more extensive testing, as they are not already found in the body. It had to 
be shown that not only did the hormones have no toxicological effects on the 
animals but also that the residual amounts left in the meat would be below a very 
low limit e.g. 50ppb TBA and 20ppb zeranol.
The agencies that carry out the testing in the US are the Food Safety and 
Inspection Service and the US Department of Agriculture. They test for the 
compounds zeranol and DES (Penner, 1992). They do not test for the natural 
hormones for a number of reasons. First of all it would be impossible to 
distinguish between naturally occurring hormones and their metabolites and 
those introduced artificially into the animals system. They also believe that the 
levels of hormones present in the meat of these animals would not approach 
dangerous levels even in cases of extreme misuse. The testing for zeranol ensures
that any use of the growth promoters is within guidelines and the residues are 
below the tolerance limit of 20ppb. The use of DES as a growth promoter is 
banned globally as it has been proven to be unsafe even in small doses. Any 
residues of this chemical must be found and the tainted meat removed from the 
food chain.
The use of hormones as growth promoters has had a number of scientific reviews 
because of the potential hazards they could present to the consumer. The Codex 
Committee on Residues of Veterinary Drugs in Foods met in June 1987 and they 
concluded that the six hormones allowed in the US (progesterone, testosterone, 
estradiol, zeranol, melengestrol acetate and trenbolone acetate) when used 
properly were unlikely to constitute a human health hazard (Gandhi and 
Snedcker, 2000). This committee consisted of eleven experts from seven 
countries. An EU Scientific Committee on Veterinary Measures relating to 
public health has concluded that for the 6 hormones permitted as growth 
promoters in the US a risk to the consumer was present if they were ingested at 
high levels (Opinion of SCVPH, 2002). This report also stated that 17P-estradiol 
should be considered as a complete carcinogen and endocrine, developmental, 
immunological, neurobiological, immunotoxic, genotoxic and carcinogenic 
effects of all 6 hormones could be envisioned. This report was unable to set 
threshold limits for any of the hormones due to their intrinsic properties and 
other epidemiological findings.
The European ban led to a conflict between the EU and the US agricultural 
community. The European directive banned most of the American produced beef 
from being sold on the European market. In retaliation for this loss in revenue the 
USA added a 100% tariff on wide range of European agricultural produce 
including canned tomatoes, fruit juices and ham. This lead in turn to the EU 
threatening to impose tariffs on other US products, (nuts and fruits). The US 
believes that the EU fears about the safety of hormone-treated meat are 
unfounded and that the ban is a clear case of unfair trade. However, the EU is 
carrying out the wishes of their citizens and they are following the advice of their 
scientific committees. In the early 1980’s DES was detected in baby food made 
from veal from treated animals. Pre-pubertal children are at the highest risk from 
these hormone residues as the amount of natural hormones present is quite low
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and the discovery of this potent xenoestrogen in baby food was a cause of grave 
concern. This and other evidence encouraged the EU to impose its ban for the 
safety of the consumer.
1.4 Immunoassays
Immunoassays can be defined as any analytical technique that employs an 
antigen-antibody interaction. Two important characteristics of antibodies, their 
specificity and the strength of their binding, have enabled immunoassays to 
expand into many areas. Immunoassays have many formats and can be used to 
measure small drugs, macromolecules and proteins. One major division of 
immunoassays is based on whether or not the antibody-antigen complex has to be 
separated from unbound reagents. Homogeneous assays do not require a 
separation step whereas heterogeneous assays do (O'Sullivan et al., 1979).
A number of different immunoassays formats will be discussed in this section 
including dot or western blots, agglutination assays, dip stick or lateral flow 
assays, immunomagnetic separation and immunofiltration. Other important assay 
formats, ELISA and biosensors, will also be discussed in detail in later chapters 3 
and 4.
Historically, radioimmunoassays, introduced by Yalow and Berson (1959), were 
the most popular form of quantitative immunoassays. The more recent trend has 
moved from these radio-labelled tracers to detection systems using safer 
molecules such as enzymes. The radiolabelled molecules can have a limited shelf 
life, they are dangerous to prepare, waste disposal can be problematic, it can be 
difficult to automate the assays and detection equipment and isotopes are 
expensive (Landon et a l, 1975).
1.4.1 Enzyme-Linked ImmunoSorbent Assay (ELISA)
ELISA is a heterogeneous immunoassay that often utilises a 96 well plastic plate 
as its solid matrix. Either the antibody or the antigen is absorbed onto the surface 
of the wells and the binding is mediated by a variety of forces including, 
electrostatic, hydrophobic, non-covalent and van der Waal’s forces. Once these 
proteins are bound the areas of the plastic that are not covered by the specific 
protein must be blocked. This step ensures that reagents added to the wells later
in the assay process do not bind non-specifically to the support. This would alter 
the outcome of the assay and produce results that do not reflect the contents of 
the samples being analysed. Blocking involves the addition of a non-specific 
protein solution to bind to the remaining sites on the plastic.
As the proteins are all bound to the surface of the plate washing steps become 
very simple. The inversion of the plate removes the reaction solutions and by 
filling the wells with a buffer and emptying them a number of times most 
unbound molecules can be eliminated (Delves, 1995).
The addition of the sample usually follows the blocking stage and, depending on 
the exact ELISA format in use, a competing antigen, second antigen-specific 
antibody or second antibody-specific antibody can be added. One of the 
components will be labelled with an enzyme such as alkaline phosphatase or (i- 
galactosidase and the amount of these bound can be detected using a substrate. 
Colourimetric substrates are often used but chemiluminescent or fluorimetric 
reagents can also be utilised (Dankwardt, 2000).
Two of the most widely used ELISA methods are the sandwich and the 
competitive formats. In sandwich ELISAs the antigen is captured onto the solid 
surface by one specific antibody and then bound by a second antibody with 
detection label (Figure 1.9). The signal observed is directly proportional to the 
amount of antigen in the sample. This system can only be used with antigens that 
contain two distinct epitopes that can be bound by different antibodies. Most 
small molecules do not have two epitopes and so the competitive format is used. 
Competitive ELISAs can coat either antibody or antigen on the surface of the 
plate and labelled reagent and sample are added (Figure 3.2). The more antigen 
contained in the sample the less labelled reagent is bound and an inverse signal 
response occurs, as shown in Chapters 3 and 4.
Chapter I: fnlrochiclion
Figure 1.9 : The binding sequence in a sandwich ELISA. The plate is coated with 
a specific antibody (light blue antibody) and then blocked (grey mounds). The 
antigen (purple teardrop) is then added and allowed to bind. The second specific 
labelled antibody (dark blue antibody with red enzyme) is added and allowed to 
bind to any antigen captured by the immobilised antibody. The amount o f antigen 
present in the sample is directly proportional to the amount o f enzyme signal.
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Biosensors can be defined as an analytical device that uses a biological or 
biologically derived sensing element integrated with a physiochemical transducer 
(Sternesjo et al., 1995). A biosensor uses a biological component such as a 
ligand/receptor or an antibody/antigen-binding interaction to detect the presence 
of some analyte. The binding is converted to a measurable signal by a transducer 
and this is fed into a data acquisition device where the signal is analysed (Figure 
1.10). There are many different types of biosensor, all using different sensing 
technologies, different transducer and different methods of signal measuring. 
Biosensors can show results and binding events in 'real-time' and that can be a 
very useful research tool in the life sciences (Hock et al, 1995). Biosensors are 
usually catagorised by their sensing method, e.g. optical, mass, piezoelectric or 
electrochemical (Malan, 1994; van Emon et al., 1998). An optical biosensor was 
used in this work and it is discussed in detail in section 4.1.5.
Biosensors can operate on a batch system by analysing one sample at a time and 
either regenerating or replacing the sensor to perform another assay. They can 
also be used as a continuous or semi-continuous flow through system that would 
allow the constant monitoring of a sample. This will be of great use for effluent 
management, water treatment or in-process monitoring in manufacturing (Sherry, 
1997)
1.4.2 Biosensors
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T ransducer
Figure 1.10 : Schematic representation o f  the principle o f a biosensor. An event 
occurs that creates a change in the system, e.g. an antibody binding to an 
antigen. The signal is then fe d  to the transducer. A  transducer is an instrument 
that changes a signal into a form compatible with a data processing device. The 
transducer senses that change and converts it into a signal. The altered signal is 
then passed to a data processing unit fo r  handling, storage and display.
f
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1.4.3 Dot Blots and Western Blots
These are heterogeneous detection systems, which use a membrane as a solid 
matrix. These two assays use very similar detection techniques although they 
both use different methods to immobilise the primary immunoreagent. With dot 
blots a reagent is dotted onto a membrane in a particular spot either manually or 
using a dot blot apparatus (Ploum et al., 1991) and is illustrated in Figure 1.11. 
This dot can be a pure analyte, a capture antibody or even a complex mixture of 
molecules. The molecules absorb onto the surface of the membrane and the rest 
of the surface is blocked with a non-specific protein solution. When carrying out 
a western blot, proteins sample are first subjected to electrophoresis and then the 
separated proteins are transferred to a membrane using an electric current 
(Towbin and Gordon, 1984). The resulting membrane contains all the proteins 
from the original sample that are now separated. This membrane is then blocked 
and the rest of the reaction is carried out.
A labelled antibody or antigen can be used to probe the membrane directly and 
after washing a substrate that promotes the deposition of an insoluble colour 
precipitate is added. This gives a localised colour where the label is bound.
1.4.4 Agglutination Assays
Agglutination assays are homogeneous and rely on the bivalency of antibodies to 
cross link particles and produce a precipitation effect. They have short incubation 
times and the assay protocols are quite simple (Wild and Davies, 1994). They 
can also be easier to automate as there is no requirement for a separation step.
In these assays the antibody (or antigen if antibody is being measured) is 
immobilised on the surface of a red blood cell (haemagglutination) or a latex 
bead, (latex agglutination). In the presence of the analyte the antibodies bind to it 
and the carrier beads or cells clump together (Figure 1.12). This clumping can be 
detected by light scattering or absorption methods.
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Figure 1.11 : Arrangement o f dot blot apparatus. 1. The sample block has a 
number o f  wells (e.g. 96) into which samples can be added. A membrane (e.g. 
nitrocellulose) is secured under wells on a plastic support. 2. The samples 
contact the membrane though a small gap in the bottom o f the plastic wells. 3. 
The membrane is then removedfrom the platform and further reagents are added 
to the entire membrane, (blocking solution, labelled antibody, precipitating 
substrate). Each dot then develops a colour or not depending on the original 
sample added
♦ ♦ ♦ ♦
Add free antigen
Figure 1.12 : Agglutination reaction. The antibodies on the carrier molecules 
bind to epitopes on the antigen and other antibodies bind to other epitopes. This 
creates a cross-linking effect, which produces the insoluble aggregates seen. The 
bivalent nature o f antibodies can also be used to bind two molecules to each 
antibody. This can form  an aggregate i f  the target molecule has more than one 
recognised epitope.
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This is a very simple, rapid immunoassay system that uses a liquid flow to 
initiate the movements of all the components of the assay to an area where the 
reaction is to happen, Figure 1.13. These assays can take the form of competitive 
assays or of sandwich (double antibody) assays (Wennig et al., 1998; Paek et al, 
2000).
In general, the sample is applied to a piece of absorbent material impregnated 
with one part of the immune reagents linked to a detection label (usually 
colloidal gold or a coloured latex bead). The sample and the reagent react 
forming a complex that moves along the test strip towards a wick at the other 
end. At a point along the strip an antibody or antigen is immobilised and the 
immune complex will bind to it, creating a visual colour signal (Price et al., 
1997). If the immune complex does not form then no colour will be seen and a 
negative result is recorded. A control line can also be included that will show 
colour when the assay is run correctly giving an internal quality check on the 
assay.
These assays are very useful in bedside, roadside, farm-based testing or any 
application that requires a quick qualitative result but they can lack the sensitivity 
needed in other more clinical applications (Ploum et al., 1991). The usefulness of 
this assay format is exemplified by a urine test strip that can carry out 10 analysis 
on a single sample (Kutter, 2000).
1.4.5 Lateral Flow Immunoassays
riiaptcr I: introduction
Control Line 
Test Line
Labelled
Reagent
Addition Pad
Figure 1.13 : Dip stick or lateral flow assay device. The sample is added to the 
first absorbent pad o f the assembly and it is pulled along the strip by capillary 
action. The sample rehydrates the labelled reagent and reacts with it. This 
mixture then moves along the nitrocellulose strip until it meets the immobilised 
reagents on the test and control line. These can be a capture antibody or antigen. 
The labelled reagent will bind to the control line and depending on the reaction 
(positive or negative) on the control line the contents o f the sample can be 
deduced.
4-1
1.4.6 Immunomagnetic Separation
Imraunomagnetic separation uses the combination of the biorecognition of the 
antibody-antigen pair and magnetic beads to allow for a fast, accurate and gentle 
method of separation. The antibodies are attached to magnetised beads either 
directly or through Protein A or G. These can be added to samples to bind cell 
surface receptors, bacterial antigens, tumour markers or biologically active 
compounds. Once bound the magnetic beads are isolated using magnets and the 
rest of the sample is removed. The resulting preparations are relatively pure and 
can be used in further analysis leading to greater sensitivity and accuracy than 
many conventional assays. They can also be utilised in the screening of 
hybridomas to extract cells displaying the required antibody specificity (Hock et 
al„ 1995).
1.4.7 Immunofiltration
The assay systems described by immunofiltration or flow through systems are 
similar to those of ELISA and immunoblotting but use a membrane as the solid 
phase rather than solid plastic. In this case the antibody (or antigen) is absorbed 
onto a membrane and the samples are applied and they pass through the 
membrane. Any components not binding to the antibody will pass through and 
have no further part in the assay. The bound components can be detected by a 
precipitating or a soluble substrate depending on the assay system in use 
(Sibanda et a l, 1999).
Advantages to using this system include the ability to pass larger volumes 
through the membrane than are used in conventional ELISAs, thus giving a more 
sensitive assay. This system has great potential in the area of bacterial cell 
detection where a very small number of cells need to be detected.
The aim of this work was to generate simple immunochemical detection methods 
for the analysis of three steroid hormone analogs that are in use as illegal growth 
promoters in meat. These methods will also be investigated for their suitability 
for use with a real sample matrix, such as bile.
The production and characterisation of polyclonal antibodies for the detection of 
trenbolone is described in chapter 3. The antibodies were applied to two ELISA 
formats and the resulting assays show good accuracy and precision for the 
detection of free trenbolone. The assay performance was also assessed using 
spiked trenbolone samples with bile as a sample matrix. The results show that 
these reagents provide a reliable and robust assay for the detection of trenbolone 
in buffer or bile matrices.
The development of assays for the detection of ethynyl estradiol in buffer and 
bile is described in chapter 4. Polyclonal antibodies were produced and applied 
to the two ELISA systems as previously described. In addition, a surface 
plasmon resonance-based immunoassay was developed. All assays were 
investigated for their performance characteristics.
The application of the polyclonal antibodies to a rapid ELISA format using a 
portable automated device is described in chapter 5. This enables the detection of 
steroids to be carried out in virtually any location by relatively unskilled 
operators.
The final results chapter (chapter 6) describes attempts to produce recombinant 
antibodies specific for the steroids under study. This would allow further 
maipulation of the assay formats and would generate an infinite supply of a 
single-chain variable fragment.
1.5 Aims of Thesis
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C h a p t e r  2  
M a t e r i a l s  a n d  M e t h o d s
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2.1 Equipment
B  lift ffTTiTm* m
BIAcore 3000 
CM5 Sensor chips
BIAcore AB, Uppsala, Sweden.
Titretek Twinreader Plus 
Sterile universal containers 
Coming pH Meter 220 
Memmert Static incubator
M.S.C., Damastown, Mulhuddert, 
Dublin 12, Ireland.
Grant Y6 Waterbath
Milipore Filtration Device (De-gassing 
apparatus)
Milli-Q Academic - Ultrapure Water 
System
A.G.B., Dublin Industrial Estate, 
Glasnevin, Dublin 9, Ireland.
Biometra T-Gradient Thermocycler 
(ramping rate 4°C sec'1)
Anachem, Anachem House, Luton, 
Bedfordshire, England.
UV-160A Spectrophotometer Shimadzu Corporation, Kyoto, 
Japan.
Orbital incubator Gallenkamp, Leicester, England.
Atto minigel AE 6100 
Atto midigel AE600 
Atto Dual minislab AE6450
Atto Corporation, Bunhyo-Kui, 
Tokyo 113, Japan.
Eppendorf Centrifuge 581 OR Eppendorf AG, 10 Signet Court, 
Swann Road, Cambridge, U.K.
Eppendorf Tubes Sarstedt, Wexford, Ireland.
Hermle Centrifuge (Z 200 M/H) Hermle Labourtechnik, 78564- 
Wehingen, Gosheimerstr. 56, 
Germany.
Image Master VDS Pharmacia Biotech, San Francisco, 
California, U.S.A.
Nunc Maxisorp Plates 
Nunc Immunotubes 
Nunc Maxisorp Break-apart wells 
Reaction wells for Rapid Elisa Device
Nunc, Kamstrup DK, Roskilde, 
Denmark.
Sorvall Refrigerated Centrifuge Du Pont Instruments, Newton, 
Connecticut, U.S.A.
Tomy Autoclave (SS325) Mason Technology, Greenville Hall, 
228 South Circular Road, Dublin 8, 
Ireland
Aquatron A400
Water Still for distilled water
Bibby Sterilin, Staffordshire, 
England.
All chemicals were supplied by Sigma-Aldrich Chemicals, Ireland unless stated 
otherwise. The steroids were also supplied by this company. The derivative EE- 
6-CMO was supplied by Steraloids, US.
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2.2 Media Formulations
Media Formulations Components
2X Tryptone Yeast Extract broth media 
(2X TY, 1L)
16g Tryptone (Oxoid)
10g Yeast Extract (Oxoid) 
5g NaCl
2X TY agar (1L) As 2X TY broth media with 
15g Technical Agar (Oxoid)
SOC (1L)
(Super optimal catabolites)
20g Tryptone 
5g Yeast Extract 
0.5gNaCl
Sterilise by autoclaving
Add 10 ml IMMgCh
Add 10 ml IM MgS0 4
Add 16 ml of 25% (w/v) Glucose
Top Agar (1L) 10g Tryptone 
5g Yeast Extract 
lOgNaCl 
7g Technical Agar
Minimal Agar (1L) 15g Agar
750 ml H20
Sterilise by autoclaving
Add 200 ml 5XM9 Salts
16 ml 25% (w/v) Glucose
1 ml20%(w/v)MgCl2
0.5 ml 1% (w/v) Thiamine-HCl
5XM9 Salts (1L) 64gNa2HP04 
15g KH2P04 
5gNH4Cl 
2.5g NaCl
Sterilise by autoclaving
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2.3 Buffer Formulations
Buffer Components
Phosphate buffered saline (PBS) 1 tablet from Oxoid dissolved in 100
ml of distilled H20  gives a solution
of Dulbecco's A PBS, pH 7.4,
containing
0.15MNaCl
2.5mM KC1
10mMNa2HP04
18mMNaH2P 04
Hepes Buffered Saline (HBS) lOmM Hepes 
0.15MNaCl
3.4mM EDTA (disodium-2-hydrate) 
0.05% (v/v) Tween 20 
pH adjusted to 7.4 with 2M NaOH, 
filtered and degassed before use
Tris Acetate EDTA buffer 
(10X TAE Buffer, Sigma T9650)
0.04M Tris Acetate 
ImM EDTA 
pH 8.3
Tris Buffer for rapid assay device (5OX) 0.124M Tris 
3.85MNaCl 
0.117M Sodium Azide 
pH to 7.5
5% (v/v) Tween 20
TES (Tris EDTA Sucrose) 200mM Tris 
0.5M Sucrose 
0.5mMEDTA 
pH to 8 with HC1
Wash 1 for Ni-NTA column 50mMNaH2P04 
300mMNaCl 
lOmM Imidazole
Wash 2 for Ni-NTA column 50mMNaH2P04
300mMNaCl
Elution Buffer for Ni-NTA column 50mM NaH2P 04 
300mM NaCl 
250mM Imidazole
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2.4.1 Preparation of steroid derivatives
2.4.1.1 Derivatisation o f trenbolone to trenbolone 17-hemisuccinate (TR-17- 
HS)
The method used was a modification of the procedure used by Jondorf (1980). 
Trenbolone (100 mg, Sigma-Aldrich Chemicals, Figure 3.1) was dissolved in 3 
ml of dichloromethane and 2 ml of dry pyridine. Succinic anhydride (187 mg) 
was added and the reaction was left at room temperature for 48 h. The reaction 
was evaporated to dryness using a rotary vacuum evaporator with a heat gun, and 
the residue was dissolved in 10 ml of chloroform. The residue was washed twice 
with water ( 2 x 5  ml) to remove excess succinic anhydride and the chloroform 
was then removed under vacuum. The residue was re-dissolved in ethanol and 
stored in the dark at room temperature (Figure 3.3).
2.4.1.2 Derivatisation o f diethylstilbestrol to monocarboxypropyl- 
diethylstilbestrol (DES-CP)
This reaction was carried out using a modification of the procedure published by 
Degand at al. (1989). DES (900 mg, Sigma-Aldrich Chemicals, Figure 6.1), NaH 
(90 mg) and bromobutrylethylester (600 mg) were placed in a round-bottomed 
flask and dissolved in dry dimethylformamide. The solution was allowed to react 
for 48 h in the dark and it was monitored by thin layer chromatography. The 
product was precipitated by pouring the mixture into a beaker containing 100 ml 
of ice cold water and 1.5 ml of HC1. The mixture was extracted with ethyl acetate 
and washed with water to remove any remaining DMF. The organic solution was 
evaporated to dryness on a rotary evaporator. The solution was purified using a 
silica column and ethylacetate:hexane (30:70) was used to elute the fraction 
required. This fraction was then evaporated to dryness.
The ethylenated product (50 mg) was mixed with 3g of KOH dissolved in 25 ml 
ethanol and refluxed for 1.5h. The resulting solution was neutralised and the 
precipitate was collected (Figure 6.2).
2.4 Methods
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2.4.2.1 Production o f steroid-protein conjugates using EDC/NHS chemistry
The production of this conjugate was carried out with a modification of the 
carbodiimide procedure described by van Look et al. (1991). The steroid 
derivative (5 mg) was dissolved in 500pl of dioxane in a glass vial. Solid NHS 
was added to give a final molarity of 0 .1M. EDC (5 mg) was dissolved in 250pl 
of distilled water and added to the steroid solution. This was incubated for 10 
min, with stirring. A solution containing 10 mg of carrier molecule (BSA, THY 
or DEX (amino dextran: Molecular Probes, Oregon, USA)) in 700 (J.1 of 0.05M 
phosphate buffer, pH 7.8, was added to the reaction mixture. The reaction was 
allowed to proceed for 75 min. The resultant mixture was dialysed for 48h 
against 4 changes of PBS at 4°C. The concentration of the protein conjugates was 
determined using a standard BCA protein microassay (Section 2.4.6.3) while the 
concentrations of the dextran conjugates was estimated.
2.4.2.2 Production o f steroid-protein conjugates using mixed anhydride 
chemistry
This was prepared using a modification of the mixed anhydride procedure 
described by Nambara et al. (1982) based on the reaction elucidated by Erlanger 
et al. (1957). The steroid derivative (10 mg) was dissolved in 200 p.1 of DMF. 
Tributylamine (8 |il) and 2.5|xl of butylchloroformate were added and the 
reaction was stirred on ice for 12 min. A solution containing 20 mg of OVA or 
BSA in 1 ml of water, 2.5 ml of DMF and 25 pi of IN NaOH was cooled to 0°C 
and added to the activated hapten. The reaction was left at 4°C for at least 20h. 
The conjugate was then dialysed overnight against 5L of PBS to remove any 
unconjugated hapten. The concentration of this antibody was determined by 
BCA microassay (Section 2.4.6.3).
2.4.2.3 Production o f steroid-horseradish peroxidase conjugates using mixed 
anhydride chemistry
This synthesis was carried out according to a modification of the procedure 
described by Meyer and Hoffmann (1987). The steroid derivative (1.5 mg) was 
dissolved in 100pl of DMF and lpl of methylmorpholine was added. This
2.4.2 Preparation of drug-protein conjugates
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solution was cooled to -15°C and 1 (il of butylchloroformate was added. The 
solution was left to stir at -15°C for 3 min. This mixture was added slowly to a 
pre-cooled (0°C) solution of 11 mg of HRP in 100 i^l water and 75 (il DMF. This 
was stirred at -15°C for 60 min followed by 0°C for 120 min. 1 mg of NaHCC>3 
was then added and the products were dialysed overnight against PBS.
2.4.3 Characterisation of drug-protein conjugates
2.4.3.1. Ultraviolet spectroscopy
Conjugates were diluted to approximately 1 mg ml'1 and their UV spectra was 
analysed from 200-400nm. The UV spectrum of the unconjugated proteins and 
drugs were also recorded. The comparison of the spectra gave an indication of 
whether the conjugation was successful and the degree of substitution of the 
conjugates. This analysis was not possible for all conjugates as the spectrum of 
some of the drugs may have been masked by the spectra of the carrier proteins.
2.4.3.2 Immunisation
In cases where the UV spectra of the hapten was masked by the carrier protein, 
the success of the conjugation was assessed by immunising mice and 
determining if a specific immune response to the free steroid was induced. The 
mice were immunised with a mixture of the conjugate and Freund's Complete 
Adjuvant. The micc were boosted after two weeks, using Freund's Incomplete 
Adjuvant, and a tail bleed was performed 10 days later. The serum was tested for 
antibodies that recognised the target molecule by non-competitive ELISA and 
competitive ELISA.
2.4.4 Antibody Production
2.4.4.1 Immunisation procedure fo r  the production o f rabbit antiserum to EE- 
6-CMO-OVA and DES-CP-OVA
Two female New Zealand White rabbits were immunised sub-cutaneously for 
each drug with 1 ml of EE-6-CMO-OVA or DES-CP-OVA conjugate at a 
concentration of 0.5 mg ml"1 mixed with an equal volume of Freund's Complete 
Adjuvant. The rabbits were then boosted with the conjugate mixed with Freund's 
Incomplete Adjuvant at 2, 5, 11, 16 and 18 weeks following initial immunisation.
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One rabbit was sacrificed at 7 weeks (EEAb2) and the other 3 at 20 weeks 
(EEAbl, DESAbl and DESAb2).
2.4.4.2 Immunisation procedure fo r  the production o f rabbit antiserum to TR- 
17-HS-THY
Two female New Zealand White rabbits were immunised with 1 ml of TR-17- 
HS-THY conjugate at a concentration of 0.5 mg ml"1 mixed with an equal 
volume of Freund's Complete Adjuvant. The rabbits were then boosted with the 
conjugate mixed with Freund's Incomplete Adjuvant at 2, 4, and 6 weeks 
following initial immunisation. The rabbits were sacrificed at 7 weeks.
2.4.4.3 Immunisation procedure fo r  the production o f recombinant scFv 
libraries
Balb/c mice were immunised intra-peritoneally with a mixture of the conjugate 
(0.5 mg ml'1) and Freund's Complete Adjuvant. The mice were boosted after 2, 4, 
8 and 12 weeks, using Freund's Incomplete Adjuvant. A tail bleed was performed 
7 days after the last booster injection and the titre and specificity of the serum 
was determined. If the titre was satisfactory the mice were sacrificed and the 
spleen was harvested (Section 2.4.10.1).
2.4.5 Preparation of Serum
2.4.5.1 Preparation o f  rabbit serum
The blood was allowed to clot at room temperature for 2-3 h at which point the 
clot was ringed, (separated from the side of the blood tube). The blood was left at 
4°C overnight to allow the clot to contract. The blood was centrifuged at 
4,000rpm for lOmin and the serum was recovered and re-centrifuged to remove 
any remaining blood cells. The serum was stored at -20°C until required.
2.4.5.2 Preparation o f mouse serum
The blood gathered from the tail bleed was centrifuged at 14,000rpm for 2min to 
separate the cells from the serum. The serum was removed to a fresh tube and 
stored at -20°C until required.
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2.4.6.1 Saturated ammonium sulphate precipitation
The IgG fraction was first isolated from the serum by differential precipitation 
using saturated ammonium sulphate (SAS) according to the method of Hudson 
and Hay (1989). 10 ml of serum was placed in a beaker on ice and an equal 
volume of SAS was added dropwise with continuous gentle stirring. This was 
left on ice for one hour and then centrifuged at 3000rpm for 20min. The pellet 
was resuspended in 10 ml of 45% (v/v) SAS and centrifuged again. This step was 
repeated and the final pellet was dissolved in 5 ml of PBS and dialysed overnight 
at 4°C against 5L of PBS to remove any residual ammonium sulphate.
2.4.6.2 Protein G affinity chromatography
2.5 ml of the dialysate from the SAS precipitation was passed through a 1 ml 
protein G-sepharose column, which had been equilibrated with PBS. The 
antibody solution was passed through the column 3 times to allow for maximum 
binding. The column was washed with PBS until protein was no longer seen in 
the wash. The bound fraction was eluted with 0.1M glycine-HCl, pH 2.2, that 
was left in contact with the column for lOmin, and 1 ml fractions were collected, 
which were immediately neutralised with 100 (il of 2M Tris-HCl, pH 8.6. The 
optical density of the fractions at 280nm was recorded and those that contained 
protein were pooled and dialysed overnight at 4°C against PBS. Sodium azide 
was added to a final concentration of 0.05% (w/v) as a preservative and the 
purified antibody was aliquotted into 0.5 ml fractions and stored at -20°C.
2.4.6.3 Bicinchoninic acid (BCA) protein assay (Pierce)
Standard protein solutions of either BSA or IgG were prepared with varying 
concentrations between 0-2 mg ml'1 depending on the type of protein to be 
analysed. 10 (il of the sample or the standard was placed in a well of a microtitre 
plate and 200 jxl of BCA working solution (50 parts reagent A to 1 part reagent 
B) was added. The plate was gently shaken and incubated for 30min at 37°C. The 
absorbance of the wells was determined at 562nm on a Titretek Twinreader Plus
2.4.6 Antibody purification and characterisation
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plate reader. A standard curve of protein concentration versus absorbance was 
constructed and the values of the unknown protein solutions were determined.
2.4.6.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- 
PAGE)
SDS-PAGE was carried out to assess the efficiency of the purification of the 
antibodies and the relative purity of the final product. The polyacrylamide gels 
(15% w/v), buffers and sample buffer were prepared as described in Table 2.1. 
The samples were diluted to approximately 1 mg ml'1 and mixed with the 5X 
sample buffer and, along with the protein markers, were boiled for 5min. The 
gels were run at 15mA per plate on an Atto AE-6450 mini-gel rig until the 
tracking dye moved to the bottom of the staking gel. At this point the current was 
increased to 20mA per plate. The gels were run until the dye had moved to the 
end of the resolving gel. The proteins on the gel were then visualised using 
Coomassie blue stain or the gel was used for western blot analysis.
2.4.6.5 Coomassie blue staining o f a SDS-PAGE gel
Coomassie staining solution (0.2% (w/v) Coomassie blue R250 in 30:10:60 
(v/v/v) methanol:acetic acid:water) was prepared and used to stain SDS-PAGE 
gels for 30min at room temperature with gentle shaking. The stain was then 
removed and the gels were destained with destaining solution (in 30:10:60 
(v/v/v) methanol:acetic acid:water) overnight with gentle shaking. The banding 
patterns on the gels were recorded by electronic image scanning.
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Table 2.1 : Components required for the construction, running and visualisation 
of SDS-PAGE gels.
Solution Components
Electrophoresis Buffer • 3 g Tris
• 14.4 g Glycine
• 1 g SDS in IL
4X Resolving Gel Buffer 
(Stored at 4°C)
• 75 ml 2M Tris-HCl, pH 8.8
• 4 ml 10% (w/v) SDS
• 21 ml distilled H20  (d H20)
4X Stacking Gel Buffer • 50 ml 1M Tris-HCl, pH 6.8
• 4 ml 10% (w/v) SDS
• 46 ml dli20
30% (w/v) Acrylamide solution • 29.2 g Acrylamide
• 0.8 gbis-acrylamide
• to 100 ml with dH20
15% (w/v) Resolving Gel (10 
ml)
• 2.5 ml 4X resolving gel buffer
• 5 ml 30% (w/v) acrylamide 
solution
• 2.5 ml dH20
• 100 (il 10% ammonium 
persulphate
• 20 jil TEMED
Stacking gel (5 ml) • 1.25 ml 4X stacking gel buffer
• 0.833 ml 30% (w/v) acrylamide 
solution
• 2.877 ml dH20
• 50 jj.1 10% (w/v) ammonium 
persulphate
• 10 jj.1 TEMED
Sample buffer • 60 mM Tris-HCl, pH 6.8
• 25% (v/v) glycerol
• 2% (w/v) SDS
• 14.4 mM 2-mercaptoethanol
• 0.1% (w/v) bromophenol blue
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2.4.7.1 Preparation o f steroid standards in buffer
A 5 mg ml"1 ethanolic stock of each of the steroids was prepared. This stock was 
diluted 1/50 with PBS (or HBS) to give a 100 |Lig ml"1 steroid solution in buffer 
containing 2% (v/v) EtOH. Subsequent dilutions were performed using PBS/2% 
(v/v) EtOH as the diluent to maintain the same buffer across the concentration
range.
2.4.7.2 Preparation and use o f  bovine bile
Bovine bile was collected from Kepak, Co. Dublin, centrifuged and stored at 
-20°C until required. Samples were defrosted and filtered through a 0.45fim 
syringe filter before use. Standards were prepared by spiking the bile with the 
steroid from the ethanolic stock and using the bile to prepare a wide range of 
concentration standards.
2.4.7.3 Non-competitive ELISA fo r  the determination o f antibody titre and 
optimal steroid-HRP concentration fo r  competitive ELIS As
A range of concentrations of anti-drug polyclonal antibody were prepared using 
0.05M carbonate buffer, pH 9.6, and these were coaled onto Nunc Maxi-sorp 
Immunoplates at 100|il/well and left overnight at 4°C. They were washed 3 times 
with PBST (PBS containing 0.05% (w/v) Tween 20) and 3 times with PBS. Each 
well was blocked with 150 ptl of 2% (w/v) marvel solution in PBS and left to 
incubate at 37°C for Ih. The plates were washed again and various dilutions of 
the hormone-HRP conjugate were applied across the differing coated 
concentrations of antibody at 100p. 1/well. The plates were incubated at 37°C for 
lh and washed. HRP enzymatic activity was detected using the O- 
Phenylenediamine Dihydrochloride (OPD) Fast Substrate system (Sigma) and 
the absorbance was read at 405 nm. 100 p.l of OPD substrate was added to each 
well and left to develop in the dark for 30 min and read on a Titretek Twinreader 
Plus at 405 nm.
2.4.7 ELISA Procedures
_S8
2.4.7.4 Competitive ELISA Procedure
Nunc Maxi-sorp Immunoplates were coated overnight at 4°C with anti-steroid 
polyclonal antibody at the optimal concentration in 0.05M carbonate buffer, pH 
9.6, (100|il/well). The plates were washed and blocked as described in section
2.4.7.3. 50(xl of a spiked sample was added to the wells followed by 50pl drug- 
HRP conjugate in PBS. The plate was left at 37°C for lh. OPD Substrate was 
used, as above, to detect the amount of HRP enzyme present. Inter and intra-day 
assays were carricd out using 5 replicates of each standard run on 5 different 
occasions (Section 2.4.7.7).
2.4.7.5 Non-competitive ELISA fo r  the determination o f antibody titre and 
optimal concentration o f protein concentration fo r  inhibitive ELIS As
A range of concentrations of hormone-BSA conjugates were prepared using PBS 
and these were coated onto Nunc Maxi-sorp Immunoplates at 100(il/well and left 
overnight at 4°C. The plates were washed and blocked as described in section
2.4.7.3. The plates were washed again and various dilutions of the polyclonal 
antibody were applied across the differing coated concentrations of steroid-BSA 
conjugates at 100[il/well. The plates were incubated at 37°C for lh and washed. 
A commercial anti-rabbit antibody conjugated with HRP was then applied to 
each well, ( 1 0 0 (1 1/well) at the recommended concentration and incubated for lh 
at 37°C. The plates were washed again and 100 fil of OPD substrate was added. 
The plates were incubated in the dark for 30 min and read on a Titretek 
Twinreader Plus at 405 nm.
2.4.7.6 Inhibition ELISA Procedure
Nunc Maxi-sorp Immunoplates were coated with steroid-BSA conjugate solution 
in PBS and blocked as described previously. The samples (50pl/wcll) were 
added, followed by the anti-hormone polyclonal antibody and left for lh at 37°C. 
lOO^ il of the secondary antibody (1/5000 dilution of commercial HRP-conjugated 
goat anti-rabbit IgG) was added to each well and left for lh at 37°C. The HRP 
enzyme was detected using OPD and inter- and intradays assays were carried out 
(Section 2.4.7.7).
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Each concentration point was run with 5 replicates in each assay. The mean 
absorbance is plotted against the concentration value to produce the calibration 
curve. The percentage coefficient of variation (% CV) is calculated as the 
standard deviation of the 5 replicates divided by the mean. This value is a 
measure of the reproducibility and precision within each assay. To assess these 
parameters between assays the assays were run on 5 different occasions. The 
absorbance of each of the standards was normalised by dividing the mean 
absorbance value for each EE concentration by the mean value for that assay's 
zero concentration value, (A/Ao). The normalised absorbance values were 
compared across the 5 assays and the mean values were plotted against the free 
drug concentrations to produce an inter-assay calibration curve. The % CV was 
calculated to assess the inter-assay reproducibility and precision.
The results obtained from the immunoassays carried out showed good agreement 
with a 4-parameter curve-fitting model. The model is described below;
2.4.7.7 Data processing of ELISA results
where y is the absorbance or normalised absorbance value, Rhi is the absorbance 
value as the concentration tends to infinity, Rio is the absorbance value as the 
concentration tends to zero, x is the concentration value and Aj and A2 are fitting 
parameters.
This model was fitted to the data using BIAevaluation 3.1 software and the 
accuracy of the model curves was calculated by comparing the actual 
concentration values with those obtained by substituting the recorded 
absorbances into the model. The comparison is shown as a percentage accuracy 
where 100% is an ideal fit.
2.4.7.8 Cross reactivity studies
A standard curve of the drug the antibody was raised against was set up in PBS 
containing 2% (v/v) ethanol. Serial dilutions of the steroid analogues to be tested 
were prepared (Figure 2.1) and run in parallel with the samples of the specific 
steroid. The concentration that suppresses the zero signal by 50% is determined
y = Rhi - Rhi -  Rio
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for each steroid being tested. The concentration of the specific steroid that gives 
50% signal in the assay is expressed as a percentage of the value calculated for 
each of the cross-reacting steroids.
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Ethynyl Estradiol
Trenbolone
19-Nortestosterone
Norgestrol
Methyl Testosterone
Diethylstilbestrol
17ß-estradiol
Estrone
Norethisterone Zeranol
Figure 2.1 : Structures o f the steroids used for the cross reactivity studies.
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2.4.8.1 Non-competitive ELISA using the rapid ELISA protocol
The wells of a 96 well plate were coated with anti-steroid specific antibody 
(TRAbl and DESAbl) and blocked as described in section 2.4.7.1. Various 
dilutions of steroid-HRP conjugate were prepared and added across the coated 
concentrations. The conjugate was left in the wells for 5min at 37°C and the 
plates were washed using two PBST washes followed by two washes in PBS. 
OPD substrate was added to the wells and the absorbance read at 5min and 
20min.
2.4.8.2 Competitive ELISA using the rapid ELISA protocol
The plates were coated with steroid-specific antibody diluted in carbonate buffer, 
with every fifth well left uncoated, and blocked as previously described, section
2.4.7.1. The steroid standards were prepared and 50 fil was added to the wells 
followed by 50 pi of the optimised steroid-HRP conjugate dilution. The plate 
was incubated for 5min at 37°C with three 10 second shakings and washed. OPD 
substrate was added to detect the bound HRP and the absorbance read after 5 and 
20mm at 37°C.
2.4.8.3 Assay protocol using the rapid assay device
The reaction wells were coated with 100 [il of the optimised anti-steroid antibody 
dilution in 0.05M carbonate buffer, pH 9.6, overnight at 4°C. The wells were
washed (3 times with PBST and 3 times with PBS) and 250 (0.1 of 2% (w/v)
MPBS was used to block each well. This was left at 37 °C for lh. The wells were 
washed again and left dry at room temperature or with PBS at 4°C until needed. 
The wells were allowed to come to room temperature before use. Each run with 
the machine used 4 wells coated with the antibody and one well that had been 
coated with buffer only. The containers used by the machine are listed below and 
the positions are illustrated in Figures 5.1 and 5.2.
• Position 1 Eppendorf with 700 (xl of sample
• Position 2 Eppendorf with 1 ml of TMB substrate
• Position 3 Eppendorf, empty (for waste)
2.4.8 Rapid ELISA Protocols
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• Position 4-8 Nunc breakapart wells with 100 |ll of conjugate solution
• Position 9-12 Reaction wells coated with antibody
• Position 13 Uncoated reaction well
• Buffer reservoir Tris Buffer
The device aliquots the sample into the 5 conjugate-carrying wells (4-8) and the 
samples are mixed briefly. The machine transfers the samples from each of the 
mixing wells to the corresponding reaction well, (4—»9, 5—»10, 6—>11, 7—»-12, 
8—>-13). The reaction wells are incubated at 35°C with mixing for 4min. The 
wells are aspirated and washed 3 times with a tris buffer. TMB is added to each 
of the reaction wells and a transmission reading is taken immediately. The 
substrate is allowed to develop for 5min with shaking and the transmission is 
read again. The ratio of the second reading to the first is used as the analytical 
value and it is normalised against the value obtained in the uncoated control well.
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2.4.9.1 Preconcentration Studies
A number of aliquots of lOmM sodium acetate with a pH range between 3.8 and 
5 were prepared. The drug derivative to be immobilised on the BIAcore CM5 
sensor chip was dissolved in each of these various solutions at a concentration of 
50 fig ml'1 and passed across the surface of the chip. The solution that gave the 
largest change in response units was deemed to be the optimal pH for the 
immobilisation of the conjugate to the dextran chip surface.
2.4.9.2 Covalent linking o f drug conjugate to BIAcore CM5 chip
The conjugate was dissolved in lOmM sodium acetate at the optimised pH and 
the required concentration (usually 50 \ig ml'1). Equal amounts of EDC (0.4M) 
and NHS (0.1M) were mixed and passed over the chip surface to activate the 
binding sites of the dextran for 7 min at 5 |il min'1. The conjugate dissolved in 
acetate buffer was then passed over the surface at a slower flow rate (2 fj,l min1) 
for 20 min. The unused binding sites were then capped by passing 1M 
ethanolamine, pH 8.5 over the surface for 7min. This procedure removed any 
remaining active sites on the chip surface.
2.4.9.3 Regeneration Studies
The optimal solutions for the removal of antibody from the conjugate 
immobilised on the chip surface and the stability of the conjugate with repeated 
exposure to that regeneration solution were determined. The antibody was passed 
over the surface and allowed to bind under the same conditions as it would be 
used in an assay. The regeneration solution was then passed over the surface and 
this cycle is repeated until the surface no longer shows an ability to bind the 
antibody at the required level.
2.4.9.4 Inhibition BIAcore assay
Samples were prepared by diluting EE in HBS/bile (1:1) and then mixing the 
standard with the appropriate dilution of antibody, diluted in HBS. This was 
incubated at 37°C for lh. The samples were then transferred to the autosampler 
of the biosensor. The assay was controlled by a computer program generated
2.4.9 BIAcore Methods
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using the BIAcore software. Flow rates on the BIAcore® 3000 were set at 5|xL 
min'1. The samples were passed over the conjugate-immobilised surface of the 
chip followed by the appropriate regeneration solution. Each standard was 
injected 3 times and the standards were analysed in random order.
The first antibody, EEAbl, was used at a concentration of 40fig ml'1 and the 
sample/antibody mixture was passed over the chip surface for 4min. The 
regeneration protocol was a two minute pulse of 1M ethanolamine, pH 13. 
EEAb2, was used at a concentration of 34.2[ig ml'1 and 20f.il of the sample was 
passed over the surface. This antibody was regenerated using a two minute pulse 
of 30mM HC1 followed by a further two minutes of 30mM NaOH containing 
10% (v/v) acetonitrile. If the assay was run at room temperature the acetonitrile 
evaporated from the sodium hydroxide solution. To maintain the acetonitrile in 
the regeneration solution the rack bases of the BIAcore® 3000 were kept at 
10°C. Intra and inter-day assays were carried out using 3 replicates of each point 
on the standard curve run on 3 different occasions.
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2.4.10.1 Extraction o f  mRNA from  spleen o f  an immunised mouse
The mouse was sacrificed by cervical dislocation and the spleen was extracted 
and weighed using aseptic technique. 1 ml of Trizol reagent was added for each 
50 mg of tissue and it was then homogenised. The mixture was left at room 
temperature for 5 min. 200 pi of chloroform was added for every 1 ml of Trizol 
used and shaken vigorously by hand for 15s followed by a 3 min room 
temperature (RT) incubation. The solution was then centrifuged at 4°C for 15 
min, at 14,000rpm. The upper aqueous phase was removed to a clean tube and 
500 pi of isopropyl alcohol was added to it and incubated at RT for 10 min and 
re-centrifuged for 10 min. The pellet was washed in 1 ml of 75% (v/v) ethanol 
and centrifuged at 4°C for 5 min at 10,000rpm. The pellet was dried briefly at 
37°C and finally dissolved in 50 pi of "RNase-free" water at 4°C overnight.
2.4.10.2 Reverse transcription o f  mouse spleen mRNA
A Promega Reverse Transcription System Kit was used to carry out the 
production of cDNA from the isolated mRNA. The components were assembled 
as described below and incubated for lOmin at RT followed by 90min at 42°C.
2.4.10 Recombinant Methods for scFv Library Production
Component Stock Concentration Concentration in 20pl
10X Buffer 10X IX
MgCl2 25 mM 5 mM
dNTP 10 mM 1 mM
RNase Inhibitor 40 U pi'1 1 U pi'1
Random Hexamer 0.5 pg pi'1 0.01 pg pi'1
Primers
AMU RT 20 U pi'1 0.75 U pi'1
mRNA 7-10 pg per reaction
Ultrapure H20 to 20 pi
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2.4.10.3 Amplification o f  the variable fragments o f  antibody heavy and light 
chains using polymerase chain reaction
2.4.10.3.1 PCR primers
The primers used to isolate and amplify the variable heavy and light chain 
antibody fragments are listed below. All the light chain primers were used for the 
light chains and similarity for the heavy chains.
The codes used for the bases are as follows:
A: Adenosine
C: Cytosine
G: Guanine
T: Thymidine
R: A or G
Y: C or T
M: A or C
K: G orT
S: C or G
W: AorT
H: A or C or T
B: C or G or T
V: A or C or G
D: A or G or T
LB I 5' gccatggcggactacaaaGAYATCCAGCTGACTCAGCC 3'
LB2 5' gccatggcggactacaaaGAYATTGTTCTCWCCCAGTC 3'
LB3 5' gccatggcggactacaaaGAYATTGTGMTMACTCAGTC 3'
LB4 5' gccatggcggactacaaaGAYATTGTGYTRACACAGTC 3'
LB5 5' gccatggcggactacaaaGAYATTGTRATGACMCAGTC 3'
LB6 5' gccatggcggactacaaaGAYATTMAGATRAMCCAGTC 3'
LB7 5' gccatggcggactacaaaGAYATTCAGATGAYDCAGTC 3'
LB8 5' gccatggcggactacaaaGAYATYCAGATGACACAGAC 3'
LB9 5' gccatggcggactacaaaGAYATTGTTCTCAWCCAGTC 3'
LB 10 5' gccatggcggactacaaaGAYATTGWGCTSACCCAATC 3'
LB 11 5' gccatggcggactacaaaGAYATTSTRATGACCCARTC 3'
LB 12 5' gccatggcggactacaaaGAYRTTKTGATGACCCARAC 3'
LB 13 5' gccatggcggactacaaaGAYATTGTGATGACBCAGKC 3'
LB 14 5' gccatggcggactacaaaGAYATTGTGATAACYCAGGA 3’
LB 15 5' gccatggcggactacaaaG AY ATTGTGATGACCCAGWT 3'
LB 16 5' gccatggcggactacaaaGAYATTGTGATGACACAACC 3'
LB 17 5’ gccatggcggactacaaaGAYATTTTGCTGACTCAGTC 3'
LBA, 5' gccatggcggactacaaaGATGCTGTTGTGACTCAGGAATC 3'
Variable Light chain forward primers
LF1 5' ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTGATTTCCAGCTTGG 3' 
LF2 5' ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAGCTTGG 3' 
LF4 5' ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAACTTTG 3' 
LF5 5' ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTCAGCTCCAGCTTGG 3'
Chapter 2: Materials and Methods
Variable Light chain back primers
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LFA, 5' ggagccgccgccgcc(agaaccaccaccacc)2ACCTAGGACAGTCAGTTTGG 3' 
Variable Heavy Chain back primers
HB1 5' ggcggcggcggctccggtggtggtggatccGAKGTRMAGCTTCAGGAGTC 3' 
HB2 5' ggcggcggcggctccggtggtggtggatccGAGGTBCAGCTBCAGCAGTC 3' 
HB3 5' ggcggcggcggctccggtggtggtggatccCAGGTGCAGCTGAAGSASTC 3' 
HB4 5' ggcggcggcggctccggtggtggtggatccGAGGTCCARCTGCAACARTC 3' 
HB5 5' ggcggcggcggctccggtggtggtggatccCAGGTYCAGCTBCAGCARTC 3' 
HB6 5' ggcggcggcggctccggtgglggtggatccCAGGTYCARCTGCAGCAGTC 3' 
HB7 5' ggcggcggcggctccggtggtggtggatccCAGGTCCACGTGAAGCAGTC 3' 
HB8 5' ggcggcggcggctccggtggtggtggatccGAGGTGAASSTGGTGGAATC 3' 
HB9 5' ggcggcggcggctccggtggtggtggatccGAVGTGAWGYTGGTGGAGTC 3' 
HB10 5' ggcggcggcggctccggtggtggtggatccGAGGTGCAGSKGGTGGAGTC 3' 
HB11 5' ggcggcggcggctccggtggtggtggatccGAKGTGCAMCTGGTGGAGTC 3' 
HB12 5' ggcggcggcggctccggtggtggtggatccGAGGTGAAGCTGATGGARTC 3' 
HB13 5' ggcggcggcggctccggtgglggtggatccGAGGTGCARCTTGTTGAGTC 3' 
HB14 5' ggcggcggcggctccggtggtggtggatccGARGTRAAGCTTCTCGAGTC 3' 
HB15 5' ggcggcggcggctccggtggtggtggatccGAAGTGAARSTTGAGGAGTC 3' 
HB16 5' ggcggcggcggctccggtggtggtggatccCAGGTTACTCTRAAAGWGTSTG 3' 
HB17 5' ggcggcggcggctccggtggtggtggatccCAGGTCCAACTVCAGCARCC 3' 
HB18 5' ggcggcggcggctccggtggtggtggatccGATGTGAACTTGGAAGTGTC 3' 
HB19 5’ ggcggcggcggctccggtggtggtggatccGAGGTGAAGGTCATCGAGTC 3'
Variable Heavy chain forward primers
HF1 5' ggaattcggcccccgaggcCGAGGAAACGGTGACCGTGGT 3’
HF2 5' ggaattcggcccccgaggcCGAGGAGACTGTGAGAGTGGT 3'
HF3 5' ggaattcggcccccgaggcCGCAGAGACAGTGACCAGAGT 3'
HF4 5' ggaattcggcccccgaggcCGAGGAGACGGTGACTGAGGT 3'
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2.4.10.3.2 Components and conditions fo r  PCR amplification o f  Vu and Vi. 
gene sequences
The PCR's were set up as follows using cDNA and the appropriate primers for 
either light or heavy chain amplification.
Component Stock Concentration Concentration in S0(j.l
Back Primers Varied 0.025nmol per reaction
Forward Primers Varied 0.025nmol per reaction
dNTP lOmM ImM
10X Buffer (incl. MgCl2) 10X IX
Template cDNA 2 |il per reaction
Ultrapure H20 to 50 nl
Taq polymerase 1 U nl"1 5 U per reaction
The PCR was carried out using the following conditions.
Step 1: 94°C X 5min
Step 2: 72°C X Hold (Add Taq enzyme for a Hot Start')
Step 3: 94°C X lmin
Step 4: 63°C X 30sec
Step 5: 58°C X 50sec
Step 6: 72°C X lmin
Repeat steps 3-6 for 8 cycles
Step 7: 94°C X lmin
Step 8: 63°C X 30sec
Step 9: 72°C X lmin
Repeat steps 7-9 for 30 cycles
Step 10: 4°C X Hold
2.4.10.4 Purification o f  amplified Vh and Vl fragments from  PCR products
PCR purification was carried out using the Wizard PCR prep DNA purification 
kit (Promega). An Atto AE-6100 gel electrophoresis system was used. The PCR 
product was run on a 1-2% (w/v) low melt agarose gel (Promega) containing 0.5 
|jg ml"1 ethidium bromide for approximately 2h at 50V. The 400bp fragment was
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excised from the gel using a clean scalpel blade and placed in a sterile microfuge 
tube. The gel was melted in a 70°C water bath and 1 ml of purification resin was 
added. The tube was mixed gently for 20s and the slurry was loaded into the 
barrel of a 5 ml syringe attached to a minicolumn. The slurry was pushed into the 
column followed by 2 ml of 80% (v/v) isopropanol to wash the resin. The 
column was centrifuged for 2min at 14,000rpm to remove any remaining alcohol 
from the resin. 50 (Jtl of sterile ultrapure water was added to the column and it 
was placed in a sterile microfuge tube and centrifuged for 20s to elute the DNA 
from the resin. The purified DNA was stored at -20°C until required.
2.4.10.5 Quantification o f  purified PCR products
The purified PCR products were electrophoresed on a 1% (w/v) agarose gel 
along with quantitative Molecular Weight Markers (Promega, lOObp Molecular 
Weight Markers). The 500bp fragment of this marker contains 150 ng of DNA 
and 50 ng of the other bands when 5 ftl is loaded onto the gel. Using these 
quantities as references, densitometry was carried out to determine the 
concentration of the purified PCR products.
2.4.10.6 Splice by overlap extension (SOE) PCR fo r  the combining o f purified 
Vh and Vi. fragments to Vhl construct
Stock concentrations of Vh and Vl PCR products at 10 ngfil1 were made for use 
in the SOE-PCR. This step joins the two 400bp products into a single 800bp 
fragment and then amplifies this construct.
2.4.10.6.1 SOE Primers
Sc back 5' ttactcgcggcccagccggccatggcggactacaaaG 3'
Sc forward 5' ggaattcggcccccgag 3’
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2.4.10.6.2 Components and conditions fo r  the SOE-PCR combining o f Vh and 
Vl PCR products
Component Stock Concentration Concentration in 50pl
10X Buffer (incl. MgCl2) 10X IX
dNTP lOmM 0.4mM
Ultrapure H20 to 50pi incl. all components
VH 1 0  ng pi' 1 0 . 2  ng pi' 1
Vl 1 0  ng jil' 1 0 . 2  ng pi' 1
scfor 0 . 2  nmol pi' 1 0.05 nmol per reaction
scback 0 . 2  nmol pi"1 0.05 nmol per reaction
Taq polymerase 1 U  p i 1 5 U  per reaction
The PCR was carried out using the following conditions.
Step 1: 94°C X lmin
Step 2: 45°C X 50sec
Step 3: 72°C X  lmin
Repeat steps 1-3 for 7 cycles
Step 4: 72°C X Hold
Add scfor and scback
Step 5: 94°C X lmin
Step 6 : 6 8 °C X 30sec
Step 7: 72°C X lmin
Repeat steps 5-7 for 25 cycles
Step 8 : 4°C X Hold
2.4.10.7 Preparation and purification o f  pAKlOO vector using Wizard miniprep 
system (Promega)
A single colony o f E. coli XLl-Blue cells containing pAKlOO (all pAK vectors 
were kindly donated by Prof. Andreas Pluckthun, University o f Zurich, 
Switzerland, Figure 2.2) was inoculated into 5 ml o f 2xTY media containing 25 
pg ml’ 1 chloramphenicol and 30 pg ml' 1 tetracycline and left to incubate 
overnight at 37°C. The bacterial cells were pelleted by centrifugation for 5 min at 
4,000rpm and the supernatant was discarded. The pellet was completely
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resuspended in 250 p.1 o f cell resuspension solution and an equal volume of cell 
lysis solution was added. The solution was mixed by inversion and incubated 
until the solution cleared, (3-5min). 10 |_tl of alkaline protease solution was added 
to the solution followed by a 5min incubation and 350 |j.I of neutralisation 
solution. The solution was then centrifuged at 14,000rpm for 10 min. The clear 
solution was transferred to a spin column and centrifuged at 14,000rpm for ) 
min. The column was firstly washed wilh 750 |il of column wash solution 
followed by a wash using 250 |il o f the wash solution. The DNA was eluted from 
the spin column using 1 0 0  [il of "nuclease-free" water by centrifugation at 
14,000rpm for 1 min and stored at -20°C until required.
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S fil S fil
Figure 2 .2: The pAKlOO phagemid vector is illustrated. Replication in E. coli is 
via the Col E l ori. Resistance is via the cam (chloamphenicol) and tet 
(tetracycline) resistance genes. For phage packaging, pAKlOO carries the 
intrinsic region from f l  phage. Directional insertion of light and heavy chain 
genes ligated to produce SOE product is via the Sfil restriction enzyme sites, 
which are downstream from the Lac promoter/operator and the pelB leader 
sequence. Downstream o f the SOE insertion position is the glLl, for phage 
surface expression o f scFv fragments.
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2.4.10.8 Digestion o f SOE-PCR products andpAKlOO using the restriction 
enzyme Sfil
S//1 is a restriction enzyme derived from Streptomyces fimbriatus that recognises 
a 4bp sequence on either side o f the position where it cuts DNA.
▼
5' GGCCNNNN NGGCC3'
3' CCGG N^NNNN CCGG 5'
The advantage o f using this enzyme is the fact that it will only cut if  it has two 
sites to restrict simultaneously and it will not self ligate due to the random bases 
contained in the actual restriction site.
2.4.10.8.1 Components and conditions fo r S fil digestion o f Vhl constructs and 
plasmid vectors
Component Stock Concentration Concentration in 20|il
NEB Buffer 2 10X IX
BSA 100X IX
Sfil 20U (il' 1 20U per reaction
The purified DNA samples were then added. For the V hl, the rest o f the reaction 
volume, usually 20|j.l, was made with the purified product of the SOE-PCR. The 
pAKlOO plasmid D N A  10 Ul was restricted in a volume of 50 fil with the rest of 
the volume being sterile ultrapure water.
The reactions were incubated overnight at 50°C and visualised on a 2% (w/v) 
agarose gel which allowed the small change in number o f base pairs in the V hl 
construct to be seen.
2.4.10.9 Ligation o f S fil restricted Vhl construct into the Sfil restricted 
PAK100 plasmid
The ligation reaction was set up using a 2 fold excess o f vector over insert. The 
concentration o f the purified, restricted pAKlOO vector and V hl was estimated 
and the amounts required for the ligation were calculated using the following 
formula.
vector (ng) x insert (kb) . , , . - insert . *-------- --------------- —-  x required molar ratio o f --------- = insert (ng)
vector (kb) vector
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2.4.10.9.1 Components and conditions fo r  ligation o f S fil digested Vhl 
constructs and plasmid vectors
Component Stock Concentration Concentration in 15[il
T4 ligase (Boerinnger 1U n f 1 3U per reaction
Mannheim)
T4 ligase buffer 5X IX
Insert Varied X
Vector Varied X
Ultrapure water to 20[il
The reaction was incubated at 15°C overnight and visualised on a 1% (w/v) 
agarose gel.
2.4.10.10 Transformation o f  E. coli XLl-Blue supercompetant cells with 
pAKlOO vector containing the Vhl construct
Escherichia coli XLl-Blue supercompetant cells (Stratagene) were thawed on ice 
along with the supplied J3-mercaptoethanol. 1 0 0  (¿1 o f cells were aliquoted into 
chilled universals, one tube each for the transformation and one for the control 
transformation. 1.7 |xl o f p-mercaptoethanol was added to each 100 |il o f cells 
and they were incubated on ice for 1 0  min with a gentle swirling every 2  min. 15 
(j.1 o f the ligation mixture produced in section 2.4.10.9.1 was added to the tube 
and left on ice for 30min, followed by a heat pulse at 42°C o f 50s and a further 
ice incubation o f 2min. At this stage 900 pi o f pre-heated SOC medium was 
added to each tube and incubated at 37°C for lh. The cells were then plated and 
titred on 2xTY agar supplemented with 1% (w/v) glucose, 25 jxg ml' 1 
chloramphenicol and 50 |ig ml' 1 tetracycline. The control reaction was plated as 
per the manufacturer's instructions. The stock plates were scraped and the cells 
were mixed with sterile 80% (v/v) glycerol to a final concentration o f 15% (v/v), 
flash frozen and stored at -80°C until required.
2.4.10.11 Rescue o f  phagemidparticles; Krebber protocol
50 ml o f 2xTY media supplemented with 1% (w/v) glucose and 25 |o.g ml' 1 
chloramphenicol was in inoculated with 1 0 0  pi o f the glycerol library stock
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(section 2.4.10.10) and incubated at 37°C with shaking until the optical density at 
600nm (O.D.6oonm) reached 0.5. The culture was then allowed to sit at 37°C for 
10min.VCSM13 helper phage (approximately 10ncfu) and 25 pi of 1M 
isopropyl-P-D-thiogalactopyranoside (IPTG) were added to the culture and 
incubated at 37°C for 15min. The culture was then diluted into 100 ml of 2xTY 
media supplemented with 1% (v/v) glucose, 25 |ig ml' 1 chloramphenicol and 
0.5mM IPTG. The culture was then shaken for 2h at 26°C. At this point the 30 (tl 
ml' 1 of kanamycin was added and the culture was returned to 26°C and left 
overnight with shaking. The phage particles were present in the culture 
supernatant.
2.4.10.12 PEG/NaCl precipitation and concentration of phage particles
The culture supernatant from section 2.4.10.11 was transferred into a sterile 
Sorvall tube and centrifuged at 10,000rpm and 4°C for lOmin. 30 ml of 
PEG/NaCl was added to the supernatant, mixed and incubated at 4°C for at least 
lh. The mixture was centrifuged at 10,000rpm and 4°C for 30min and the pellet 
was resuspended in 40 ml of sterile ultrapure (u.p.) water and 8  ml of PEG/NaCl 
was added and left on ice for 20min. The mixture was centrifuged at 10,000rpm 
and 4°C for 20min. The supernatant was removed and the pellet was 
recentrifuged for lOmin. All remaining liquid was removed and the pellet was 
suspended in 2 ml of sterile PBS. This was centrifuged at 4,000rpm and 4°C for 
10mm to remove any bacterial debris. This was stored at 4°C and used within a 
week.
2.4.10.13 Titre o f phage particles
A single colony of E. coli XLl-Blue cells was inoculated into 4 ml of 2xTY with 
50 fig ml"1 tetracycline and left to grow overnight at 37°C with shaking. The 
culture was diluted 1/100 (50 pi in 5 ml) into the same media and incubated until 
the O.D.6oonm reached 0.5. At this point the culture was left at 37°C for 15min 
without shaking. Serial dilutions of the phage particles were made using this 
culture, (10 MO'10) and left to infect the cells for 30min at 37°C without shaking. 
100 |il of each dilution was then spread plated on 2xTY agar containing 1%
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(w/v) glucose and 25 [Xg ml' 1 chloramphenicol and incubated overnight at 37°C 
and the colony forming units were counted.
2.4.10.14 Biopanning of phagemid library using immunotubes
Nunc immunotubes were coated with 500 fil of a drug conjugate at an 
appropriate dilution in PBS at 4°C overnight. The tubes were washed 4 times 
with PBST and 4 times with PBS. The tubes were then blocked completely with
4.5 ml of PBS containing 3% (w/v) marvel milk powder and incubated at 37°C 
for lh. The tubes were washed as before and 200 fll of the eluted phage was 
added along with 300 (il of PBS containing 3% (w/v) milk and left to bind at 
37°C for at least lh. The tubes were washed and the bound phage were eluted by 
adding 800 (il of 0.1M glycine/HCl, pH 2.2, and incubating for lOmin. The 
solution was then neutralised with 50 (il of 2M Tris/HCl, pH 8 .6 . 20 fil of the 
eluted phage was used to titre the phage (Section 2.4.10.13) and the rest of the 
phage were re-infected into XLl-Blue E. coli cells (Section 2.4.10.15).
2.4.10.15 Re-infection of XLl-Blue E. coli cells with phage eluted after 
biopanning
A single colony of E. coli XLl-Blue cells was inoculated into 4 ml of 2xTY with 
50 |ig ml' 1 tetracycline and left to grow overnight at 37°C with shaking. The 
culture was diluted 1/100 (50 fil in 5 ml) into the same media and incubated until 
the O.D.6oonm reached 0.4. At this point the culture was left at 37°C for lOmin 
without shaking. 700 |ol of the eluted phage from section 2.4.10.14 was added to 
the cells and incubated at 37°C for 30min to allow for infection. The cells were 
centrifuged and the pellet was resuspended in 600 fi.1 of 2xTY media. The cells 
were then plated onto 2xTY/l% (w/v) glucose/25 fig ml' 1 chloramphenicol agar 
and incubated overnight at 37°C. The resulting colonies were scraped from the 
plates into 2xTY media, supplemented with 80% (v/v) glycerol to a final 
concentration of 15% and titred.
2.4.10.16 Rescue of phagemid particles in 96 well plate format for the purposes 
of screening
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96 individual colonies, from the plates used to titre the phage eluted from the 
immunotube, were each inoculated into 150 pi of 2xTY media supplemented 
with 1% (w/v) glucose and 25 pg ml' 1 chloramphenicol in a sterile 96 well plate 
and incubated overnight at 37°C with shaking. This was termed the masterplate. 
A replica plate was prepared using 180 pi per well of the above media into which 
20 pi from the masterplate was added. 30 pi of 80% (v/v) glycerol was added to 
the masterplate and this was stored at -20°C. The replica plate was incubated at 
37°C until the culture had become turbid (4-5h) and 25 pi of 2xTY media 
containing 1% (w/v) glucose, 25 pg ml' 1 chloramphenicol, 4.5 mM IPTG and 5 x 
109 VCSM13 helper phage per ml was added to each well. The plate was 
incubated at 37°C for 30min without shaking, followed by lh with agitation. The 
cells were pelleted by centrifugation and the media in the plates was replaced 
with 2xTY containing 1% (w/v) glucose, 25 pg ml' 1 chloramphenicol, 1.5mM 
IPTG and 30 pg ml' 1 kanamycin. The plates were left to produce phage particles 
overnight at 26°C. The plates were centrifuged to pellet the cells and the 
supernatant was used in further analysis (Section 2.4.10.17).
2.4.10.17 Non-competitive ELISA for the screening of phage particles fo r the 
presence o f antigen-specific binders
Nunc immunoplates were coated with a drug conjugate at a concentration 
between 2-20 pg ml' 1 in PBS and incubated overnight at 4°C. The plates were 
washed and blocked as previously described in section 2.4.7.1. Following 
washing, 50 pi of supernatant produced according to section 2.4.10.16 was added 
to the corresponding well of the ELISA plate along with 50 pi o f PBS/4% (w/v) 
milk and incubated at 37°C for lh. Commercial anti-fd bacteriophage polyclonal 
antibody was used at a dilution of 1/1000 in PBS/2% (w/v) milk, 100 pi per well, 
and incubated for lh at 37°C. This antibody was then detected with a HRP- 
conjugated goat anti-rabbit IgG antibody, 1/5000 dilution in PBS/2% (w/v) milk, 
100 pi per well, lh at 37°C. The HRP label was detected using OPD substrate 
and the absorbance read at 405nm after 30min incubation at room temperature. 
The reaction may also have been stopped using 25 pi of 2M H2 SO4 and read at 
492 nm.
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The methods are as described for the Krebber system with the following 
exceptions.
•  The host E. coli strain was TGI and the helper phage was M13K07 
(Strategene).
• The growth media was 2xTY supplemented with 2% (w/v) glucose.
•  The phagemid vector carried ampicillin resistance gene. This was used as the 
selection antibiotic.
•  The helper phage used were M13 K07.
•  TGI stocks were maintained on minimal agar.
•  PEG/NaCl precipitation was only used for the first round o f panning after 
that the culture supernatants were used.
2.4.11 Recombinant Antibody Procedures for the naive human Library
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2.4.11.1 Production and Purification of soluble scFv fragments with 
Immobilised Metal Affinity Chromatography (IMAC)
10 ml of 2xTY containing 2% (w/v) glucose and 100 pg ml'1 ampicillin was 
inoculated with TGI cells harbouring the specific phagemid and grown overnight 
at 30°C. This was diluted into 500 ml of 2xTY containing 0.1% (w/v) glucose 
and 100 pg ml'1 ampicillin and left to grow till the OD60o reached 0.9. 500 pi of 
1M IPTG was added and the culture was left for 4h. The culture was centrifuged 
and the pellet was resuspended gently in 10 ml of cold tris-EDTA-sucrose (TES). 
This was transferred to a cool universal tube and 15 ml of 20% (w/v) TES was 
added and left to incubate on ice for 30min. The solution was centrifuged at 
14,000rpm at 4°C for lOmin to pellet the cell debris.
1.6 ml of Ni-NTA metal affinity slurry (800 pi resin, Qiagen) was washed in 
wash buffer 2 and 50 pi of 1M MgCl2 and 200 pi of protease inhibitor cocktail 
(Roche) was added. The supernatant from the TES isolation above was added to 
the resin and the mixture was allowed to interact overnight at 4°C with gentle 
rotation. The resin was pelleted by centrifugation at 2,000rpm for 5min at 4°C 
and washed twice in 50 ml of wash buffer 2. The pellet was resuspended in 3 ml 
of wash buffer 1 and loaded into a plastic support column. The column was 
washed twice with 600 pi of wash buffer 2. 200 pi of the elution buffer was 
added to the column and the flow through was collected. 500 pi aliquots of the 
elution buffer were passed through the column. To remove imidazole from the 
solutions containing the scFv the fractions were passed through a NAP-5 column 
pre-equilibrated with 10 ml PBS. The majority of the scFv was seen in the first 
two fractions (1 ml) from the Ni-NTA column.
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3.1 Introduction
3.1.1 Trenbolone
17(3 - Trenbolone (TR, Figure 3.1) is a powerful synthetic steroidal androgen 
with a molecular weight o f 270.4g that is used as a growth promoter in cattle. It 
has been used to improve the feed conversion rate and carcass characteristics o f  
cattle destined for the human food chain (Phillips and Harwood, 1982). It can be 
used in on its own but when used in concert with an estrogenic compound the 
best results are obtained (O' Keefe, 1984).
OH
Figure 3.1 : Structure of the androgenic steroid, 17p -  trenbolone, (17p -  
hydroxyestra -4 ,9,  11 - triene - 3 -  one).
Trenbolone acetate (TBA) is rapidly hydrolysed to 17(3-trenbolone after 
administration to cattle (Schiffer etal., 2001). This metabolite, 170-trenbolone is 
the active form o f trenbolone acetate and is the main metabolite found in muscle 
and fat tissues o f implanted cows (van Ginkel et al., 1988). 17a-trenbolone is the 
other major metabolite and it is the main form found in liver and kidney tissues 
(van der Merwe and Pieterse, 1994). Both 17p-trenbolone and 17a-trenbolone 
have been found to be devoid o f genotoxic activity and are not thought tot be 
initiators o f cancer (Richold, 1988)
Like all steroids TR and TBA have been banned as growth promoters for use in 
cattle rearing within the European Union (van Ginkel et a l, 1988). The EU is not 
convinced o f the safety o f treating animals used for meat production with 
steroids to increase their weight gain. Insufficient information is available on the
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effects of these steroids on the consumer when they are ingested in meat 
products. Commercial growth-promoting treatments consisting of estrogens and 
androgens are available for sale and use in others parts of the world (Lange et al., 
2001). Trenbolone acetate is one of the six FDA permitted compounds used 
within the USA as a growth promoter. Meat coming from outside the EU must be 
tested for this compound, or its metabolites, and removal of such treated meat 
from the food chain in Europe is necessary. Each country is required to have a 
testing system in place to enforce the EU ban on the use of these growth 
promoters and so prevent the use of these substances and their subsequent 
incorporation into the food chain (Sawaya et al., 1998b).
3.1.2. D etection  o f  T R
Over the course of the past 30 years many assay systems have been developed 
for the detection of trenbolone acetate and its metabolites. Hoffmann and Oettel 
(1976), described a radioimmunoassay for the detection of trenbolone and 
trenbolone acetate in bovine tissue and plasma. A lengthy procedure was used to 
extract the free steroids in tissue to a buffer matrix. Any conjugated steroids 
remaining in the sample were subjected to an enzymatic deconjugation. The 
assay had a sensitivity o f 40pg for the detection of trenbolone and approximately 
70pg for the detection of trenbolone acetate in fat. TBA can only be found in the 
implantation site, and in the fat of the animal, making it a difficult compound to 
measure. TR was detected in the plasma at low nanogram levels up to 67 days 
after administration and, in general, the conjugated TR amounted to 
approximately 20% of the free TR. The analysis of 100 samples would require 
the input of one technician for 5 days. This testing level is far too low for any 
effective screening method.
In 1987 Meyer and Hoffmann described a microtitre plate-based enzyme 
immunoassay for the detection of trenbolone. Their paper described the pre­
treatment of the biological matrices, bile, urine, muscle, liver and faeces to 
extract trenbolone to be detected using the assay. Some of these extraction steps, 
while isolating the trenbolone, required considerable time to complete with some 
procedures using an 18h incubation in conjunction with organic extraction 
methods. The assay itself was very sensitive with an absolute detection limit of
S.'S
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lpg. However, the assay did require approximately 23h of incubations, so that 
each sample needed 3 days to complete the analysis from collection to result, 
van Ginkel et al. (1988) described an assay system that combined an 
immunoaffinity clean-up step with HPLC-TLC detection. This system analyses 
bovine urine for the presence of the metabolites of TBA. The samples were 
deconjugated enzymatically and passed through an anti-trenbolone 
immunoaffinity column. The TR-containing fractions were then extracted and 
applied to a HPLC column. The resulting fraction from the column containing 
the TR was then subjected to TLC and developed. This is a lengthy and 
complicated procedure that requires much sophisticated equipment and trained 
personnel. It does, however, have a detection limit of 1-2 ng ml'1 by on-line 
HPLC monitoring at 350 nm but the off-line TLC detection showed greater 
sensitivity with a detection limit of 0.5 ng ml' .
3.1 .3  A cceptab le residue lim its for  T R
The use of all steroid hormones in cattle is illegal within the EU so a confirmed 
positive result indicates that the animal was dosed. These drugs have a high 
potency and so are administered at low levels (Rodriguez et al., 1994). The 
present maximum residue level accepted by the FAO/WHO for TBA is 2 ng g 1 
(Sawaya et al., 1998a). Enzyme immunoassays have the capability to detect these 
low levels. They also have the advantage of being able to test samples in large 
batches. The HPLC-TLC method in section 3.1.2 can analyse 40 samples in 4h. 
ELISAs, depending on the exact format, can test up to 48 samples and standards, 
in duplicate, in as little as 1.5h. The type of analysis that is required must also be 
considered. There are conditions where a result for a single sample would be 
required as opposed to multiple sample analyses. The type of result required, the 
time allowed, the equipment required and the conditions under which the assay 
must be performed should all be considered when a choice of assay system is to 
be made (Turkes et al., 1981).
3.1 .4  C hoice o f  m atrix
Due to the numerous and diverse matrices that can be used to detect non- 
endogenous steroids within a bovine system each assay must be validated to
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ensure that any positive results are as a result of the detection of the target 
analyte. It is important that the false negative rate due to interference effects from 
the matrix in use is low and so any assay must be validated in the sample matrix 
to be used (Cooper e ta l,  1998). This is especially important when the lest matrix 
is to be used with little or no pre-treatment. Administered steroids have been 
found to persist longer in bile than in urine, thus implying that bile be chosen as 
the superior matrix for analysis (McEvoy et al., 1998).
Bile and faeces were determined to be the most appropriate matrices for the 
detection of trenbolone (Hewitt et al., 1993). Bile is also a liquid and so unlike 
solid matrices such as faeces, hair and eyeballs, which can retain high levels of 
steroid for analysis, it can be handled easily and quickly. This allows it to be 
used rapidly within any of the assay formats described in this chapter.
3.1 .4  E nzym e-L inked Im m unoS orb en t A ssay (ELISA ) Technology
Enzyme-linked immunosorbent assay was the form of enzymatic immunoassay 
used in this study. This format used a solid phase, an antibody and enzymes to 
create an assay system that can be used to detect amounts of free drug. The 
advantages of the microplate system are its simplicity, speed, ease of use and it 
can analyse up to 96 individual wells at the one time (van Weemen et al., 1979). 
Larger plate formats have also been developed allowing for even greater 
numbers of samples to be analysed (Roda et al., 2000). Two formats of 
heterogeneous competitive ELISAs have been developed. They have been 
designated a competitive assay and an inhibition format for ease of identification, 
(Figure 3.2).
The solid phase used is a 96 well immunoplate and, in all cases, a horse radish 
peroxidase (HRP) label is used for detection. Both of the formats are shown in 
Figure 3.2 and the exact protocol is described in section 2.4.7. The inhibitive 
assay begins with the coating of the drug on the wells of the plate. The 
adsorption of the small drug molecule, such as a steroid, can be very problematic 
and so a conjugate is used. The larger protein carrier facilitates a much more 
stable and even coating of the wells. The conjugates are absorbed to the wells 
during an incubation stage and any remaining uncoated sites on the plastic wells 
are blocked by a protein solution to prevent non-specific binding.
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The free drug solution (the sample or standard) and the specific antibody are 
added to the wells and allowed to reach binding equilibrium, (usually this will 
occur quickly and lh  at 37°C is sufficient time). In some assays the specific 
antibody may be labelled with an enzyme but if it is not a labelled secondary 
antibody that will recognise the idiotype of the specific antibody can be used. In 
either case the enzyme label is delected using a substrate that will change colour 
in the presence of the enzyme. The colour is then read using a 
spectrophotometric plate reader. The wells are washed to remove any unbound or 
loosely bound material between each of the steps described. This ensures that 
only the molecules bound to the plate remain in the well and arc involved in 
further binding or detection steps. The unbound fractions are removed and can 
not cause any interference.
The alternative format, designated competitive in this thesis, is also shown in 
Figure 3.2. Here the specific antibody is coated to the wells of the plate and 
blocked as described above. The free drug is then added along with a HRP- 
labelled drug conjugate. The two drugs then compete for binding to the 
immobilised antibody, equilibrium is reached and the unbound is removed. The 
amount of bound HRP is measured.
The HRP enzyme is detected using O-phenylenediamine dihydrochloride (OPD) 
substrate. This changes from a clear liquid to a yellow/orange colour in the 
presence of HRP. This colour can be read at either 450nm or 405nm as it 
contains two absorbance peaks. For the inhibitive and competitive ELISAs the 
substrate absorbance was read at 405nm. In both of these assay formats the 
amount of free drug present is inversely proportional to the absorbance. The 
maximum level of absorbance is seen at zero free drug concentration and it drops 
as the concentration of the sample or standard rises.
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Inhibitive ELISA C om petitive ELISA
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Figure 3.2 : Schematic representation o f the inhibitive and competitive ELISA 
formats. (1) represents the coating o f either the drug conjugate or the specific 
antibody to the plate. (2) shows the blocking o f the free areas o f the plastic of the 
immunoplates. (3) shows the reaction between the immobilised reagent, the 
sample and the competing substance, (labelled drug or specific antibody), while 
(4) shows the method o f detection for each of the assay types.
£  Drug-protein conjugate
O  Blocking protein
Enzyme-labelled anti-specific antibody
^  Free drug, (sample or standard) 
^  Drug enzyme conjugate 
Specific antibody
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3.2.1 Production and conjugation of trenbolone hapten
The reaction to convert trenbolone (TR) to the derivative TR-17-hemisuccinate 
(TR-17-HS, Figure 3.3) was carried out as described in section 2.4.1.1. The 
success o f the reaction was confirmed by nominal mass spectrometry. This 
showed the presence o f derivative with a weight o f 368 daltons, (See appendix 
B). This weight corresponds to that o f an alkalinated form o f TR-17-HS. This 
derivative was used to produce ovalbumin (OVA), bovine serum albumin (BSA), 
thyroglobulin (THY) and horse radish peroxidase (HRP) conjugates of 
trenbolone using both mixed anhydride and the NHS ester chemistries for use as 
immunogens and assay reagents. The chemistries used for each conjugate are 
listed below,
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3.2 Results
C onjugate Linking Chem istry
TR-17-HS-OVA Mixed anhydride
TR-17-HS-BSA Mixed anhydride
TR-17-HS-HRP Mixed anhydride
TR-17-HS-THY EDC/NHS
All the conjugates were investigated spectrophotometrically and the presence o f 
a peak at about 350nm was taken to confirm the presence o f the hapten bound to 
the proteins (Jansen et al., 1985). The proteins alone do not show this peak and 
therefore if  it present after the dialysis o f  the conjugate it must indicate the 
successful conjugation. Dialysis should remove all the unbound trenbolone 
derivative as it is to small to be retained by the dialysis tubing, MW cut-off 
lOkDa.
To test the suitability o f  the conjugates as immunogens the OVA and THY 
conjugates were used to immunise mice. 10 days after the immunisation the mice 
were bled. The sera were tested against a number o f conjugates and carrier 
proteins. The results showed that the OVA conjugates were not particularly good 
immunogens but the THY conjugates gave a much higher response and also one 
that was directed against the hapten and not the carrier protein, (Figure 3.4 and 
3.5). The anti-TR-17-HS-THY sera did not recognise the TR-17-HS-OVA
90
Chapter 3 : Anti-trenbolone polyclonal antibodies
conjugate although it recognised the other conjugates tested to some degree. This 
implies that the conjugation o f TR to OVA was not as successful as shown by the 
spectrophotometer analysis. The background response is high in this assay and 
that obscures some o f the other more specific responses. This problem may be 
overcome by continuing the immunisation protocol. TR-17-HS-THY was used in 
all subsequent immunisations.
Figure 3.3 : Structure o f trenbolone-17-hemisuccinate, the derivative used to 
link carriers to trenbolone.
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Serum Dilution (1/x)
Figure 3.4 : Specificity o f anti-TR-17-HS-OVA sera against various TR 
conjugates and carrier proteins. The antibodies show recognition of OVA and a 
slight response to THY. No specific response is seen towards TR.
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Figure 3.5 : Serum dilution of anti-TR-17-HS-THY antibody and it's specificity 
against various TR conjugates and carrier proteins. A response is seen against 
TR-THY and TR-BSA. There is also recognition of the THY carrier protein but it 
is much below the level seen for the conjugate.
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The immunisation schedule was followed as outlined in section 2.4.4.2. The two 
New Zealand White female rabbits were immunised and boosted with 1 ml of 
THY conjugate and the serum was collected at the completion of the protocol. 
The immunoglobulin fraction of the serum was isolated using SAS precipitation 
followed by protein G affinity chromatography. The absorbance of the eluted 
samples at 280nm was measured and used to estimate their protein content. 
Figure 3.6 shows the typical elution profile from the protein G column. As can be 
seen the majority of the bound protein eluted in fractions 1 - 8  and these fractions 
were pooled, dialysed and used as the reagents TRAbl and TRAb2 depending on 
the rabbit of origin. TRAbl was determined to have an IgG concentration of 4.76 
mg ml"1 by BCA assay and TRAb2 had a concentration of 6.59 mg ml'1.
The purity of the final samples was determined by running the crude serum, the 
SAS-purified and the affinity-purified fractions on SDS-PAGE. Each of the 
samples was diluted to approximately 1 mg ml"1 before loading onto the gel. 
SDS-PAGE is a technique that dissociates any protein chains that are held 
together by disulphide bridges and it also coals the proteins with a uniform 
negative charge so that proteins can be analysed with respect to their component 
chains and their molecular weight. The results can be seen in Figure 3.7. The 
heavy and light chains of the antibody are visible at approximately 50 and 
25kDa, respectively.
3.2.2 Polyclonal antibody production and characterisation
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Fraction number
i .6  : Isolation o f immunoglobulin fraction ofTRAbl and TRAb2 from a I 
ml Protein G affinity column using 0.1M glycine-HCl, pH 2.2. 1 ml fractions 
■were collected and fractions 1 - 8 contained measuable amounts o f protein.
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Figure 3.7 : Coomassie stained SDS-PAGE gel with protein markers in lane 1 
and 8. Lane 2: Serum from rabbit I, lane 3: dialysed SAS cut of rabbit 1 serum, 
lane 4: protein G affinity-purified IgG fraction fl'RAbl) and lane 5: serum from 
rabbit 2, lane 7 ; dialysed SAS cut of rabbit 2 serum, lane (: protein G affmity- 
purified IgG fraction (TRAb2).
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3.2.3 Optimisation of parameters for the inhibitive and competitive ELISAs 
for the detection o f free TR
The optimisation of the use of these antibodies and conjugates in ELISA systems 
was carried out. Competitive and inhibitive formats were developed. These are 
described in section 3.1.4.
The non-competitive checkerboard ELISAs were carried out as described in 
sections 2.4.7 to determine the optimal coating concentration either of TR-17- 
HS-BSA conjugate or anti-TR antibody, depending on the assay format, and the 
optimal concentration for the competing solution. A range of different coating 
concentrations was run with differing amounts of competing reagent. The lowest 
coating concentration that showed a steep dose response curve with strong 
measurable signals in the assay was chosen as the optimum. The optimal 
antibody dilution, (inhibitive ELISA) or HRP-conjugate dilution (competitive 
ELISA) was also elucidated from the results of these assays. Using the dose 
response curve generated using the optimal coating concentration, the amount of 
either antibody or TR-HRP conjugate that gave approximately 70% of the 
maximum signal of that curve were used in further assays. An example of the 
results of these assays is shown in Figure 3.8. The coating and competing 
concentrations used in the ELISAs are listed in Table 3.1.
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Antibody Dilution (1/x)
Figure 3.8 : Non-competitive checkerboard ELISA for the determination of 
optimum TR-HS-BSA conjugate coating concentration and optimum TRAb2 
antibody dilution to be used in the inhibitive ELISA.
Table 3.1 : Optimal coating and competing concentrations for competitive and 
inhibitive ELISAs using both anti-TR polyclonal antibodies.
Assay Coating Solution Competing Solution
TRAbl Inhibitive 0.64 pg ml'1 TR-HS-BSA 0,79 pg ml'1 TRAbl
TRAbl Competitive 4.76 jig ml'1 TRAbl 0.10 |jg ml'1 TR-HS-HRP
TRAb2 Inhibitive 1.29 pg ml'1 TR-HS-BSA 1.98 pg ml'1 TRAb2
TRAb2 Competitive 6.59 pg ml"1 TRAb2 0.10 pg ml*1 TR-HS-HRP
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3.2.3.1 Range of detection of free TR in competitive and inhibitive ELIS As 
using TRAbl and TRAb2 polyclonal antibodies
A wide range of concentration standards for TR (0.38 - 100,000 ng m l1) was 
prepared in PBS/2% (v/v) EtOH. These were run in the optimised ELIS As using 
the parameters described in section 3.2.3. From the resulting dose response curve 
a detection range was selected that included the most sensitive part of the curvc, 
the pseudo-linear portion and approximately two points either side of this 
section. The ranges chosen were 0.76 - 781 ng ml' for the competitive assay and 
a range of 3.05 - 3,125 ng ml"1 for the inhibitive assay. The results for the 
competitive format are shown, as an example of these assays, in Figure 3.9. This 
section of the dose response curve gives a good approximation to the 4-parameter 
curve-fitting model.
Chapter 3 : Anti-trenbolone polyclonal antibodies
TR Concentration (ng ml'1)
Figure 3.9 : Determination of range of detection o f TR using either TRAbl or 
TRAb2 in the competitive ELISA format. Standards ranging from 0.38 - 100,000 
ng m l1 were run in the ELISA using the optimised parameters fo r  the assay. 
Black lines bound the pseudo-linear portion, chosen as the range for the ELISA, 
on the graph.
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3.2.4 Competitive and Inhibitive ELISAs using pab TRAbl and TRAb2 for 
the detection of TR in PBS/2 % (v/v) EtOH
A range of standards of TR was prepared as described in section 3.2.3.1. The 
standards were added to a TR-17-HS-BSA-coated plate at 50 pi per well together 
with anti-TR pab (TRAbl or TRAb2) at the required dilution with the inhibitive 
assay format. After the incubation and washing steps had been completed HRP- 
labelled anti-rabbit pab was added to the plates. In the competitive ELISA format 
the standards and the appropriate TR-17-HS-HRP dilution were added to an anti- 
TR pab-coated plate. After washing, the bound HRP conjugate was detected in 
both assays as specified previously, (section 2.4.7).
For intra-day assay variation studies each concentration standard was assayed 5 
times on a single day and the mean absorbance was plotted against the TR 
concentration. Figures 3.10, 3.11, 3.14 and 3.15 show the intra-day assay results 
for the two assay formats using both antibodies. The accompanying tables 3.2, 
3.3, 3.6 and 3.7 show the means, the standard deviations, the coefficients of 
variation (C.V.'s) and the percentage accuracy of the standard curve using 4- 
parameter curve fitting.
The inter-day assay variation was determined by carrying out the assay over 5 
separate days. The absorbance of each of the standards was normalised by 
dividing the mean absorbance value for each TR concentration by the mean value 
for the day's zero concentration value, (A/Ao). The A/Ao value was compared 
across the 5 days. Figures 3.12, 3.13, 3.16 and 3.17 show the inter-day assays for 
both assay formats using both antibodies. The accompanying tables 3.4, 3.5, 3.8 
and 3.9 show the means, the standard deviations, the coefficients of variation 
(C.V.'s) and the percentage accuracy of the standard curve using 4-parameter 
curve fitting.
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Figure 3.10 : Intra-day studies on inhibitive ELISAs using the anti-TR Pab, 
TRAbl for the detection of free TR in PBS/2% (v/v) EtOH. The inhibition assay 
uses TR-I7-HS-BSA conjugate coated at 0.644 jug m l1 and the antibody at a 
dilution o f0.793 fig m l1.
Table 3.2 : Intra-day CVs and accuracies for TRAbl inhibition ELISA in PBS. 
Five sets of eleven standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
T renbolone C alculated M ean C oefficients o f Accuracy,
C oncentration ± SD, variation (CVs), (% )
f (ng ml'1) (A bs) (% )
3125.00 0.190 ± 0.007 3.57 94.35
1562.50 0.224 ± 0.006 2.67 97.66
781.25 0.266 ± 0.010 3.71 106.24
390.63 0.327 ± 0.009 2.77 101.62
195.31 0.382 ± 0.015 3.96 110.49
97.66 0.470 ± 0.008 1.68 80.86
48.83 0.520 ± 0.016 3.14 78.97
24.41 0.526 ± 0.012 2.29 142.85
12.21 0.566 ± 0.004 0.76 124.48
6.10 0.583 ± 0.023 3.95 149.65
3.05 0.624 ± 0.020 3.26 2.89
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Figure 3.11 : Intra-day studies on competitive ELISAs using the anti-TR Pab, 
TRAbl for the detection of free TR in PBS/2% (v/v) EtOH. The plates were 
coated with 4.76 pg  m l1 solution of TRAbl and the conjugate TR-I7-HS-HRP 
was used at 0.10 fig m t1.
Table 3.3 : Intra-day CVs and accuracies for TRAbl competition ELISA in 
PBS/2% (v/v) EtOH. Five sets o f eleven standards were analysed on the same 
day and the CVs were calculated. A four-parameter equation was used to fit a 
curve to the data using BIAevaluation software and its percentage accuracy was 
calculated.
Trenbolone  
C oncentration  
(ng ml ')
C alculated M ean  
= SD ,
(A bs)
C oefficients o f  
variation (C V s), 
(% )
A ccuracy, 
(% ) ‘
781.25 0.089 ± 0.002 2.56 88.78
390.63 0.104 ± 0.003 2.63 97.28
195.31 0.121 ± 0.010 7.91 113.83
97.66 0.154 ± 0.007 4.73 101.97
48.83 0.195 ± 0.006 2.92 96.09
24.41 0.232 ± 0.007 2.94 107.30
12.21 0.293 ± 0.004 1.27 90.99
6.10 0.344 ± 0.009 2.51 90.57
3.05 0.372 ± 0.007 1.87 122.66
1.53 0.433 ± 0.005 1.19 94.08
0.76 0.467 ± 0.017 3.67 95.50
101
Chapter 3: Anti-txenbolone polyclonal antibodies
Trenbolone Cone, (ng ml'1)
Figure 3.12 : Inter-day studies on inhibitive ELISAs using the anti-TR Pab, 
TRAbl for the detection of free TR in PBS/2% (v/v) EtOH. The inhibition assay 
uses TR-17-HS-BSA conjugate coated at 0.644 fig m t1 and the antibody at a 
dilution ofO. 793 fig m t1.
Table 3.4 : Inter-day CVs and accuracies for TRAbl inhibition ELISA in PBS. 
Five sets of eleven standards were analysed over five different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Trenbolone C alculated M ean C oefficients o f A ccuracy,
C oncentration dz SD variation (% )
1 (ng m l 1) <A/A«> (C V s), (%)
3125.00 0.271 ± 0.023 8.57 85.75
1562.50 0.287 ± 0.008 2.71 121.08
781.25 0.344 ± 0.025 7.16 98.38
390.63 0.403 ± 0.034 8.54 99.04
195.31 0.480 ± 0.045 9.47 96.80
97,66 0.567 ± 0.040 7.10 94.59
48.83 0.639 ± 0.031 4.84 106.43
24.41 0.718 ± 0.053 7.40 109.57
12.21 0.803 ± 0.018 2.28 95.09
6.10 0.870 ± 0.042 4.87 80.42
3.05 0.887 ± 0.067 7.51 120.67
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Figure 3.13 : Inter-day studies on competitive ELISAs using the anti-TR Pab, 
TRAbl for the detection of free TR in PBS/2% (v/v) EtOH. The plates were 
coated with 4.76 pg m t1 solution o f TRAbl and the conjugate TR-17-HS-HRP 
was used at 0.10 pg m t1.
Table 3.5 : Inter-day CVs and accuracies for TRAbl competition ELISA in 
PBS/2% (v/v) EtOH. Five sets o f eleven standards were analysed over five 
different days and the CVs were calculated. A four-parameter equation was used 
to fit a curve to the data using BIAevaluation software and its percentage 
accuracy was calculated.
Trenbolone Calculated Mean Coefficients of Accuracy,
Concentration ± SD, variation (% )
(ng m l1) (A/A0) (CVs), (%)
781.25 0.203 ± 0.025 12.32 88.94
390.63 0.224 ± 0.022 9.76 105.39
195.31 0.264 ± 0.026 9.67 102.92
97.66 0.322 ± 0.020 6.15 97.83
48.83 0.378 ± 0.031 8.21 112.29
24.41 0.489 ± 0.028 5.82 91.07
12.21 0.574 ± 0.018 3.11 99.14
6.10 0.665 ± 0.024 3.61 103.26
3.05 0.746 ± 0.020 2.62 110.91
1.53 0.841 ±  0.013 1.54 93.65
0.76 0.889 ± 0.039 4.40 105.56
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Figure 3.14 : Intra-day studies on inhibitive ELISAs using the anti-TR Pab, 
TRAb2 for the detection of free TR in PBS/2% (v/yj EtOH. The inhibition assay 
uses TR-17-HS-BSA conjugate coated at 1.289 pg m l1 and the antibody at a 
dilution o f 1.983 fjg m l1.
Table 3.6 : Intra-day CVs and accuracies for TRAb2 inhibition ELISA in PBS. 
Five sets o f eleven standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Trenbolone Calculated Mean Coefficients of Accuracy,
Concentration ± SD, variation <%)
{ng m l1) (Abs) (CVs), (%)
3125.00 0.289 ± 0.010 3.59 82.41
1562.50 0.312 ± 0.007 2.26 115.88
781.25 0.364 ± 0.013 3.63 114.45
390.63 0.429 ± 0.008 1.91 103.52
195.31 0.502 ± 0.017 3.43 90.05
97.66 0.573 ± 0.022 3.87 75.99
48.83 0.604 ± 0.028 4.59 100.44
24.41 0.626 ± 0.003 0.46 145.58
12.21 0.681 ± 0.016 2.41 110.79
6.10 0.719 ± 0.020 2.71 85.50
3.05 0.742 ± 0.006 0.86 74.42
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Figure 3.15 : Intra-day studies on competitive ELISAs using the anti-TR Pab, 
TRAb2 for the detection of free TR in PBS/2% (v/v) EtOH. The plates were 
coated with 6.59 p g  m t1 solution of TRAb2 and the conjugate TR-17-HS-HRP 
was used at 0.10 pgmT1.
Table 3.7 : Intra-day CVs and accuracies for TRAb2 competition ELISA in 
PBS/2% (v/v) EtOH. Five sets o f eleven standards were analysed on the same 
day and the CVs were calculated. A four-parameter equation was used to fit a 
curve to the data using BIAevaluation software and its percentage accuracy was 
calculated.
Trenbolone Calculated Mean Coefficients of Accuracy,
Concentration 1 ± SD variation (% )
(ng ml*1) (Abs) (CVs), (%)
781.25 0.122 ± 0.005 4.44 96.69
390.63 0.131 ± 0.004 2.69 120.47
195.31 0.159 ± 0.005 3.00 90.15
97.66 0.187 ± 0.004 2.35 98.23
48.83 0.224 ± 0.005 2.16 105.81
24.41 0.289 ± 0.007 2.25 92.27
12.21 0.342 ± 0.003 0.96 102.79
6.10 0.397 ± 0.006 1.46 113.80
3.05 0.481 ± 0.009 1.79 85.12
1.53 0.517 ± 0.010 1.90 101.22
0.76 0.552 ± 0.012 2.14 106.56
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Figure 3.16 : Inter-day studies on inhibitive ELISAs using the anti-TR Pab, 
TRAb2 for the detection o f free TR in PBS/2% (v/vj EtOH. The inhibition assay 
uses TR-17-HS-BSA conjugate coated at 1.289 fjg m t1 and the antibody at a 
dilution o f1.983 fjg m t1.
Table 3.8 : Inter-day CVs and accuracies for TRAb2 inhibition ELISA in PBS. 
Five sets o f eleven standards were analysed over five different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Trenbolone Calculated M ean Coefficients of Accuracy,
Concentration z z SD, variation (% )
(ng m l'1) (A/A,,) (CVs), (% )
3125.00 0.309 ± 0.043 14.04 95.17
1562.50 0.353 ± 0.048 13.67 102.05
781.25 0.408 ± 0.047 11.53 105.27
390.63 0.474 ± 0.048 10.09 103.41
195.31 0.546 ± 0.057 10.49 102.46
97.66 0.647 ± 0.046 7.12 76.40
48.83 0.665 ± 0.065 9.80 127.04
24.41 0.751 ± 0.063 8.45 98.62
12.21 0.802 ± 0.052 6.47 102.25
6.10 0.851 ± 0.052 6.14 95.02
3.05 0.883 ± 0.052 5.94 101.47
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Figure 3.17 : Inter-day studies on competitive EIJSAs using the anti-TR Pab, 
TRAb2 for the detection of free TR in PBS/2% (v/v) EtOH. The plates were 
coated with 6.59 pg  m t1 solution o f TRAb2 and the conjugate TR-17-HS-HRP 
was used at 0.10 jug m l1.
Table 3.9 : Inter-day CVs and accuracies for TRAb2 competition ELISA in 
PBS/2% (v/v) EtOH. Five sets o f eleven standards were analysed over five 
different days and the CVs were calculated. A  four-parameter equation was used 
to fit a curve to the data using BIAevaluation software and its percentage 
accuracy was calculated.
Trenbolone Calculated M ean Coefficients of Accuracy,
C oncentration 4- SD, variation (% )
(ng ml'1) (A/Au) (CVs), (% )
781.25 0.181 ± 0.015 8.38 87.71
390.63 0.202 ± 0.011 5.67 106.18
195.31 0.240 ± 0.012 5.18 106.25
97.66 0.290 ± 0.004 1.42 104.50
48.83 0.356 ± 0.009 2.42 100.66
24.41 0.452 ± 0.016 3.60 85.12
12.21 0.513 ± 0.028 5.37 105.79
6.10 0.611 ± 0.030 4.98 101.88
3.05 0.709 ± 0.033 4.60 98.43
1.53 0.805 ± 0.026 3.18 93.27
0.76 0.877 ± 0.028 3.17 98.30
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3.2.5 Cross Reactivities of antibodies, TRAbl and TRAb2
Both antibodies were tested for their ability to recognise other related steroid 
compounds. The assays were carried out as described in section 2.4.7.8. Table
3.10 shows the percentage cross reactivities that were found.
Table 3.10 : Cross reactivity o f the polyclonal antisera to TR and other 
structurally related steroid hormones and cross-reacting compounds in inhibition 
ELISAs. Percentage cross reactivity was calculated as (IC5o[EE]/IC5o[test 
compound])* 100.
Compounds Tested TRAbl TRAb2
% Cross Reactivity“'
Trenbolone 100.00 100.00
EE <0.10 <0.10
Diethyl stilbestrol <0.10 <0.10
a-Estradiol <0.10 <0.10
ß-Estradiol <0.50 <0.50
Estrone <0.50 <0.50
Norgestrol 1.00 <0.50
19-Nortestosterone 4.00 2.00
Methyl Testosterone <0.50 <0.50
Zeranol <0.10 <0.10
Norethisterone 1.67 0.67
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Both ELISA formats were used to detect free TR in spiked bile samples. The bile 
was prepared as described in section 2.4.7.2 and the TR standards were prepared 
using the bile as the diluent. The spiked bile was diluted with an equal volume of 
PBS before being applied to the assay plate. In the competitive assay using bile 
as a diluent, the TR-17-HS-HRP conjugate was used at a 1/10000 (0.5 (ig ml'1) 
instead of 1/50000 (0.1 fig ml"1). The signals measured when the lower 
concentration of the HRP conjugate was used were very low and so to enhance 
the measurable signals the amount of TR-HRP conjugate used was increased. 
Figure 3.18 shows the different curves obtained when the two concentrations 
were used. The steeper dose response curve seen with the higher concentration of 
TR-HRP will give a more accurate assay and so it was chosen as the better 
dilution to use in the assay. The rest of the ELISA protocols were as previously 
described in Table 3.1.
Intra-day and inter-day assay variations were investigated as described for the 
ELISAs using PBS/2% (v/v) EtOH as diluent. Figures 3.19, 3.20, 3.23 and 3.24 
show the intra-assay variations along with tables 3.11, 3.12, 3.15 and 3.16 The 
inter-assay variations are shown in Figures 3.21, 3.22, 3.25 and 3.26 and the 
accompanying tables 3.13, 3.14, 3.17 and 3.18.
3.2.6 Detection of TR in Spiked Bile Samples
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Trenbolone concentration (ng mf')
Figure 3.18 : Effect o f raising the amount o f competing TR-HRP conjugate when 
bile is used as the assay diluent. The greater concentration o f conjugate 
(1/10000, 0.5 pg  m tl)  shows a  steeper curve and so a greater change in 
absorbance with changes in concentration.
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Figure 3.19 : Intra-day studies on inhibitive ELISAs using the anti-TR Pab, 
TRAbl for the detection of free TR in bile. The inhibition assay uses TR-17-HS- 
BSA conjugate coated at 0.644 jug m f1 and the antibody at a dilution of 0.793 jig 
m f1.
Table 3.11 : Intra-day CVs and accuracies for TRAbl inhibition ELISA in bile. 
Five sets o f eleven standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Trenbolone Calculated Mean Coefficients of Accuracy»
Concentration a- SO variation (% )
(ng m l1) (Abs) (CVs), (%)
3125.00 0.347 ± 0.019 5.38 103.50
1562.50 0.389 ± 0.012 3.14 93.64
781.25 0.423 ± 0.017 4.04 102.31
390.63 0.465 ± 0.011 2.30 92.14
195.31 0.493 ± 0.018 3.70 103.01
97.66 0.512 ± 0.017 3.31 132.98
48.83 0.549 ± 0.016 2.95 93.19
24.41 0.578 ± 0.014 2.43 52.36
12.21 0.582 ± 0.016 2.73 85.36
6.10 0.577 ± 0.025 4.30 224.14
3.05 0.600 ± 0.026 4.35 67.81
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Figure 3.20 : Intra-day studies on competitive ELISAs using the anti-TR Pab, 
TRAbl for the detection of free TR in bile. The plates were coated with 4.76 pg  
m t1 solution o f TRAbl cmd the conjugate TR-17-HS-HRP was used at 0.5pg m t1.
Table 3.12 : Intra-day CVs and accuracies for TRAbl competition ELISA in 
bile. Five sets of eleven standards were analysed on the same day and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Trenbolone Calculated M ean Coefficients of Accuracy,
C oncentration dr SD, variation (% )
(ng m l1) (Abs) (CVs), (% )
781.25 0.098 ± 0.003 3.10 98.49
390.63 0.116 ± 0.004 3.20 100.51
195.31 0.141 ± 0.004 2.98 96.51
97.66 0.166 ± 0.003 1.59 102.91
48.83 0.192 ± 0.005 2.40 105.67
24.41 0.223 ± 0.004 1.75 83.84
12.21 0.239 ± 0.006 2.42 86.84
6.10 0.243 ± 0.007 2.77 139.22
3.05 0.256 ± 0.002 0.59 99.09
1.53 0.259 ± 0.005 1.79 144.81
0.76 0.269 ± 0.006 2.38 0.00
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Figure 3.21 : Inter-day studies on inhibitive ELISAs using the anti-TR Pab, 
TRAbl for the detection of free TR in bile. The inhibition assay uses TR-17-HS- 
BSA conjugate coated at 0.644 jug m t1 and the antibody at a dilution of 0.793 fig 
m t1.
Table 3.13 : Inter-day CVs and accuracies for TRAbl inhibition ELISA in bile. 
Five sets o f  eleven standards were analysed over five different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
T rcobolone C alculated M ean C oefficients o f Accuracy,
C oncentration SD variation (% )
(ng n i l 1) (A/Au) (C V s), (% )
3125.00 0.518 ± 0.097 18.72 102.32
1562.50 0.572 ± 0.071 12.38 89.16
781.25 0.608 ± 0.109 17.85 112.95
390.63 0.687 ± 0.109 15.80 91.96
195.31 0.747 ± 0.108 14.51 96.84
97.66 0.803 ± 0.126 15.68 104.36
48.83 0.866 ± 0.115 13.32 96.29
24.41 0.925 ± 0.092 9.96 78.90
12.21 0.947 ± 0.107 11.27 103.74
6.10 0.969 ± 0.078 8.03 129.23
3.05 1.012 ± 0.066 6.51 59.87
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Figure 3.22 : Inter-day studies on competitive ELISAs using the anti-TR Pah, 
TRAbl for the detection o f free TR in bile. The plates were coated with 4.76 pg  
m t1 solution o f TRAbl and the conjugate TR-I7-HS-HRP was used at 0.5/jg m l1.
Table 3.14 : Inter-day CVs and accuracies for TRAbl competition ELISA in 
bile. Five sets o f eleven standards were analysed over five different days and the 
CVs were calculated. A four-parameter equation was used to fit a curve to the 
data using BIAevaluation software and its percentage accuracy was calculated.
T mibolone Calculated Mean Coefficients of Accuracy, ]
Concentration SD variation (% )
(ng n il1) (A/Ad) (CVs), (%)
781.25 0.365 ± 0.021 5.65 97.31
390.63 0.430 ± 0.016 3.77 106.48
195.31 0.536 ± 0.017 3.24 96.76
97.66 0.636 ± 0.024 3.69 98.44
48.83 0.727 ± 0.029 3.97 105.66
24.41 0.826 ± 0.046 5.52 96.69
12.21 0.897 ± 0.044 4.89 92.77
6.10 0.934 ± 0.037 3.92 110.24
3.05 0.972 ± 0.027 2.74 102.62
1.53 0.995 ± 0.037 3.70 98.43
0.76 1.011 ± 0.020 1.98 80.52
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Figure 3.23 : Intra-day studies on inhibitive ELISAs using the anti-TR Pab, 
TRAb2 for the detection o f free TR in bile. The inhibition assay uses TR-17-HS- 
BSA conjugate coated at 1.289 jug m l1 and the antibody at a dilution of 1.983 jug 
m l1.
Table 3.15 : Intra-day CVs and accuracies for TRAb2 inhibition ELISA in bile. 
Five sets o f  eleven standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
T renbolone C alculated M ean C oefficients o f Accuracy,
C oncentration * S D , variation (% )
(UK m l ') (A bs) (C V s), (% )
3125.00 0.431 ± 0.017 3.99 94.13
1562.50 0.472 ±  0.022 4.66 118.16
781.25 0.569 ±  0.017 2.99 86.47
390.63 0.626 ± 0.006 0.92 94.49
195.31 0.657 ±  0.017 2.66 132.96
97.66 0.750 ± 0.013 1.78 66.24
48.83 0.758 ±  0.019 2.49 112.42
24.41 0.779 ± 0.025 3.21 132.88
12.21 0.812 ± 0.011 1.35 65.25
6.10 0.815 ± 0.010 1.23 105.33
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Figure 3.24 : Intra-day studies on competitive ELISAs using the cmti-TR Pab, 
TRAb2 for the detection of free TR in bile. The plates were coated with 6.59 pg  
m l1 solution o f TRAb2 and the conjugate TR-17-HS-HRP was used at 0.5pg m t1.
Table 3.16 : Intra-day CVs and accuracies for TRAb2 competition ELISA in 
bile. Five sets o f eleven standards were analysed on the same day and the CVs 
were calculated. A  four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Trenbolone Calculated Mean Coefficients of Accuracy,
Concentration iz SD variation (% )
(ng m l1) (Abs) (CVs), (%)
781.25 0.110 ± 0.002 1.38 93.41
390.63 0.133 ± 0.004 2.64 108.52
195.31 0.167 ± 0.004 2.18 102.43
97.66 0.202 ± 0.005 2.26 100.77
48.83 0.237 ± 0.006 2.48 93.97
24.41 0.269 ± 0.006 2.22 88.56
12.21 0.284 ± 0.006 2.12 116.16
6.10 0.311 ± 0.010 3.17 96.69
3.05 0.325 ± 0.011 3.25 109.00
1.53 0.336 ± 0.012 3.47 127.76
0.76 0.353 ± 0.009 2.52 66.44
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Figure 3.25 : Inter-day studies on inhibitive ELIS As using the anti-TR Pab, 
TRAb2 for the detection of free TR in bile. The inhibition assay uses TR-17-HS- 
BSA conjugate coated at 1.289 ¡jg m t1 and the antibody at a dilution of 1.983 /ig 
m t1.
Table 3.17 : Inter-day CVs and accuracies for TRAb2 inhibition ELISA in bile. 
Five sets o f  eleven standards were analysed over five different days and the CVs 
were calculated. A  four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Trenbolone C alculated M ean C oefficients o f A ccuracy,
C oncentration •HSD, variation <%)
(ng m l 1) (A/A,,) (C V s), (% )
3125.00 0.447 ± 0.051 11.32 91.55
1562.50 0.498 ± 0.050 9.98 114.17
781.25 0.590 ± 0.079 13.43 99.35
390.63 0.672 ± 0.089 13.29 92.86
195.31 0.735 ± 0.086 11.64 100.50
97.66 0.819 ± 0.095 11.65 81.88
48.83 0.860 ± 0.107 12.42 100.95
24.41 0.899 ± 0.086 9.55 121.20
12.21 0.947 ± 0.072 7.58 117.74
6.10 1.021 ± 0.066 6.43 55.94
3.05 1.021 ± 0.090 8.85 111.39
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Figure 3.26 : Inter-day studies on competitive ELISAs using the cmti-TR Pab, 
TRAb2 for the detection of free TR in bile. The plates were coated with 6.59 pg  
m t1 solution ofTRAb2 and the conjugate TR-17-HS-HRP was used at 0.5pg  m t1.
Table 3.18 : Inter-day CVs and accuracies for TRAb2 competition ELISA in 
bile. Five sets o f eleven standards were analysed over five different days and the 
CVs were calculated. A four-parameter equation was used to fit a curve to the 
data using BIAevaluation software and its percentage accuracy was calculated.
T renbolone C alculated M ean C oefficients o f A ccuracy,
C onceutration ¿:SD, variation (% )
(ng ml"1) (A /A h) ( c v s ) ,  m
781.25 0.340 ± 0.024 7.02 96.37
390.63 0.400 ± 0.018 4.52 108.82
195.31 0.507 ± 0.028 5.57 95.89
97.66 0.608 ± 0.022 3.59 97.13
48.83 0.702 ± 0.021 3.01 102.88
24.41 0.793 ± 0.017 2.14 105.28
12.21 0.879 ± 0.042 4.79 95.70
6.10 0.928 ± 0.025 2.70 106.51
3.05 0.976 ± 0.035 3.53 93.61
1.53 1.005 ± 0.031 3.12 87.46
0.76 1.012 ± 0.018 1.73 133.01
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Trenbolone has no chemical side groups through which it could be easily 
conjugated. To facilitate the production of conjugates for use as both 
immunogens and as ELISA assay reagents it was decided to produce the 
trenbolone-17-hemisuccinate (TR-17-HS) derivative of trenbolone. The two 
major metabolites of trenbolone acetate are 17(3- and 17a- trenbolone, differing 
in the orientation about the 17-position only. To facilitate the production of an 
antibody that would bind to both epimers the conjugate was constructed through 
this position.
This hapten has been used previously to produce polyclonal antibodies specific 
for trenbolone (van Ginkel et al., 1988). Trenbolone was reacted with succinic 
anhydride using pyridine as a catalyst. After the product was extracted and the 
excess succinic anhydride was removed the product was sent for analysis by 
nominal mass spectrometry. This confirmed the presence of a molecule of weight 
368AMU, corresponding to an alkalinated derivative of TR-17-HS, (appendix 
B).
This derivative was then used to produce conjugates for use as both immunogens 
and as assays reagents. The majority of the conjugates were produced using 
mixed anhydride chemistry. However, the THY conjugate was produced using 
the NHS ester method. Both of these procedures are described in sections 2.4.2. 
The spectrum of each of the conjugates was analysed. TR shows a peak at 348 
nm and the presence of this peak in the post-dialysed conjugate implies the 
presence of bound TR on the carrier protein. During dialysis if the TR was not 
bound to the protein it would have been free to pass through the dialysis 
membrane, which had a molecular weight cut off point of 10,000Da. Each of the 
TR-17-HS conjugates showed the presence of the peak at 348nm, which is 
characteristic of this derivative and not of the carrier proteins.
After initial immunisation experiments it was decided to use TR-17-HS-THY as 
the conjugate for antibody production. The other potential candidate, an OVA 
conjugate, was shown not to induce specific antibody production in mice. The 
sera produced from the immunisation using the THY conjugate was able to 
recognise TR but it did not, however, show specificity for the OVA conjugate.
3.3 Discussion
!. ¡9
This OVA conjugate was not used in ELISA and fresh conjugates were made for 
use in the recombinant antibody techniques, (Chapter 5).
New Zealand White rabbits were immunised with the TR-17-HS-THY conjugate 
and the resulting polyclonal antibodies were purified and characterised as 
described in section 2.4.6. The initial purification was carried out by saturated 
ammonium sulphate precipitation and the resulting mixture was subjected to 
protein G affinity chromatography for further purification. Figure 3.6 shows the 
elution profile from the protein G affinity column when low pH elution was used. 
The fractions were analysed for their protein content by their absorbance reading 
at 280nm. All the fractions with significant amounts of protein, above 0.15 
absorbance units, were pooled and dialysed.
The success of the purification is shown by the purity of the final sample. The 
SDS-PAGE, (Figure 3.7), shows the contents of this sample and that of the crude 
serum and the SAS purified fraction. Only two bands, corresponding to the 
dissociated heavy and light chains of the antibodies, are visible in the purified 
fraction whereas the other samples show many other proteins.
The antibodies were applied to inhibitive and competitive ELISA formats, for the 
detection of free TR in both PBS/2% (v/v) EtOH and bile. The competitive assay 
uses a competition between free drug in a sample and labelled drug for binding to 
an immobilised specific antibody. The inhibitive format utilises the inhibiting 
effect of free drug in a sample to prevent the binding of added specific antibody 
to the immobilised drug conjugate on the plate surface. In both assays the 
measured signal is inversely proportional to the amount of free drug present in 
the sample.
To allow these assays to function effectively it is imperative that the parameters 
for the assays are optimised. The assays were optimised using non-competitive 
ELISAs; i.e. no free drug was used. From these assays the optimal dilutions of 
the immunoreagents were chosen for use in the ELISAs, (Table 3.1).
Using these conditions a wide range of concentrations of free TR in PBS/2% 
(v/v) EtOH, 0.38 - 100,000 ng ml'1 were assayed. In these model assays both 
antibodies showed competition within this range (Figure 3.9). For the 
competitive ELISA the antibodies showed a detection range of 0.76 - 781 ng ml' 
\  whereas the inhibition ELISAs showed a higher range of 3.05 - 3,125 ng ml'1. 
These results were similar regardless of which antibody was used. This implies
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that the sensitivities o f the antibodies are similar. The optimal ranges for the 
assays were used to carry out intra and inter-assay analysis o f the ELIS As.
The results o f this analysis for the detection o f free TR in PBS is shown in 
Section 3 .2.4. When using PBS as a diluent both formats and antibodies showed 
good reproducibility and in most cases excellent agreement with the 4-parameter 
curve-fitting model. Table 3 .19 is a summary o f  the coefficients o f variation 
found when PBS was used as a diluent.
Table 3.19 : Ranges o f %  CVs o f the standards in ELISAs for the detection of 
free TR in PBS/2% (v/v) EtOH for the interval o f 3.05 - 3,125 ng ml"1 in the 
inhibitive and 0.76 - 781 ng ml'1 in the competitive assay formats.
inhib itive C om petitive
Intra-assay Inter-assay Intra-assay Inter-assay J
TRAbl 0.76 - 3.96% 2.28 - 9.47% 1.19-7.91% 1.54 -12.32%
TRAb2 0.46 - 4.59% 5.94 -14.04% 0.96 - 4.44% 1.42 - 8.38%
These ranges show both the intra-assay and inter-assay reproducibility o f the 
assays. They show that the assays can be used reliably to quantify the amount of 
free TR contained within a sample. The two assays that have ranges that are over 
10% at their upper limit may not be as precise as the others described here. To 
avoid these errors it may be advantageous to use TRAbl in the inhibitive assay 
while using TRAb2 in the competitive ELISA. However, all o f the % CVs are 
below 15%, which is within the tolerated limits for assays o f this type (Findlay et 
a t,  2000).
The accuracy o f the 4-parameter model to fit the measured data o f the ELISA 
was also investigated. The accuracy o f the fit can be determined by comparing 
the actual TR concentration in the sample with the concentration values obtained 
when the mean absorbance for each standard was substituted into the curve 
equation. The acceptable range for the accuracy has been reported to be 80 - 
120% for many assays although some workers have suggested a less stringent 
criteria o f a 25% deviation from the norm for antibody based assays (Findlay et 
at., 2000). Table 3.20 summarises the accuracy ranges for the ELISAs using both 
antibodies to  detect the presence o f TR in PBS/2% (v/v) EtOH. The difference in 
the accuracy levels o f the two assay formats is immediately noticeable. The
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competitive assay fits the 4-parameter model more closely than the inhibitive 
assay with all o f  the accuracy ranges falling well within the 75-125% interval.
Table 3.20 : Accuracy ranges o f the standards in ELISAs for the detection o f 
free TR in PBS/2% (v/v) EtOH for the interval o f 3.05 - 3,125 ng ml"1 in the 
inhibitive assay and 0.76 - 781 ng ml'1 in the competitive.
Inhibitive Competitive
Intra-assay hitcr-assay Intra-assay Inter-assay J
TRAbl 2.89 - 149.65% 80.42- 121.08% 88.73 - 122.66% 88.94- 112.29%
TRAb2 74.42 - 145.58% 76.40 - 127.04% 85.12- 120.47% 85.12 - 106.25%
The competitive ELISA is 4-fold more sensitive than the corresponding 
inhibitive ELISA is. This is the same regardless o f which antibody was used. 
This is different to the trend seen with the anti-EE antibodies in Chapter 4. Each 
o f those antibodies shows a distinct detection range that does not alter 
significantly when the format is changed. Those antibodies were produced with 
different numbers o f  booster injections. However, the anti-TR antibodies were 
produced using identical protocols. This may contribute to the finding o f similar 
sensitivities within assay formats as both animals were exposed to the antigen for 
the same period.
Neither antibody showed any significant recognition o f the estradiols that were 
tested. This was expected as the immunogen was linked at the 17 position 
allowing the A-ring more access to the immune system. The A-ring o f this 
compound and the estradiols is distinctly different. The compounds that do cross 
react with the compounds, i.e. norgestrol, 19-nortestosterone, and norethisterone; 
all have similar constructs about the A-ring. This implies that the antibodies are 
directed towards this area o f the molecule. These compounds do inhibit the 
binding o f the specific antibody and conjugate in the assay yet they do not do so 
at high levels. The low level o f cross-reaction seen with these antibodies 
indicates they can be used to develop specific assays for the detection o f TR 
without significant interference from related compounds that may be present in 
the sample.
The assays were then tested in a real biological matrix. The model system 
described above worked very well and was able to detect low nanogram amounts 
o f TR but to be o f  a practical use the assay must be able to deal with the
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detection of free TR in a biological matrix. The use of bile as the sample matrix 
has been discussed previously (section 3.1.4). It was chosen as it is an easy 
matrix to work with, being a liquid, and it retains steroid residues for a longer 
period than other matrices. The bile is simply diluted before its application to the 
assay. This is ample pre-treatment for the determination of TR concentration in 
spiked samples. For real samples it may be necessary to deconjugate the samples 
prior to application to the ELISA (Meyer and Hoffmann, 1987). This frees any 
and all TR that may have become conjugated by the natural processes of the 
animal's metabolism.
The assay reagents were applied to samples using bile/PBS as a standard diluent. 
In the competitive ELISAs the amount of labelled drug was seen to be 
insufficient at the level it was used at for the PBS assays as the signal became 
quite low and the dose response curve became shallow. To counter these issues 
the amount of TR-17-HS-HRP was increased from 0.1 |ig ml'1 to 0.5 fig ml'1. 
The resulting dose response curve is steeper and shows a more accurate assay. 
The need for more conjugate may indicate that something in the bile has a high 
affinity for the TR, or that the enzyme is being denatured or becomes inactive by 
its incubation with the bile. The range of detection of the assays does remain 
constant when this alteration is made indicating that some of the conjugate is 
being bound by interfering elements contained in the bile fluid.
The assays have been shown to be reproducible and accurate when bile is used as 
the sample matrix. The coefficients of variation of the bile assays are all of 
similar magnitude to the corresponding assays using PBS as the sample diluent, 
(Sections 3.2.4 and 3.2.6). None of the % CVs exceed the suggested limits of 
10% within assays and under 20% between assays.
Table 3.21 : Ranges of % CVs of the standards in ELISAs for the détection of 
free TR in bovine bile for the interval of 3.05 - 3,125 ng ml'1 in the inhibitive 
assay and 0.76 - 781 ng ml'1 in the compétitive.
Inhibitive Competitive
Intra-assay Inter-assay Intra-assay Inter-assay J
TRAbl 2.30 - 5.38% 6.51 - 18.72% 0.59-3.20% 1.98 -5.65%
TRAb2 0.92 - 4.66% 6.43 - 13.43% 1.38 -3.47% 1.73 - 7.02%
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When bile is used as a diluent the competitive assay retains its reproducibility 
better than the inhibitive format. One possible reason for this could be the use of 
an extra antibody, increasing the amount o f errors brought to the system. But 
these errors are not seen in the previous model ELISAs and the bile has no 
contact with this secondary antibody. These data indicate that the format itself is 
less reproducible when bile is used as the matrix, that is the antibody - drug 
binding reaction is more susceptible in this format.
Using bile as a diluent reduces the accuracy o f both the inhibitive and 
competitive assays (Table 3.22). To avoid these inaccuracies it may be necessary 
to raise the lower limit o f  the detection range. This will remove standards that are 
tending towards the asymptotes o f the curve model. In this area o f the curve 
small errors in measurement can cause large changes in calculated concentration 
values leading to very inaccurate determination o f  the concentration o f a sample.
Table 3.22 : Accuracy ranges o f the standards in ELISAs for the detection of 
free TR in bile for the interval o f  3.05 - 3,125 ng ml'1 in the inhibitive assay and 
0.76 - 781 ng ml"1 in the competitive.
Inhibitive Competitive
Intra-assay Inter-assay Intra-assay Inter-assay
TRAbl 52.36 - 224.14% 59.87 - 129.23% 0 - 144.81% 80.52- 110.24%
TRAb2 65.25 - 132.96% 55.94 - 121.20% 66.44 - 127.76% 87.46 - 133.01%
As seen in the PBS assays the accuracies o f the competitive assays are superior 
to those o f the inhibitive assays. By limiting the range o f detection more accurate 
assays may be shown. The shorter detection ranges and the accuracy ranges that 
they represent for the assay that will benefit from a limiting o f their detection 
range are listed in Table 3.23.
Table 3.23 : Detection and accuracy ranges for optimum accuracy o f the 4- 
parameter model fit.
Assay Intra-/Intcr-assay Detection range Accuracy Range
TRAbl Inhibitive Inter-assay 12-3,125 ng ml"1 78.90- 112.95%
TRAbl competitive Inter-assay 3 - 7 8 1  ng ml"1 83.84 - 139.22%
TRAb2 competitive Inter-assay 1.53 -781 ng ml"1 87.46- 108.82%
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Most of these assays are now within ±25% of the normal value. Unfortunately to 
achieve assays of these accuracy levels it was required to lower their sensitivity.
In combination the % CV and the accuracy levels indicate the usefulness of these 
assays for the detection of free TR in bovine bile samples.
The assays described in this chapter are for the detection of TR in bovine bile 
compare well to the published assays for TR. The competitive assays described 
can quantify a sample in less than 2 hours with minimal sample pre-treatment. 
They can detect as low as 0.76 ng ml'1 in a single sample, which is less than the 
maximum residue limit for this steroid of 2 ng ml'1, and it needs only 50 fll of 
bile to complete the assay.
The radioimmunoassay for the detection of TR and TBA in bovine tissue and 
urine described by Hoffman and Oettel (1976) was able to detect very low 
amounts (40pg and 70pg, respectively) of both steroids. Bile was not tested in 
this study but the sample pre-treatment was more involved that described here. 
Even though this assay is more sensitive than the ELISAs described in this 
chapter for the detection of TR residues, it uses radioisotopes as the labels in the 
assay. The advantages of using enzyme-labels in place of radioactive labels are 
listed in section 1.4 and include safer handling and easier disposal. This assay 
was also carried out in single tubes and not on a 96 well format, which allows for 
up to 96 assays to be carried out simultaneously. The plate format is more 
suitable for use as a screening assay as it can handle more samples and it is easier 
to automate.
The system described by Meyer and Hoffmann (1987) is an assay similar to the 
competitive ELISAs in this chapter. This assay requires the incubation of the 
sample along with an alkaline phosphatase-TR tracer and a hormone-specific 
rabbit antibody in an anti-rabbit IgG-coated well. This incubation step alone 
takes 18h to complete, followed by 2h for the substrate to develop. The 
purification procedures used for the different sample matrices are also very time- 
consuming. The preparation of bile samples involves an overnight hydrolysis 
step. The amount of conjugated TR has been estimated at only 20% of the total 
TR present and so this step, which adds a day to the analysis time of a sample, 
may be superfluous. The assays presented in this chapter provide analysis of bile
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samples to a level below that of the maximum residue permitted and it does so in 
less than 2h giving it many advantages over the this enzyme immunoassay. 
Another method for the quantification of trenbolone used specific antibodies for 
the isolation of 17a-trenbolone and l7p-trenbolone before their separation and 
detection by HPLC-TLC (van Ginkel et al., 1988). This assay can detect both 
isoforms of the drug but it requires specialised and expensive equipment. The 
assay is not as easy to use or as rapid as the analysis of samples using the 
ELISAs procedures developed here and the limit of detection of this assay was 
comparable, 0.78 ng ml'1 to 0.5 ng ml'1 with the off-line TLC. The ELISA also 
has a higher throughput with a single technician able to assay hundreds of 
samples per day. The immunoaffinity column clean up followed by HPLC-TLC 
can analyse up to 20 samples per day. A screening method must have a high 
throughput capability and the ELISA can provide this. A single technician can 
analyse many hundreds of samples each day with the ELISA system.
The applications of the assays developed here are numerous. They are very 
useful as screening methods when a great number of samples must be analysed 
quickly. These samples may originate from farm inspections or from slaughter 
houses. An abattoir is the area that the assays are most suitable. An employee 
with minimal training can analyse hundreds of samples in a small lab with only 
basic equipment. The capital outlay required for the introduction of this type of 
testing system is quite low compared to other systems such as the HPLC system 
described above or even a biosensor-based assay. The assay reagents could also 
be adapted for use with other sample matrices such as serum or urine to allow for 
easier sample collection from live animals. If single samples needed to be 
analysed individually, for example on-site at a farm, it may be possible to utilise 
a rapid ELISA system to provide quick on the spot results, (see Chapter 5).
In conclusion, trenbolone was derivatised to trenbolone-17-hemisuccinate using 
succinic anhydride and pyridine as a catalyst. This derivative was conjugated to 
BSA, OVA, THY and HRP. The THY conjugate was used to immunise rabbits 
and produce polyclonal antibodies. The polyclonal antibodies were purified and 
applied to two ELISA formats, competitive and inhibitive. Assays were 
developed for the detection of free TR in both PBS/2% (v/v) EtOH and bovine 
bile. These assays were analysed for their reproducibility and their accuracy
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when fitted to the 4-parameter model. The cross-reactivity of the antibodies with 
related steroids was also investigated. The two antibodies produced had very low 
cross reactivity to most of the compounds tested with only slight recognition of 
nortestosterone, norethisterone and norgestrol. All assays were capable of 
detection of low nanogram quantities of free trenbolone in both PBS/2% (v/v) 
EtOH and bile and the assay compares well and, in some cases, out-performs 
previously described detection methods.
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4.1 Introduction
4.1.1 Ethynyl Estradiol Structure and Function
Ethynyl estradiol (EE) is a very potent synthetic xenobiotic estrogenic compound. 
It is an analogue o f the natural estrogen, 17-p estradiol, which has been ethynylated 
at the 17 position o f the steroid nucleus (Figure 4.1). It has been used extensively 
as the main estrogenic component o f the oral contraceptive pill. This was its first 
major use and it has continued unabated since the boom o f the combined oral 
contraceptive pill that occurred in the 1970's (Agasan et al., 1994). Today, this is 
still its most common usage.
OH
Figure 4.1: Chemical structure o f ethynyl estradiol, (17-a ethynylestra - 1,3,5 (10) 
- triene -3 , 17 p  - diol). Relative molecular weight o f 296.4. The four rings are 
labelled A, B, C and D in accordance with the conventions o f standard steroidal 
structure nomenclature.
Ethynyl estradiol is more estrogenic than its natural analogue 17-p estradiol 
(Gutendorf and Westendorf, 2001) and, as such, it is useful as a growth promoter in 
animals. Anabolic steroids act by increasing the feed to muscle ratio o f the animals, 
as discussed previously in this dissertation, (section 1.3.3.1). Due to its potency, it 
is important that residues from this compound are not found in the final meat 
products. Some natural hormones pose risks to the end consumer, particularly in 
the case o f prepubertal children (Opinion o f the Scientific Committee on 
Veterinary Measures relating to Public Health, 2002).
The synthetic estrogens have also been linked to increase in breast and vaginal 
cancer, (estrogen dependant cancers), endometriosis, testicular and prostate cancer 
and reduced sperm counts in humans (Folmar et al,  2000). The levels o f natural, 
synthetic and xenoestrogens found in some surface waters and even in drinking
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water supplies have been found at levels high enough to produce reproductive 
abnormalities.
Natural estrogens are short-lived within the body and are broken down efficiently 
in the liver whereas synthetic estrogens are more stable and tend to remain in the 
body for a longer period (Tapiero et al., 2002). EE has been shown to have a 100- 
fold higher liver activity than estradiol, due to the fact that it is more metabolically 
stable in humans than the natural steroids (Diel and Michna, 1998). This can lead 
to a toxic build up of these substances over a period of time if contaminated 
foodstuffs are being consumed.
To protect the consumer the European Union (EU) has banned the use of these 
fattening agents in meat producing animals under EU directives 81/602/EEC and 
96/22/EC. This has lead to the need for testing programmes within the European 
Union to ensure that the animal products being consumed are free from these 
residues. The links to the health problems described previously are not conclusive 
and the EU has a duty to prevent these substances from entering the food chain 
until they are proven safe.
4.1.2 Detection of EE
Many methods have been described for the detection of EE in a number of matrices 
using both polyclonal and monoclonal antibodies. A radioimmunoassay was 
developed using a monoclonal antibody to detect EE in plasma and buffer (Agasan 
et al., 1994). This assay had low detection limits of lOpg ml'1 in buffer and 43pg 
ml"1 in plasma but the samples were extracted before use in the assay using 
dichloromethane. This added another step to the assay and it required time and 
equipment. The recovery was also not optimal as only 78% of the steroid was 
recovered from the spiked samples. An ether extraction method was tested but it 
was shown to have high backgrounds and higher variation between the assays than 
the dichloromethane protocol, even though it had higher recovery efficiencies of up 
to 96%. Throughout this assay the coefficients of variation were consistently above 
10% even when buffer was used. To be of practical use an assay must be 
reproducible and these results show that this assay system has a high level of 
inherent errors. Despite this assay using a mixture of 3 anti-EE monoclonal 
antibodies the cross reactivities are substantial, with up to 100% cross-reactivity
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against norethynodrel and high levels detected against norethisterone, EE-3- 
sulphate, 19-nortestosterone and levonorgestrel.
An enzyme immunoassay was described for EE (Turkes et al., 1981), using 
polyclonal sera with a sensitivity of 2pg per assay tube, (lOpg ml'1). This 
polyclonal antibody showed significant cross-reaction with a number of related 
steroids so to avoid this problem a pre-absorption step was introduced. This 
allowed the extraction of the estrogens from the plasma sample but it also added 
another overnight incubation to the assay so that at least 2 days elapsed before a 
sample could be analysed.
An ELISA method has also been described for EE and compared to GC-MS 
analysis (Sawaya et al., 1998b). This paper outlines the use of a commercial kit for 
the quantification of EE in both chicken muscle and sheep urine. Both matrices 
were subjected to lengthy extraction procedures before they were used in the assay. 
The average recovery of EE was 85 ± 11.8%. This study suggested an ELISA cut 
off point of 0.3 ng ml"1 to prevent false positive results using this method of 
analysis.
This chapter describes an assay for the detection of EE in both buffer and bile using 
polyclonal antibodies with low cross-reactivities with minimal pre-treatment of the 
sample.
4.1.3 A cceptable Limits
The maximum residue limits for anabolic steroids in general are difficult to set due 
to the presence of endogenous steroid in the animal itself. Some testing methods 
have circumvented this problem by setting action limits above which the animal is 
assumed to have been dosed (Draisci et al., 2000). This problem is not as prevalent 
where the detection of synthetic steroids is concerned. By nature of the fact that 
these compounds are synthetic and are, therefore, not found naturally, any 
confirmed presence indicates that the animal was dosed. It is, therefore, imperative 
that any assay system for the analysis of EE be very specific and not be liable to 
interference from endogenous steroids. In practice, tolerance limits of between 0.5- 
2 ng ml'1 depending on the matrix have been suggested for the presence of this 
drug (Johansson and Hellenas, 2001).
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4.1.4 Choice of Matrix
EE has been found to be excreted rapidly into bile (Grabowski and Park, 1984). 
This results in very little (0.02%) EE being found in serum 18h after 
administration. The circulating levels in animals would therefore only be 
significant while the animal is being dosed. Bile is a good choice of matrix to avoid 
the problems associated with the rapid disappearance of EE from the plasma. It 
also contains large quantities of EE and, hence, it takes a significant amount of 
time for it to be cleared.
The metabolism of EE in the bile of rats has been investigated. EE is metabolised 
mainly to glucuronides but males also produced arylsulphates, all of which were 
found to be linked by hydroxy or methoxy groups at the 2 position (Maggs et al, 
1983). This indicates that bile may require an enzymatic deconjugation prior to any 
analysis for free EE. However, due to the fact that the derivatives are in the A-ring 
of the steroid nucleus an antibody with specificity for the D-ring of the steroid may 
supply an assay that could avoid this problem.
4.1.5 BIAcore Technology and Surface Plasmon Resonance (SPR)
The biosensor-based assay described in this chapter uses a BIAcore 3000. BIAcore 
covers an array of instruments produced by the company that all utilise the same 
sensing technology. The BIAcore 3000 uses a refractive index sensitive optical 
transducer based on surface plasmon resonance for mass detection (Quinn et al., 
1999). The mass detection occurs at a biospecific surface that is composed of a 
carboxymethylated dextran surface onto which biomolecules, such as antigens or 
antibodies, can be linked. The binding of any compounds to the ligands 
immobilised on this surface can be detected and quantified using a phenomenon 
called surface plasmon resonance.
Surface plasmon resonance (SPR) is a phenomenon dependant on the incoming 
light and the refractive index of the materials it is passing through and arises from 
the total internal reflection of light at a metal film-liquid interface (Fagerstam et al., 
1992). The production of an SPR angle is represented in Figure 4.2. For this 
explanation, SPR will be discussed in relation to its use in the BIAcore biosensor. 
The sensing platform consists of a glass prism with a sensor chip docked against 
one side. The sensor chip has a thin gold layer, which lies next to the prism, and
has a carboxymethylated hydrogel linked to it through an inert linker layer on the 
opposite side (Wong et al., 1997). When light is passed through an optically dense 
medium (the glass prism) at an angle greater than the critical angle, upon reaching 
an interface with the medium of a lower refractive index (e.g. buffer) the light is 
totally internally reflected back into the prism (Fagerstam et al., 1992). Even 
though the light is totally reflected a small electromagnetic field component of the 
light called an evanescent wave penetrates into the lower refractive index medium 
to a distance close to one wavelength.
If the interface between the two media is coated with a thin metal layer, such as 
gold in the case of BIAcore, and the light is monochromatic and polarised the 
evanescent wave will interact with the electron cloud (plasmons) at the surface of 
the metal film (Quinn and O'Kennedy, 1999). Light energy is then lost to the metal 
film when surface plasmon resonance occurs and the intensity of the reflected light 
shows a decrease. This dip in intensity will occur at a sharply defined angle, SPR 
angle, which is dependent on the refractive index of the media on the side of the 
evanescent wave, once all other parameters are kept constant (Sternesjo et al, 
1995).
If the refractive index changes at the surface out to a distance of about lfxm, a 
change in the angle of the intensity dip will be seen. This is measured and it forms 
the basis for the response units measured in BIAcore technologies, (Figure 4.3). 
The measured change in refractive index can be caused by either a change in bulk 
refractive index or by a change in the mass concentration at a surface of the chip. 
The refractive index will be affected by something binding to the dextran hydrogel 
layer or something being removed from the surface (Wong et al., 1997). All of 
these changes can be monitored in real-time using the SPR phenomenon. Since the 
SPR response is related to the mass change on the sensing surface it is usual to 
immobilise the smaller of the binding partners to maximise the SPR signal (Gomes 
and Andreu, 2002).
4.1.5.1 Biosensor-based assays
The format used in the BIAcore assay is similar to the inhibitive ELISA described 
in section 3.1.4. The conjugate is linked to the dextran hydrogel using EDC/NHS 
chemistry. The sample and the specific antibody are then mixed and allowed to
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come to equilibrium outside the machine. These samples are then passed over the 
surface of the chip and the amount of antibody binding was recorded. The antibody 
was then removed from the surface with a regeneration solution ready to start a 
new binding cycle.
I '-4
Chapter 4: Anti-ethynyl estradiol polyclonal antibodies
Evanescent Wave
Figure 4.2 : Diagram of the generation of the SPR signal. When the media is at a 
certain refractive index, the dip in light intensity due to the evanescent wave 
producing a surface plasmon is found at angle A. As the refractive index changes 
so does the SPR angle. This is monitored and converted to resonance units by 
BIAcore software to allow for ease o f analysis.
Figure 4.3 : The intensity dips seen at different refractive indices. When the SPR 
angle is at angle A, a response is seen on the sensogram corresponding to the 
number of resonance units A. When the SPR angle shifts to B after, for example a 
binding cycle, a resonance signal o f B is  seen on the sensogram.
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4.1.6 Detection of EE using Biosensors
Johansson and Hellenas (2001), have described a sensitive assay for the detection 
of EE using a BIAcore 2000, a polyclonal antibody preparation with the EE 
directly immobilised on the sensorchip. The drug was directly immobilised onto 
the surface of a BIAcore CM5 chip using an amino-modified surface and 
EDC/NHS chcmistry. The advantage of this method of linkage is that the surface is 
extremely stable and can withstand many regeneration cycles. When a conjugate, 
consisting of a hapten and carrier, is subjected to repeated cycles of regeneration 
with lO-lOOmM NaOH or HC1, 1-20% (v/v) acetonitrilc, high salt concentrations 
or ethanolamine it may often be less stable than the hapten linked covalently dircct 
to the chip surface.
The anti-EE polyclonal antibody was diluted in double strength running buffer and 
mixed with the sample or standards. This assay showed excellent sensitivity with 
an IC50 of 0.35 ng ml’1 for the drug in buffer. This study proves the usefulness of 
both the antibody and the biosensor for the detection of free EE in buffer, but the 
reproducibility and accuracy of the assays were not investigated. The antibodies 
were also not tested in any biological matrices to show the resistance of the 
antibody to interference from the components of biological matrices.
This chapter describes the production, purification and characterisation of two 
polyclonal antibodies raised against EE-6-CMO-OVA. These antibodies were 
applied to the detection of EE using two ELISA formats and a biosensor-based 
assay. These assays were investigated for both their precision and accuracy. The 
test systems were then applied to the determination of EE in bovine bile.
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4.2 Results
4.2.1 Preparation of Ethynyl Estradiol conjugates
The conjugates were prepared from the EE derivative EE-6-CMO (Figure 4.4) 
using either mixed anhydride or EDC/NHS chemistry as described in section 2.4.2. 
This derivative has been found to produce more specific antiserum compared to the 
antiserum raised when the 17 position is used to link estrogenic steroids (Lindner et 
al., 1972; Wright et al., 1973).
Conjugate Linking Chemistry
EE-CMO-BSA EDC/NHS
EE-CMO-OVA Mixed anhydride
EE-CMO-HRP Mixed anhydride
EE-CMO-THY EDC/NHS
A minimum o f 20 times excess o f  steroid to carrier was used in each reaction. 
Ethynyl estradiol has a peak at 310nm when investigated spectrophotometrically. 
The spectrum o f  each o f the conjugates was recorded after dialysis and a peak at 
310nm indicated the presence o f the hapten coupled to the carrier. Each conjugate 
was then tested in an ELISA system to confirm the linkage o f the hapten to the 
protein carrier.
Figure 4.4 : Structure o f ethynyl estradiol-6-carboxymethyl oxime, the derivative 
used to link carriers to ethynyl estradiol
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4.2.2 Production and purification of rabbit anti-EE-CMO-OVA polyclonal 
antibodies
The protocol used for the production of the polyclonal antibodies was outlined in 
section 2.4.4.1. Two rabbits were immunised with 1ml of 0.5 mg ml'1 EE-CMO- 
OVA. The immunoglobulin fraction was isolated from serum after the rabbits were 
sacrificed. Figure 3.6. shows a typical purification profile of immunoglobulin from 
a Protein G affinity column. All fractions containing significant amounts of protein 
were pooled and dialysed. The purified samples were subjected to SDS-PAGE and 
each fraction was diluted to approximately 1 mg ml'1 before loading onto the gel, 
(Figure 4.5). The lane containing the final affinity-purified solution shows 2 bands 
corresponding to the heavy and light chains of immunoglobulin as they appear 
under denaturing conditions. The concentration of the purified IgG was estimated 
using a BCA protein assay, with an IgG standard. The polyclonal antibody from the 
first rabbit was designated EEAbl and had a concentration of 4.01 mg ml'1. The 
polyclonal antibody from the second rabbit, EEAb2, had a concentration of 3.42 
mg ml'1.
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Figure 4 3 } Coomassie stained SDS-PAGE gel with protein markers in lane I and 
8. Lane 2: serum from rabbit 1, lane 3: dialysed SAS cut o f rabbit 1 serum, lane -I: 
protein g  affinity-purified IgG fraction (EEAbl) and lane 5: serum from rabbit 2, 
lane 6: dialysed SAS cut of rabbit 2 serum, lane 7: protein G affinity-purified IgG 
fraction (EEAb2).
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4.2.3 Optimisation of parameters for the inhibitive and competitive ELISAs 
for the detection of free EE
The non-competitive checkerboard ELISAs were carried out as described in 
sections 2.4.7 to determine the optimal coating concentration either of EE-6-CMO- 
BSA conjugate or anti-EE antibody, depending on the assay format, and the 
optimal competing solution. The lowest coating concentration that showed a steep 
dose response curve with strong measurable signals in the assay was chosen as the 
optimum. The optimal antibody dilution, (inhibitive ELISA) or HRP conjugate 
dilution (competitive ELISA) was also elucidated from the results of these assays. 
At the coating concentration chosen above, the amount of either antibody or EE- 
HRP conjugate that gave approximately 70% of the maximum signal was used in 
further assays. An example of the results of these assays is shown in Figure 4.6. 
The coating and competing concentrations used in the ELISAs are listed in Table 
4.1.
The optimal concentrations established were used in the subsequent intra- and 
inter-day analysis of the two ELISA formats. A wide range of standards (0.38 - 
100,000 ng ml'1) was prepared and using the optimal coating and competing 
concentrations, the working ranges of the assays were ascertained, (Figure 4.7).
The detection ranges for the assays are listed below.
• EEAbl Inhibitive 3.1 - 50,000 ng ml"1
EEAbl Competitive 1.5 - 25,000 ng ml"1
• EEAb2 Inhibitive 1.5 - 50,000 ng ml"1
EEAb2 Competitive 48.8 - 50,000 ng ml"1
These ranges and the optimised parameters were used to conduct reproducibility 
studies on the ELISAs.
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Figure 4.6 : Checkerboard ELISA for the determination of optimum EE-6-CMO- 
BSA conjugate coating dilution and EEAb2 antibody dilution for an inhibitive 
ELISA. Dilutions of 1/16,000 EE-6-CMO-BSA (0.2 pg  m l1) and 1/12,000 EEAb2 
(0.57 pg m t1)  were chosen as the optimum assay parameters.
Table 4.1 : Optimal coating and competing concentrations for competitive and 
inhibitive ELISAs using both anti-EE polyclonal antibodies.
A ssay C o a t in g  S o lu t io n C o m p e t in g  S o lu t io n
EEAbl Inhibitive 0.16 |ig ml'1 EE-CMO-BSA 0.50 |Jg ml'1 EEAbl
EEAbl Competitive 2 \xg ml'1 EEAbl 0.119 ng ml'1 EE-CMO-HRP
EEAb2 Inhibitive 0.2 |ig ml'1 EE-CMO-BSA 0.57 |ig ml'1 EEAb2
EEAb2 Competitive 1.71 jxg ml'1 EEAb2 0.478 Mg ml’1 EE-CMO-HRP
Dilution of EE-BSA
♦ 1000 
■ 2000 
A 4000
eooo 
—* —  16000  
•  3 2 0 0 0
— I— 6 4 0 0 0
----—0
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EE C o n c e n tra tio n  (pg  m l'1)
Figure 4 .7 : Determination o f the range o f detection for the ELISAs using EEAbl. 
A lai ge number of standards were tested in the assay and the region in which they 
recognised EE was chosen as the detection range.
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4.2.4 Competitive and Inhibitive ELIS As using antibodies EEAbl and EEAb2 
for the detection of EE
A range of standards of EE was prepared as described in section 2.4.7.1. With the 
inhibitive assay these were added to an EE-CMO-BSA-coated plate at 50 jul per 
well together with 50 [il of anti-EE pab (EEAbl or EEAb2) at the required dilution. 
After the incubation and washing steps had been completed HRP-labelled anti­
rabbit pab was added to the plates. In the competitive ELISA the standards were 
added to an anti-EE pab-coated plate with the optimal dilution of EE-CMO-HRP. 
For both assays the bound HRP-conjugates were detected using the OPD substrate. 
For intra-day assay variation each concentration of standard was assayed 5 times 
on a single day and the mean absorbance was plotted against the EE concentration 
of the standard. Figures 4.8, 4.9, 4.12 and 4.13 show the intra-day assays for both 
assay formats using both antibodies. Tables 4.2, 4.3, 4.6 and 4.7 show the means, 
the standard deviations, the coefficients of variation (CVs) and the percentage 
accuracy of the standard curve using 4-parameter curve fitting.
The inter-day assay variation was determined by carrying out the assay over 5 
separate days. The A/Ao value was compared across the 5 days. Figures 4.10, 4.11, 
4.14 and 4.15 show the inter-day assays for both assay formats using both 
antibodies. The accompanying tables 4.4, 4.5, 4.8 and 4.9 show the means, the 
standard deviations, the coefficients of variation (CVs) and the percentage accuracy 
of the standard curve using 4-parameter curve fitting.
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Figure 4.8 : Intra-day studies on inhibitive ELISA using the anti-EE Pab, EEAbl 
for the detection o f free EE in PBS/2% (v/v) EtOH. The inhibition assay uses EE-6- 
CMO-BSA conjugate coated at 0.16 fig m t1 and the antibody at a concentration 
o f 0.5 pg  m!1.
Table 4.2 : Intra-day CVs and accuracies for EEAbl inhibition ELISA in PBS. 
Five sets o f fifteen standards were analysed on the same day and the CVs were 
calculated. A  four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethyuyl Estradiol Calculated mean Coefficients of Accuracy, ]
Concentration, ±SD , variation (%)
(ng ml*1) (Abs) (CVs), (%)
50000.0 0.222 ± 0.010 4.29 53.69
25000.0 0.219 ± 0.007 3.15 114.52
12500.0 0.243 ± 0.004 1.77 132.64
6250.0 0.282 ± 0.004 1.39 129.43
3125.0 0.337 ± 0.006 1.64 112.13
1562.5 0.404 ± 0.007 1.77 95.33
781.3 0.469 ± 0.013 2.88 89.01
390.6 0.549 ± 0.009 1.69 70.31
195.3 0.575 ± 0.016 2.72 102.80
97.7 0.624 ± 0.011 1.84 109.36
48.8 0.669 ± 0.005 0.81 113.68
24.4 0.704 ± 0.006 0.87 126.87
12.2 0.733 ± 0.012 1.63 140.77
6.1 0.779 ± 0.006 0.74 80.32
3.1 0.808 ± 0.011 1.35 42.59
1
10 100 1000 10000 100000 
EE concentration (ng ml'1)
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Figure 4.9 : Intra-day studies on competitive ELISAs using the anti-EE Pab, 
EEAbl for the detection of free EE in PBS/2% (v/v) EtOH. In the competition 
ELISA the plates are coated with 2 pg  m t1 solution of EEAbl and the conjugate 
EE-6-CMO-HRP was used at 0.119 pg  m t1.
Table 4.3 : Intra-day CVs and accuracies for EEAbl competition ELISA in PBS. 
Five sets o f fifteen standards were analysed on the same day and the CVs were 
calculated. A  four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± SD, variation (%)
(n g m l1) (Abs) (CVs), (%)
25000.0 0.228 ± 0.009 3.87 43.10
12500.0 0.222 ± 0.010 4.55 160.07
6250.0 0.235 ± 0.011 4.66 97.01
3125.0 0.244 ± 0.010 3.95 118.71
1562.5 0.261 ± 0.002 0.83 105.54
781.3 0.278 ± 0.009 3.08 114.47
390.6 0.301 ± 0.018 5.94 116.74
195.3 0.344 ± 0.015 4.44 76.27
97.7 0.372 ± 0.016 4.30 77.72
48.8 0.383 ± 0.015 3.79 119.93
24.4 0.418 ± 0.009 2.06 95.45
12.2 0.434 ± 0.020 4.59 119.06
6.1 0.455 ± 0.015 3.32 111.80
3.1 0.469 ± 0.011 2.30 116.38
1.5 0.490 ± 0.019 3.90 49.40
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Figure 4.10: Inter-day studies on inhibitive ELISAs using the anti-EE Pab, EEAbl 
for the detection of free EE in PBS/2% (v/v) EtOH. The inhibition assay uses EE-6- 
CMO-BSA conjugate coated at 0.16 /jg m l1 and the antibody at a concentration 
of0 .5 /jg m r}.
Table 4.4 : Inter-day CVs and accuracies for EEAbl inhibition ELISA in PBS. 
Five sets o f fifteen standards were analysed on five different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ±S D , variation (%)
(ng ml'1) (A/Ao) (CVs), (%)
50000.0 0.246 ± 0.017 6.98 62.30
25000.0 0.255 ± 0.010 4.00 105.33
12500.0 0.281 ± 0.014 4.82 137.14
6250.0 0.335 ± 0.017 5.12 126.01
3125.0 0.399 ± 0.017 4.26 115.68
1562.5 0.484 ± 0.017 3.62 92.46
781.3 0.564 ± 0.020 3.49 79.57
390.6 0.639 ± 0.005 0.84 71.76
195.3 0.667 ± 0.026 3.91 104.90
97.7 0.719 ± 0.025 3.51 111.10
48.8 0.754 ± 0.021 2.75 138.78
24.4 0.804 ± 0.010 1.28 124.64
12.2 0.837 ± 0.012 1.41 131.05
6.1 0.881 ± 0.018 2.03 84.56
3.1 0.916 ± 0.023 2.53 41.00
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Figure 4.11 : Inter-day studies on competitive ELISAs using the anti-EE Pab, 
EEAbl for the detection of free EE in PBS/2% (v/v) EtOH. In the competition 
ELISA the plates are coated with 2 jjg m t1 solution of EEAbl and the conjugate 
EE-6-CM0-HRP was used at 0.119 jug m t1.
Table 4.5 : Inter-day CVs and accuracies for EEAbl competition ELISA in PBS. 
Five sets o f fifteen standards were analysed on five different days and the CVs 
were calculated. A  four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ±SD , variation (%)
(ng m l1) (A/A0) (CVs), (%)
25000.0 0.435 ± 0.050 11.55 73.88
12500.0 0.448 ± 0.050 11.17 97.34
6250.0 0.470 ± 0.039 8.24 108.25
3125.0 0.497 ± 0.046 9.29 113.61
1562.5 0.523 ± 0.036 6.94 131.20
781.3 0.570 ± 0.040 7.09 109.98
390.6 0.626 ± 0.049 7.84 88.30
195.3 0.688 ± 0.052 7.55 72.08
97.7 0.724 ± 0.057 7.93 87.78
48.8 0.755 ±  0.037 4.88 116.73
24.4 0.817 ± 0.047 5.73 102.51
12.2 0.868 ± 0.043 4.93 105.58
6.1 0.919 ± 0.040 4.35 104.66
3.1 0.962 ± 0.053 5.53 114.93
1.5 1.030 ± 0.080 7.80 79.75
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Figure 4.12: Intra-day studies on inhibitive ELISAs using the anti-EE Pab, EEAb2 
for the detection o f free EE in PBS/2% (v/v) EtOH. The inhibition assay uses EE-6- 
CMO-BSA conjugate coated at 0.2 ¡jg m l1 and the antibody at a dilution of 0.57 fig 
m l1.
Table 4.6 : Intra-day CVs and accuracies for EEAb2 inhibition ELISA in PBS. 
Five sets o f  sixteen standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
1 Ethynyl Estradiol Calculated mean Coefficients of Accuracy»
Concentration, ± S l) variation (%)
(ng m l1) (Abs) (CVs), (%)
50000.0 0.102 ± 0.003 2.77 48.47
25000.0 0.104 ± 0.004 4.14 91.04
12500.0 0.113 ± 0.004 3.27 140.46
6250.0 0.158 ± 0.007 4.59 116.20
3125.0 0.217 d r 0.006 2.94 109.55
1562.5 0.296 ± 0.007 2.29 101.37
781.3 0.387 ± 0.008 2.14 92.12
390.6 0.477 ± 0.009 1.97 79.87
195.3 0.527 ± 0.014 2.74 90.59
97.7 0.559 ± 0.020 3.50 115.34
48.8 0.572 it 0.016 2.71 185.73
24.4 0.602 ± 0.011 1.88 192.53
12.2 0.621 ± 0.016 2.54 204.39
6.1 0.652 ± 0.014 2.15 13.84
3.1 0.657 ± 0.019 2.83 ND
1.5 0.679 ± 0.017 2.56 ND
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Figure 4.13 : Intra-day studies on competitive ELISAs using the anti-EE Pab, 
EEAb2 fo r the detection o f free E E  in PBS/2% (v/v) EtOH. In the competitive 
ELISA the plates are coated with 1.7 1 /jg m t1 dilution o f EEAb2 and the conjugate 
EE-6-CM 0-H R P was used at 0.478 jug m t1.
Table 4.7 : Intra-day CVs and accuracies for EEAb2 competition ELISA in PBS. 
Five sets o f eleven standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± SD, variation (%)
(ng ml"1) (Abs) (CVs), (%)
50000.0 0.071 ± 0.003 4.91 ND
25000.0 0.078 ± 0.004 5.56 135.13
12500.0 0.090 ± 0.005 5.99 80.66
6250.0 0.106 ± 0.003 3.23 97.50
3125.0 0.152 ± 0.004 2.74 95.76
1562.5 0.228 ± 0.013 5.76 100.18
781.3 0.324 ± 0.012 3.84 106.05
390.6 0.419 ± 0.030 7.24 97.40
195.3 0.474 ± 0.009 1.81 71.92
97.7 0.484 ± 0.010 2.11 92.08
48.8 0.480 ± 0.016 3.37 229.30
149
Chapter 4: Anti-ethynyl estradiol polyclonal antibodies
EE concentration (ng ml'1)
Figure 4 .14 : Inter-day studies on inhibitive ELIS As using the anti-EE Pab, EEAb2 
fo r  the detection o f free E E  in PBS/2% (v/v) EtOH. The inhibition assay uses E E -6- 
CM O-BSA conjugate coated at 0.2 jug m l1 and the antibody at a dilution o f 0.57 ng  
m l1.
Table 4.8 : Inter-day CVs and accuracies for EEAb2 inhibition ELISA in PBS. 
Five sets o f sixteen standards were analysed over five different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± S D variation (%)
(ng m l1) (A/A«) (CVs), (%)
50000.0 0.142 ± 0.011 7.98 49.77
25000.0 0.147 ± 0.015 10.42 89.33
12500.0 0.163 ± 0.013 8.14 133.38
6250.0 0.220 ± 0.020 8.92 123.95
3125.0 0.297 ± 0.022 7.42 117.46
1562.5 0.408 ± 0.022 5.39 102.98
781.3 0.547 ± 0.028 5.20 84.38
390.6 0.660 ± 0.033 5.07 80.75
195.3 0.733 ± 0.050 6.88 94.14
97.7 0.793 ± 0.038 4.81 111.40
48.8 0.827 ± 0.040 4.85 156.59
24.4 0.888 ± 0.028 3.18 136.08
12.2 0.923 ± 0.032 3.49 128.50
6.1 0.943 ± 0.041 4.32 134.67
3.1 0.966 ± 0.052 5.36 70.00
1.5 1.011 ± 0.053 5.29 ND
150
Chapter 4: Anti-ethynyl estradiol polyclonal antibodies
EE concentration (ng ml'1)
Figure 4.15 : Inter-day studies on competitive ELISAs using the anti-EE Pab, 
EEAb2 fo r  the detection o f free E E  in PBS/2% (v/v) EtOH. In the competitive 
ELISA the plates are coated with 1.7 1 jug m l1 dilution o f EEAb2 and the conjugate 
EE-6-CM O -H K P was used at 0.478 pg m t1.
Table 4.9 : Inter-day CVs and accuracies for EEAb2 competition ELISA in PBS. 
Five sets o f twelve standards were analysed over five different days and the CVs 
were calculated. A  four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration. ± SD variation (%)
L  (ng m l1) (A/A„) (CVs), <%)
50000.0 0.164 ± 0.013 8.09 380.43
25000.0 0.171 ± 0.010 5.99 135.31
12500.0 0.188 ± 0.008 4.44 105.97
6250.0 0.233 ± 0.011 4.73 91.61
3125.0 0.311 ± 0.024 7.61 94.97
1562.5 0.444 ± 0.039 8.77 99.04
781.3 0.633 ± 0.066 10.40 100.50
390.6 0.801 ± 0.068 8.52 109.62
195.3 0.957 ± 0.015 1.56 97.44
97.7 1.074 ± 0.100 9.35 16.23
48.8 1.045 ± 0.100 9.53 133.89
24.4 1.040 ± 0.104 10.05 299.04
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Both ELISA formats were used to detcct free EE in spiked bile samples. The bile 
was prepared as described in section 2.4.7.2 and the EE standards were prepared 
using the bile as the diluent. The spiked bile was diluted with an equal volume of 
PBS before being applied to the assay plate. The rest of the ELISA protocols were 
as previously described in section 4.2.3.
Intra-day and inter-day assay variations were investigated as described for the 
ELISAs using PBS/2% EtOH as diluent. Figures 4.16, 4.17, 4.20 and 4.21 show the 
intra-assay variations along with tables 4.10, 4.11, 4.14 and 4.15. The inter-assay 
variations are shown in Figures 4.18, 4.19, 4.22 and 4.23 and the accompanying 
tables 4.12, 4.13, 4.16 and 4.17.
Chap» 4: Aciij-eihynyl ¿’$tradi»‘i polydoniil ano.f*xhes
4.2.5 Detection o f EE in Spiked Bile Samples
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Figure 4.16: Intra-day studies on inhibitive ELISAs using the anti-EE Pah, EEAbl 
for the detection of free EE in bile. The inhibition assay uses EE-6-CMO-BSA 
conjugate coated at 0.16 jug m l1 and the antibody at a concentration of 0.5 fjg m t1.
Table 4.10 : Intra-day CVs and accuracies for EEAbl inhibition ELISA in bile. 
Five sets of fifteen standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol 
Concentration, 
(ng m l1)
Calculated mean 
± SD,
(Abs)
Coefficients of 
variation
(CVs), (%)
Accuracy,
(%)
50000.0 0.421 ± 0.024 5.65 137.29
25000.0 0.467 ± 0.015 3.11 72.42
12500.0 0.486 ± 0.011 2.19 82.63
6250.0 0.496 ± 0.016 3.22 122.73
3125.0 0.529 ± 0.017 3.29 83.19
1562.5 0.556 ± 0.012 2.24 66.26
781.3 0.577 ± 0.011 1.89 60.43
390.6 0.568 ± 0.021 3.78 170.29
195.3 0.559 ± 0.019 3.33 465.85
97.7 0.621 ± 0.015 2.39 83.42
48.8 0.651 ± 0,007 1.10 42.90
24.4 0.657 ± 0.012 1.84 63.76
12.2 0.663 ± 0.029 4.39 96.01
6.1 0.676 ± 0.019 2.82 98.23
3.1 0.684 ± 0.014 2.09 127.20
153
Chapter 4: Anti-ethynyl estradiol polyclonal antibodies
EE concentration (ng ml*1)
Figure 4 .17  : Intra-day studies on competitive ELISAs using the anti-EE Pab, 
E E A b l fo r the detection o f free E E  in bile. The plates were coated with 2 jug m l1 
solution o f E E A bl and the conjugate EE-6-CM O -H RP was used at 0.119 pig m l1.
Table 4.10 : Intra-day CVs and accuracies for EEAbl competition ELISA in bile. 
Five sets o f fifteen standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± SD, variation (%)
(ng m l1) (Abs (CVs), <%)
100000.0 0.267 ± 0.011 4.18 112.71
50000.0 0.270 ± 0.008 2.99 136.43
25000.0 0.279 ± 0,012 4.42 104,09
12500.0 0.298 ± 0.015 5.19 56.63
6250.0 0.293 ± 0.009 3.05 148.93
3125.0 0.314 ± 0.010 3.30 107.54
1562.5 0.330 ± 0.015 4.55 117.88
781.3 0.361 ± 0.014 3.90 85.82
390.6 0.380 ± 0.015 3.90 96.17
195.3 0.396 ± 0.015 3.90 114.48
97.7 0.424 ± 0.012 2.78 90.19
48.8 0.442 ± 0.009 2.13 84.85
24.4 0.446 ± 0.018 4.11 140,12
12.2 0.457 ± 0.013 2.85 149.27
6.1 0.477 ± 0.012 2.44 51.34
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Figure 4.18: Inter-day studies on inhibitive ELISAs using the anti-EE Pab, EEAbl 
for the detection o f free EE in bile. The inhibition assay uses EE-6-CMO-BSA 
conjugate coated at 0.16 fig m t1 and the antibody at a concentration of 0.5 fjg m t1.
Table 4.12 : Inter-day CVs and accuracies for EEAbl inhibition ELISA in bile. 
Five sets o f fifteen standards were analysed on five different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± SD, variation (%)
(ng m f1) (A/Ao) (CVs), (%)
50000.0 0.656 ± 0.068 10.30 107.55
25000.0 0.677 ± 0.072 10.70 109.73
12500.0 0.701 ± 0.067 9.52 114.41
6250.0 0.733 ± 0.070 9.59 104.28
3125.0 0.785 ± 0.069 8.80 68.62
1562.5 0.824 ± 0.067 8.19 61.55
781.3 0.818 ± 0.066 8.01 138.61
390.6 0.805 ± 0.038 4.72 362.91
195.3 0.913 ± 0.016 1.79 70.81
97.7 0.938 ± 0.027 2.87 74.04
48.8 0.952 ± 0.036 3.82 96.93
24.4 0.980 ± 0.027 2.71 72.83
12.2 0.981 ± 0.020 2.09 140.13
6.1 1.014 ± 0.031 3.01 47.21
3.1 0.999 ± 0.033 3.27 246.08
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Figure 4.19 : Inter-day studies on competitive ELISAs using the anti-EE Pab, 
EEAbl for the detection of free EE in bile. The plates are coated with 2 pg m t1 
solution o f EEAbl and the conjugate EE-6-CMO-HRP was used at 0.119 pg  m t1.
Table 4.13 : Inter-day CVs and accuracies for EEAbl competition ELISA in bile. 
Five sets of fifteen standards were analysed on five different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy, ]
Concentration, (ng ± SD, variation (%)
E  m l1) (A/A.0 (CVs), (%)
100000.0 0.640 ± 0.060 9.31 89.79
50000.0 0.642 ± 0.069 10.80 146.18
25000.0 0.652 ± 0.056 8.63 143.10
12500.0 0.684 ±  0.042 6.21 77.89
6250.0 0.707 ± 0.056 7.97 85.45
3125.0 0.744 ± 0.050 6.70 84.06
1562.5 0.755 ± 0.029 3.87 138.20
781.3 0.821 ± 0.034 4.09 99.38
390.6 0.875 ± 0.071 8.16 85.77
195.3 0.906 ± 0.036 3.97 97.56
97.7 0.926 ± 0.027 2.92 126.35
48.8 0.973 ± 0.022 2.25 50.26
24.4 0.974 ± 0.061 6.28 94.81
12.2 0.982 ±  0.048 4.89 105.19
6.1 0.987 ± 0.060 6.11 139.22
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Figure 4.20: Intra-day studies on inhibitive ELISAs using the anti-EE Pab, EEAb2 
for the detection of free EE in bile. The inhibition assay uses EE-6-CMO-BSA 
conjugate coated at 0.2 fig m t1 and the antibody at a dilution o f 0.57 fig m l1.
Table 4.14 : Intra-day CVs and accuracies for EEAb2 inhibition ELISA in bile. 
Five sets o f ten standards were analysed on the same day and the CVs were 
calculated. A  four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ±SD , variation <%)
(ng m l') f Ah«) (CVs), (%)
100000.0 0.104 ± 0.002 1.99 84.38
50000.0 0.114 ± 0.004 3.21 113.45
25000.0 0.142 ± 0.004 2.87 104.63
12500.0 0.184 ± 0.001 0.62 99.86
6250.0 0.233 ± 0.003 1.19 92.75
3125.0 0.266 ± 0.003 1.19 102.29
1562.5 0.286 ± 0.013 4.37 126.84
781.3 0.315 ± 0.011 3.56 70.55
390.6 0.318 ± 0.003 0.99 100.27
195.3 0.295 ± 0.007 2.43 784.49
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Figure 4.21 : Intra-day studies on competitive ELISAs using the cmti-EE Pah, 
EEAh2 fo r the detection o f free E E  in bile. In the competitive ELISA the plates are 
coated with 1.71 jug m l1 dilution o f EEAb2 and the conjugate EE-6-CMO-HRP 
was used at 0.478 jug m l1.
Table 4.15 : Intra-day CVs and accuracies for EEAb2 competition ELISA in bile. 
Five sets o f eight standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol 
Concentration, 
(iii* ml"1)
Calculated mean
± SD,
(Abs)
Coefficients of 
variation 
(CVs). (%)
Accuracy,
(%)
100000.0 0.085 ± 0.002 2.11 99.96
50000.0 0.097 ± 0.003 3.29 98.49
25000.0 0.106 ± 0.002 2.35 121.69
12500.0 0.126 ± 0.002 1.97 76.01
6250.0 0.130 ± 0.004 2.85 118.25
3125.0 0.144 ± 0.004 3.02 101.97
1562.5 0.153 ± 0.006 3.98 102.51
781.3 0.162 ± 0.007 4.36 101.25
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Figure 4.22: Inter-day studies on inhibitive ELlSAs using the anti-EE Pab, EEAb2 
for the detection of free EE in bile. The inhibition assay uses EE-6-CM0-BSA 
conjugate coated at 0.2 jug m t1 and the antibody at a dilution o f 0.57 /jg m t1.
Table 4.16 : Inter-day CVs and accuracies for EEAb2 inhibition ELISA in bile. 
Five sets o f  ten standards were analysed on five different days and the CVs were 
calculated. A  four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± SD, variation (%)
(ng m l1) (A/A0) (CVs), (%)
100000.0 0.340 ± 0.021 6.16 98.22
50000.0 0.432 ± 0.029 6.69 97.77
25000.0 0.523 ± 0.028 5.40 106.12
12500.0 0.656 ± 0.041 6.33 87.82
6250.0 0.735 ± 0.028 3.78 98.36
3125.0 0.807 ± 0.038 4.66 105.23
1562.5 0.866 ± 0.033 3.79 109.47
781.3 0.947 ± 0.041 4.37 48.10
390.6 0.935 ± 0.024 2.61 130.94
195.3 0.971 ± 0.026 2.73 76.55
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Figure 4.23 : Inter-day studies on competitive ELISAs using the anti-EE Pab, 
EEAb2 for the detection of free EE in bile. In the competitive ELISA the plates are 
coated with 1.71 fig m t1 dilution o f EEAb2 and the conjugate EE-6-CMO-HRP 
was used at 0.478 fig m t1.
Table 4.17 : Inter-day CVs and accuracies for EEAb2 competition ELISA in bile. 
Five sets o f eight standards were analysed on five different days and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol 
Concentration, 
(n g n il1)
Calculated mean 
± SI),
(a /a ())
Coefficients of 
variation 
(CVs), (%)
Accuracy,
(%)
100000.0 0.566 ± 0.046 8.17 93.46
50000.0 0.607 ± 0.044 7.24 98.91
25000.0 0.669 ± 0.039 5.80 109.79
12500.0 0.799 ± 0.046 5.79 92.25
6250.0 0.898 ± 0.040 4.50 98.30
3125.0 0.970 ±  0.045 4.68 109.50
1562.5 1.032 ± 0.043 4.17 96.44
781.3 1.062 ± 0.050 4.73 78.64
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4.2.6 Cross Reactivity Studies on EEAbl and EEAb2
Cross reactivity studies were carried out as described in section 2.4.7.8. Both 
antibodies were tested against a number of structurally related compounds to 
identify the extent o f their cross reactivity. Sets o f standards were prepared using 
EE and each of the steroids to be tested. These were all run in duplicate and in 
parallel in the optimised inhibitive ELISA. For each compound the concentration 
that suppressed 50% o f the zero signal was calculated. This value for each drug 
was compared to that obtained for EE. The percentage cross reactivity was 
calculated according to the following formula;
% Cross reactivity = ------------------------ x 100
IC50 of compound
The drugs tested and the calculated cross reactivities are shown in Table 4.18.
Table 4.18 : Cross reactivity o f the polyclonal antisera to EE and other structurally 
related steroid hormones and cross-reacting compounds in inhibition ELISAs. 
“Percentage cross reactivity was calculated as (ICjo[EE]/ICjo[test compound])* 100.
Compounds Tested EEAbl EEAb2
% Cross Reactivity "
EE 100.00 100.00
Trenbolone 1.24 <0.10
Diethylstilbestrol <0.03 <0.10
a-Estradiol <0.03 <0.10
ß-Estradiol 1.78 1.51
Estrone <0.03 <0.10
Norgestrol <0.03 14.35
19-Nortestosterone <0.47 6.20
Methyl Testosterone 1.42 12.19
Zeranol 0.03 <0.10
Norethisterone 0.50 73.46
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4.2.7 Optimisation of BIAcore 3000 assay for the detection of EE
4.2.7.1 Optimisation o f p H  fo r  the chip coupling reaction
This was carried out as described in section 2.4.9.1. The solutions containing EE- 
CMO-BSA at various pHs were passed over a fresh chip surface and the amount of 
conjugate that associated with the surface was noted. The pH at which the highest 
response was seen was taken to be the optimum pH for the EDC/NHS coupling 
reaction. Figure 4.24 shows this response curve and it can be noted that pH 4.2 
gave the optimal response. This was used in all subsequent chip coatings.
4.2.7.2 Immobilisation o f E E -C M O -B SA
A 50 (ig ml'1 solution of EE-CMO-BSA was prepared in lOmM sodium acetate 
buffer, pH 4.2. This was immobilised to the surface of a sensor chip as described in 
section 2.4.9.2. Figure 4.25 shows a typical profile for the immobilisation of this 
drug onto the dextran surface.
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Figure 4.24 : Preconcentration curve for the determination o f the optimum buffer 
pH  to carry out the immobilisation ofEE-CMO-BSA to BIAcore CMS sensor chip.
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Figure 4.25 : Typical BIAcore sensogram for the immobilisation of EE-CMO-BSA 
to the surface of the CM5 sensor chips. The numbered areas refer to the different 
stages o f the immobilisation procedure. Section I is the machine baseline, with 
HBS buffer flowing over the surface of the chip. 2 refers to the refractive index 
change in the liquid when the EDC/NHS mixture is passed across the chip and 3 is 
the return to HBS buffer. A minimal increase in response units is seen at 3. Section 
4 shows the binding of the conjugate to the activated dextran matrix and 5 is the 
return to HBS buffer flow. The surface is then capped with ethanolamine to remove 
any loosely bound conjugate and to deactivate any remaining active sites on the 
dextran surface (6 - 7). The total amount o f conjugate bound is the difference 
between 3 and 7, labelled 8, (approximately 17,000RU in this example).
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4.2.7.3 Background binding o f both E E  polyclonal antibody preparations in the 
BIAcore-based assay
It is vital to show that the antibody is not binding to any other component present 
on the surface of the sensor chip other than the immobilised drug, EE. Solutions of 
the polyclonal antibodies were prepared in HBS buffer and were passed over three 
chip surfaces, a dextran chip surface, a BSA-immobilised surface and an EE-CMO- 
BSA-immobilised surface. A specific antibody would be expected to only bind to 
the conjugate-immobilised surface. The amount of binding to the other surfaces is 
an indication of the background binding, if any, that can be expected in the 
biosensor assay. Figure 4.26 shows these binding curves and it can be seen that 
only the conjugate surface had antibody binding in appreciable amounts. The 
results obtained for EEAb2 in these controls are not shown, as they were similar to 
those displayed for EEAbl.
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Figure 4.26 : Binding curves o f E E A b l to a dextran surface, a BSA-immobilised 
surface and a BSA-conjugate-coated surface. The amount o f antibody binding to 
the dextran and the BSA surfaces is very low. Both the BSA and dextran surfaces 
show less than 5 R U  o f  antibody binding compared to more than 500 R U  fo r the 
E E  conjugate-coated surface.
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Figure 4.27 : Regeneration study fo r  EEAbl using 1M ethanolamine, pH  13.6. 20 
cycles o f  the regeneration protocol were performed to equilibrate the surface 
before the regeneration study or any assays were carried out. Over the course o f 
the 75 regeneration cycles this surface actually begins to bind more antibody. An 
increase o f  60 RU  in binding occurs over the 75 regeneration cycles.
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Figure 4.28 : Regeneration curve fo r  EEAb2 using 30mM HCl followed by 30mM  
NaOH/10% acetonitrile. 12 cycles o f  the regeneration protocol were performed to 
equilibrate the surface before the regeneration study or any assays were 
performed. The drop in response over the 60 regeneration cycles is 102 RU.
¡68
2323235348484853485353905323
Chapter 4: Ana-eihyriyl estradiol polyciona) antibodies
4.2.8 Biosensor-based assays for the detection of EE using a BIAcore 3000
sensor
The BIAcore was used as the system to produce the biosensor assay. The 
carboxymethylated dextran surfaces of the sensor chips were activated and the EE- 
CMO-BSA conjugate was covalently attached to the surface. The samples were 
prepared in either HBS/2% (v/v) EtOH or bile depending on the matrix being 
investigated. The bile was diluted with an equal volume of HBS before use in the 
assay. The samples were mixed 1:1 with the appropriate antibody dilution and 
incubated for 1 hour at 37°C. They were then applied to the biosensor where each 
sample was assayed in triplicate. Figure 4.29 shows the typical binding curves 
obtained for a number of different EE concentrations. The differences in signal are 
clearly visible.
Figures 4.30 to 4.33 show the intra and inter-day assay standard curves for the 
BIAcore-bascd assay using EEAbl and EEAb2 to detcct free EE in HBS/2% (v/v) 
EtOH. Figures 4.34 to 4.37 show the intra and inter-day assay standard curves for 
the BIAcore-based assay using EEAbl and EEAb2 to detect free EE in bile/HBS.
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Figure 4.29 : Binding curves fo r  inhibitive BIAcore assay at different 
concentrations o f free EE. As in all competitive immunoassays the highest signal is 
obtained at the lowest concentration o f  free drug.
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Figure 4.30 : Intra-day BIAcore assays fo r  E E  in HBS/2% (v/v) EtOH  using 
E E A b l polyclonal antibody. The BSA conjugate was coated at 50 pg m t‘ onto the 
surface o f the chip fo r  the assays. The antibody was used at a concentration o f  
16 p g  m t1.
Table 4.19 : Intra-day CVs and accuracies for EEAbl inhibition BIAcore assay in 
HBS. Three sets of thirteen standards were analysed on the same day and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol 
Concentration, 
(ng nil"1)
Calculated mean 
± SD,
(RU)
Coefficients of 
variation 
(CVs), (%)
Accuracy, 
<%) ‘
25000.0 158.0 ± 1.1 0.71 95.20
12500.0 177.6 ± 1.5 0.82 102.15
6250.0 200.0 ± 1.0 0.51 103.69
3125.0 223.0 ± 1.5 0.65 106.55
1562.5 253.2 ± 1.0 0.40 92.43
781.3 288.4 ± 3.0 1.02 73.30
390.6 296.9 ± 3.7 1.25 118.10
195.3 321.2 ± 9.4 2.94 129.00
97.7 372.4 ± 1.9 0.52 76.27
48.8 389.3 ± 4.9 1.25 103.56
24.4 364.1 ± 3.7 1.00 370.32
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Figure 4.31 : Inter-day BIAcore assays fo r E E  in HBS/2% (v/v) EtOH  using 
E E A b l polyclonal antibody. The BSA conjugate was coated at 50 jug m tl onto the 
surface o f the chip fo r  the assays. The antibody was used at a concentration o f  
16 jug m t1.
Table 4.20 : Inter-day CVs and accuracies for EEAbl inhibition BIAcore assay in 
HBS. Three sets o f eleven standards were analysed on three different days and the 
CVs were calculated. A four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± SD, variation (%)
(ng m l1) (RU) (CVs), (%)
25000.0 165.5 ± 7.8 4.70 103.52
12500.0 175.8 ± 14.2 8.08 121.61
6250.0 209.0 ± 8.5 4.05 73.56
3125.0 222.4 ± 14.6 6.57 100.30
1562.5 240.9 ± 16.6 6.89 123.98
781.3 286.7 ± 3.0 1.05 81.30
390.6 301.6 ± 4.2 1.40 111.93
195.3 329.7 ± 11.8 3.59 102.75
97.7 349.3 ± 25.4 7.26 105.88
48.8 379.3 ± 15.7 4.13 43.92
24.4 369.7 ± 15.7 4.26 166.34
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Figure 4.32 : Intra-day BIAcore assays fo r  E E  in HBS/2% (v/v) EtOH  using 
EEAb2 polyclonal antibody. The BSA conjugate was coated at 50 ng m t1 onto the 
surface o f the chip fo r  the assays. The antibody was used at a concentration o f  
15.2 pg m t1.
Table 4.21 : Intra-day CVs and accuracies for EEAb2 inhibition BIAcore assay in 
HBS. Three sets o f ten standards were analysed on the same day and the CVs were 
calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
Concentration, ± SD, variation <%)
(ns m l1) (RV) (CVs), (%)
50000.0 51.0 5.2 10.13 102.09
25000.0 67.7 ± 5.0 7.35 108.56
12500.0 96.9 ± 6.3 6.48 94.29
6250.0 130.6 ± 6.6 5.02 86.19
3125.0 157.2 ± 4.8 3.08 97.50
1562.5 173.9 ± 9.2 5.27 136.31
781.3 216.0 db 1.7 0.80 102.11
390.6 253.6 ± 6.3 2.50 62.47
195.3 262.8 ± 3.4 1.30 83.59
97.7 265.2 ± 0.6 0.21 148.32
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Figure 4.33 : Inter-day BIAcore assays fo r  E E  in HBS/2% (v/v) EtO H  using 
EEAb2 polyclonal antibody. The BSA conjugate was coated at 50 ng m t1 onto the 
surface o f the chip fo r the assays. The antibody was used at a concentration o f  
15.2 fjg m t1.
Table 4.22 : Inter-day CVs and accuracies for EEAb2 inhibition BIAcore assay in 
HBS. Three sets o f ten standards were analysed on three different days and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy,
j Concentration, ± SD, variation (%)
(ng m l1) (Rl>) (CVs), (%)
50000.0 55.3 ± 4.5 8.05 108.40
25000.0 76.8 ± 15.9 20.74 95.92
12500.0 101.8 ± 10.0 9.77 95.15
6250.0 128.3 ± 8.3 6.50 102.81
3125.0 162.5 ± 13.8 8.52 99.65
1562.5 190.2 ± 17.7 9.30 110.62
781.3 224.5 ± 10.5 4.69 97.70
390.6 252.0 ± 4.6 1.81 83.01
195.3 260.5 ± 5.5 2.12 117.91
97.7 275.5 ± 9.9 3.58 105.35
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Figure 4.34 : Intra-day BIAcore assays for EE in bile using EEAbl polyclonal 
antibody. The BSA conjugate was coated at 50 jug m i1 onto the surface of the chip 
for the assays and the antibody was used at a concentration o f 40 jugm t1.
Table 4.23 : Intra-day CVs and accuracies for EEAbl inhibition BIAcore assay in 
bile. Three sets o f fourteen standards were analysed on the same day and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol 
Concentration, 
(ng ml'1)
Calculated mean 
±  Si),
(RU)
Coefficients of 
variation 
(CVs), (%)
Accuracy, i 
<%)
100000.0 95.3 ± 3.3 3.41 98.24
50000.0 102.5 ± 11.3 11.01 89.46
25000.0 107.5 ± 2.8 2.59 116.61
12500.0 122.6 ± 2.8 2.29 88.17
6250.0 129.6 ± 0.5 0.36 123.47
3125.0 156.1 ± 0.9 0.57 82.40
1562.5 169.5 ± 2.8 1.68 103.63
781.3 189.2 ± 0.5 0.28 110.20
390.6 221.2 ± 1.3 0.60 82.63
195.3 229.3 ± 9.9 4.30 128.60
97.7 266.6 ± 3.8 1.43 71.56
48.8 268.8 =fc 7.1 2.64 131.11
24.4 292.5 ± 3.3 1.11 87.97
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Figure 4.35 : Inter-day BIAcore assays fo r E E  in bile using E EA bI polyclonal 
antibody. The BSA conjugate was coated at 50 p g  m l' onto the surface o f the chip 
fo r  the assays. The antibody was used at a concentration o f 40 pg m l'.
Table 4.24 : Inter-day CVs and accuracies for EEAbI inhibition BIAcore assay in 
bile. Three sets o f fourteen standards were analysed on three different days and the 
CVs were calculated. A four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol 
Concentration, 
(ng nil ’)
Calculated mean 
± S D ,
(RH)
Coefficients of 
variation 
(CVs), <%)
Accuracy,
(%)
100000.0 83.3 ± 12.3 14.82 81.92
50000.0 90.7 ± 10.5 11.63 95.69
25000.0 96.4 ± 13.0 13.47 134.40
12500.0 113.9 ± 9.5 8.30 111.14
6250.0 139.4 ± 12.0 8.61 82.76
3125.0 156.2 ± 0.9 0.58 95.68
1562.5 175.2 ± 5.0 2.87 107.98
781.3 201.3 ± 10.6 5.26 102.40
390.6 225.2 ± 5.3 2.34 104.06
195.3 257.7 ± 25.7 9.98 77.20
97.7 262.5 ± 30.7 11.71 131.59
48.8 284.3 ± 40.7 14.32 118.06
24.4 309.8 ± 14.9 4.82 68.34
12.2 312.3 ± 61.5 19.70 117.29
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Figure 4.36 : Intra-day BIAcore assays fo r  EE in bile using EEAb2 polyclonal 
antibody. The BSA conjugate was coated a t 50 jug m t1 onto the surface o f the chip 
fo r  the assays and the antibody was used at a  concentration o f 34.2 jug m t1 fo r  
EEAb2.
Table 4.25 : Intra-day CVs and accuracies for EEAb2 inhibition BIAcore assay in 
bile. Three sets o f eleven standards were analysed on the same day and the CVs 
were calculated. A four-parameter equation was used to fit a curve to the data using 
BIAevaluation software and its percentage accuracy was calculated.
Ethyny! Estradiol Calculated mean Coefficients of A  p p n p vV- V  W  1  m  V  |  ^
Concentration, ± SD, variation (%)
(nji m l1) (RU) (CVs), (%)
100000.0 108.6 ± 4.6 4.24 78.82
50000.0 112.8 ± 3.2 2.85 145.76
25000.0 169.8 ± 4.8 2.80 108.41
12500.0 232.8 ± 6.1 2.62 77.73
6250.0 266.5 ± 3.8 1.43 88.77
3125.0 287.0 ± 15.4 5.37 124.50
1562.5 344.4 ± 21.3 6.17 81.02
781.3 356.5 ± 1.5 0.42 123.17
390.6 387.0 ± 29.1 7.53 110.63
195.3 408.9 ± 7.4 1.80 106.80
97.7 431.4 ± 14.2 3.28 77.24
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EE concentration (ng ml*1)
Figure 4.37 : Inter-day BIAcore assays fo r  E E  in bile using EEAb2 polyclonal 
antibody. The BSA conjugate was coated at 50 pg m t1 onto the surface o f the chip 
fo r  the assays. The antibody was used at a concentration o f 34.2 p g  m t1.
Table 4.26 : Inter-day CVs and accuracies for EEAb2 inhibition BIAcore assay in 
bile. Three sets o f  eleven standards were analysed on three different days and the 
CVs were calculated. A four-parameter equation was used to fit a curve to the data 
using BIAevaluation software and its percentage accuracy was calculated.
Ethynyl Estradiol Calculated mean Coefficients of Accuracy, ]
Concentration, ± S D , variation (%)
(ng n il1) (R li) I (CVs), (%)
100000.0 104.8 ± 3.6 3.46 84.70
50000.0 114.5 ± 7.5 6.57 134.46
25000.0 168.4 ± 12.7 7.51 93.44
12500.0 215.3 ± 17.4 8.10 86.15
6250.0 246.1 ± 19.4 7.88 104.75
3125.0 279.5 ± 6.6 2.35 118.86
1562.5 327.0 ± 43.9 13.41 91.85
781.3 362.6 ± 24.3 6.70 66.90
390.6 349.2 ± 39.7 11.38 205.95
195.3 396.0 ± 39.4 9.94 40.43
97.7 391.0 ± 35.6 9.10 126.14
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The structure of EE has no side groups which could be easily conjugated that are 
not involved in either the function of the molecule or its uniqueness compared to 
other steroids. To allow the conjugation of this small molecule to a carrier a 
common derivative, EE-6-CMO, is used. This molecule provides a carboxy group 
at the 6 position through which attachment can be carried out without affecting the 
recognition sites on the molecule. Two chemistries were used for conjugation of 
EE-6-CMO, i.e. a mixed anhydride and a NHS-ester method. Both of these 
chemistries form an amide bond between the -COOH group of EE-6-CMO and - 
NH2 groups located on the carrier molecule.
All conjugates were dialysed extensively in dialysis tubing with a molecular weight 
cut-off of 10,000. This allows any unconjugated steroids to pass into the dialysis 
vessel, as EE-6-CMO has a M.W. of 383.4, whereas all the protein and any EE 
bound to it will remain inside the tubing. This ensures that any further analysis of 
the conjugation will not show any interference from any free EE-6-CMO. The 
spectrums of the conjugates were analysed to confirm the success of the 
conjugation. EE-6-CMO shows a distinct peak at 310nm that is not a characteristic 
of any of the protein carriers. The presence of this peak in the spectrogram of the 
dialysed conjugate indicated the presence of the bound hapten. The conjugates 
were also tested against commercial antibodies (data not shown) to further confirm 
the presence of the bound hapten.
Polyclonal antibodies were produced using New Zealand White Rabbits and the 
EE-6-CMO conjugates. The rabbits were boosted until the titre reached at least 
1/256,000 and were then sacrificed. Rabbit two was sacrificed after two booster 
injections and rabbit one was left for a further three boosts. The antibodies were 
purified by saturated ammonium sulphate precipitation followed by protein G 
affinity chromatography, using low pH elution conditions. The purified proteins 
were characterised by SDS-PAGE, (Figure 4.5) and the two bands corresponding to 
the heavy and light chains of the antibody can be seen. The heavy and light chains 
are dissociated and separated clearly as SDS-PAGE separates proteins by size 
under denaturing conditions. No other bands are seen in the purified sample.
The polyclonal antibodies were produced for use in testing systems for the 
detection of free EE in solution. The ELISA test systems were developed first with
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4.3 Discussion
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competitive and inhibitive formats (Figure 3.1.4). With the competitive assay free 
EE and EE-6-CMO-HRP compete for binding to the polyclonal antibody that is 
absorbed on the surface of a 96 well immunoplate. The amount of bound HRP is 
then detected. To optimise the antibody concentration required for the coating the 
antibody must be the limiting reagent in the assay. If too much antibody is 
available to bind the free and conjugated EE, the assay will not show a significant 
change in signal with small increases in free EE concentration. The optimal 
working dilutions for the EE-6-CMO-HRP conjugate were taken from the linear 
region of the conjugate dilution curve, at approximately 50-70% of maximum 
binding. At this stage of the response curve small changes in conjugate 
concentration give the maximum change in signal. Non-competitive ELISAs were 
carried out to determine the optimum dilutions for the assays and the results were a 
coating of 2 (ig ml'1 of EEAbl with an EE-6-CMO-HRP concentration of 0.119 [ig 
ml'1, and 1.71 ^g ml'1 of EEAb2 and 0.478 ^g ml'1 of EE-6-CMO-HRP.
In the inhibition formal the EE-6-CMO-BSA conjugate is absorbed onto the plate 
and the antibody and free EE is added. The free EE inhibits the amount of antibody 
that can bind to the conjugate on the surface of the plate. A HRP-labelled 
secondary antibody then detects the amount of antibody bound. In the inhibition 
assay it is also necessary to have the concentrations of the coating and the added 
components optimised. The antibody is still the limiting reagent even though it is 
no longer bound to the surface of the plate but it is also necessary to ensure that the 
amount of conjugate absorbed to the surface of the plate is not too high. This would 
result in the antibody no longer being the limiting factor as it could all be bound to 
the immobilised conjugate. Non-competitive ELISAs were carried out to determine 
the optimum concentrations of both the antibody and the coating conjugate and 
they resulted in an EE-6-CMO-BSA concentration of 0.16 fig ml'1 being used with 
an EEAbl concentration of 0.5 fig ml'1 and 0.57 |jg ml"1 of EEAb2 with a coating 
of 0.2 |ig ml"1 BSA conjugate.
Using the optimised conditions for the assays the detection ranges of the assays 
were determined. A wide range of free EE concentrations from 0.38 - 100,000 ng 
ml"1 were prepared in PBS/2% (v/v) EtOH and assayed within the ELISA test 
systems. The antibodies showed competition in these ranges for both assay formats. 
The EEAbl competitive assay had a range of detection of 1.5 - 25,000 ng ml'1. The
i 80
Chapter 4: Anti-ethynyl estradiol polyclonal antibodies
inhibitive assay had a range of 3 - 50,000 ng ml'1. The EEAb2 antibody had a range 
of 48.8 - 50,000 ng ml*1 in the competitive assay and 1.5 - 50,000 ng ml*1 in the 
inhibitive format.
The results o f  these assays were statistically analysed to show their reproducibility. 
Intra-assay (5 replicates within an assay) and inter-assay (5 assays over 5 days) 
variations were analysed. The coefficients o f  variations (standard deviation o f the 
data set as a function o f the mean) were calculated and Table 4.27 shows a 
summary o f the ranges o f CVs found in each assay.
Table 4.27 : CV ranges o f the inhibitive and competitive ELISAs for the detection 
o f free EE in PBS/2% (v/v) EtOH.
Competitive Inhibitive
Intra-assay Intcr-assay Intra-assay Intcr-assay j
EEAbl 0.83 - 5.94% 4.35 - 11.55% 0.74 - 4.29% 0.84- 6.98%
EEAb2 1.81-5.99% 1.56- 10.40% 1.88 -4.59% 3.48 - 10.42%
The CVs for all these assays are well within the suggested acceptable limits for the 
precision o f an immunoassay o f below 20% (Findlay et al., 2000).
The data sets showed good agreement with a 4-parameter model fit. This model 
was used to fit trendlines to the data using BIAevaluation 3.1 software.
While the CVs are acceptable for the majority o f these assays, at the extreme points 
o f the range the accuracies become unworkable. At the present time an accuracy 
range o f  80-120% is recommended, although some workers have suggested a less 
stringent criteria o f 75-125% for immuno-based analytical techniques (Findlay et 
al., 2000).
The accuracies o f these assays can be improved by reducing the working range of 
the assays to one that does not include the inaccurate outlying points. These points 
are tending towards the asymptotes o f the dose response curve and in these areas a 
large change in concentration may only affect a minimal difference in measurable 
signal, leading to large errors. The working range o f the assays should not contain 
these areas o f the dose response curves, as the assay cannot assess the 
concentration o f a sample accurately at these extremes. The following list gives the 
recommended ranges for the detection o f free EE in PBS/2% (v/v) EtOH in each of 
the ELISAs.
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■ EEAbl Inhibitive
■ EEAbl Competitive
■ EEAb2 Inhibitive
■ EEAb2 Competitive
6.1 -25,000 ng ml'1
3.1 -6,250 ng ml'1 
97 - 25,000 ng ml'1
195 - 12,500 ng ml'1
Once the principle o f the ELISA assays had been proven using these antibodies and 
conjugates, the ability o f the reagents to detect EE within a biological matrix was 
assessed. There are many different matrices that could have proven useful for the 
detection o f illegally administered steroid hormones including urine, hair and 
serum, but it was decided to use bile for these assays. Bile is the natural storage 
area for steroid hormones in the body and it has been shown that some residues 
from administered steroids persist there longer than in other biological fluids 
(M°Evoy et al., 1998).
The bile reduced the measurable signal when it was used neat in the assays so to 
minimise this effect it was diluted 50:50 with PBS before use. By carrying out this 
slight pre-treatment o f the matrix many o f the interference effects were reduced. 
However, it would also raise the overall lower limit o f detection o f the assay. The 
assay graphs (Figures 4.16 - 4.23) and accompanying statistical tables (Tables 4.10 
- 4.17) are shown for the assays when bile was used as the sample diluent.
The CVs for the assays are comparable with those found in the assays using PBS as 
a sample diluent. A comparison o f  the CV ranges (Table 4.27 and 4.28) shows that 
the variation within the assay when bile is used as a sample matrix is almost as low 
as that found in the model assay.
Table 4,28 : CV ranges o f the inhibitive and competitive ELISAs for the detection 
o f free EE in bovine bile.
Competitive Inhibitive
Intra-assay Inter-assay Intra-assay Inter-assay J
EEAbl 2.13-5.19% 2.25 -10.80% 1.10-5.65% 1.79-10.70%
EEAb2 1.97-4.36% 4.17- 8.17% 0.62 - 4.37% 2.61 - 6.69%
The 4-parameter model was used to fit standard curves to the ELISA data and used 
to calculate the accuracies o f the assays. The inaccuracy o f the bile assays is greater 
than those found for the assays using PBS/2% (v/v) EtOH. As seen for the model
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assays the elimination of inaccurate points at the extreme ends of the limits of 
detection can bring about some improvement for some of the assays but not all.
The assays in general fit well to the 4-parameter model but the inhibitive assay 
using EEAbl antibody for the detection of EE in bile shows a very inaccurate mid­
section. This trend was seen throughout both the intra- and inter-assay tests. This 
dip was not seen in the same assay when PBS was used as a diluent and it was not 
seen in the competitive assay using the same antibody and diluent. If it were a 
problem inherent with the antibody it would be expected that the error would be 
present in other assays using it and this is not the case. Is the bile matrix affecting 
the assay? This is possible but again the trend is not seen in the other assays using 
bile. One theory to explain the anomaly may be the interaction of the polyclonal 
antibody population with the bile but again the use of the same antibody but with a 
different assay format did not show this anomaly. It is possible that in the 
competitive assay format the fact that the antibody was immobilised on the surface 
may confer some immunity to this error. These standards were also run on the edge 
of a plate, one across the bottom and one across the top. This seems like a possible 
explanation but these wells were used in other assays and the inaccuracy was not 
seen. The assay was also run changing the positioning of the standards but this did 
not alter the outcome. It is recommended, in the light of these points, not to use this 
assay for the detection of EE in the range where the anomaly is present.
The use of bile as the sample matrix alters the limit of detection of the assays. It 
affects all of the assays in a similar way. In all cases the assays lose sensitivity, 
being 4-fold for both competitive assays and the EEAb2 inhibitive assay and 8-fold 
in the case of EEAbl inhibitive assay. The upper limit of detection is also raised 
but not necessarily to a similar extent as the lower limit. This means that the dose 
response curve has been shifted to the right, (comparing Figures 4.8 - 4.15 to 4.16 - 
4.23). This may be due to some of the proteins contained within the bile that would 
ordinarily associate with natural estradiols. These may bind to free, conjugated or
■ EEAbl Inhibitive
■ EEAbl Competitive
■ EEAb2 Inhibitive
■ EEAb2 Competitive
48 - 50,000 ng ml'1 
12 - 12,500 ng ml’1 
390 - 100,000 ng m l1 
781 - 100,000 ng ml'1
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immobilised EE and not allow the binding reactions with the antibodies to occur as 
they do in the assays using PBS/2% (v/v) EtOH as the diluent. The constituents of 
the bile fluid may also be inhibiting the antibody binding reaction by occupying the 
antigen binding sites of the antibodies or binding the steroids themselves. Despite 
this, the assays described are reproducible and maintain a good level of accuracy 
with the spiked bile samples.
To assess the specificity of the anti-EE polyclonal antibodies that were produced 
for this project they were both tested against a number of related compounds (as 
listed in Table 4.18). EEAbl contains a more specific antibody population as it has 
much lower cross reactivities to related molecules with all the steroids tested 
having a cross-reaction value of less than 2%. EEAb2 shows much greater levels of 
cross-reaction with the same panel of drugs, e.g. 73.46% with norethisterone. This 
could have major implications for the use of this antibody for the detection of EE in 
different contexts. EE is often used in concert with norethisterone in the 
contraceptive pill (Dyas et al., 1981). Each of the compounds that cross-react with 
the polyclonal antibodies to any extent are similar to EE about the D ring. They 
each have a similar group at the 17 position and in addition they may have the 
same groups with the same orientation at positions 13 and 14. This indicates that 
the antibodies are directed against this end of the molecule. The point of 
attachment for the immunogen was position 6, which allows more of the D-ring to 
be exposed to the immune system than any other part of the molecule.
The data also shows much higher cross reactivities with EEAb2, the antibody that 
was harvested after only 2 booster injections. This kind of high cross reaction could 
be due to the shorter immunisation schedule. For example, norethisterone cross- 
reacts with EEAb2 at a level of 73% and this falls to 0.5% after a further 3 booster 
injections. This difference could be a function of the different immune systems of 
the two rabbits but it may also be affected by longer exposure of the antigen to the 
immune system, allowing for a refinement of the antibody population.
The most sensitive assay developed in this study is a competitive assay using the 
EEAbl anti-EE polyclonal antibody. It can detect as little as 12 ng ml'1 of EE in a 
sample of bile with minimal pre-treatment.
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The radioimmunoassay described by Agasan et al. in 1994 is able to detect much 
lower amounts of EE in both buffer and plasma. However, the monoclonal 
antibodies used showed high cross-reactivity with norethynodrel (25.7-100%), 
norethLsterone (5.5-26.1%) and ethynylestradiol-3-sulphate (11.4-52.3%) (Agasan 
et al., 1986). The assays developed here may not be as sensitive but they do not 
show the same high levels of cross-reactivity and the are also free from radio-active 
labels and so the assays are easier to carry out and safer for the workers involved. 
Turkes et al. (1981) described an enzyme immunoassay for the detection of EE in 
plasma samples. The plasma was extracted and subjected to the EIA procedure. 
The sensitivity again was much lower than the ELISAs developed in this chapter 
but this assay uses 2 overnight incubations, one in the extraction procedure and one 
in the assay itself. This is a substantial time lag if results are required to prevent 
food entering the food chain. Also this assay is run in immunotubes and so requires 
more reagents and space to run assays. Microtitre plates are much easier to handle 
and can be used to screen many samples simultaneously.
The commercial ELISA kit used by Sawaya et al. (1998b) to measure the amounts 
of EE in sheep urine and chicken muscle was produced by R-Biopharm. This assay 
was sensitive to a low pg ml'1 level. After investigation of the two matrices a cut­
off concentration of 0.3ppb was chosen. Below this amount the false positive rate 
was substantial and the introduction of the cut-off point reduced the number of 
negative results being treated as positive. The ELISA assays in this chapter are not 
as sensitive as this kit assay but they again have the advantage of simple sample 
pre-treatment.
The assays developed here must be improved further to obtain an assay that can 
compete with those described above. The assay must be able to detect low 
nanogram quantities of EE in samples. The EU has a zero tolerance for this 
compound in animals but in practice this translates to action values of 2ppb in urine 
and 0.5ppb in muscle. Any screening assay must be able to detect at these levels to 
be useful in the elimination of residues of this steroid from the food chain. The use 
of chemiluminescent or fluorescent-based assays may improve the sensitivity of the 
assays described. Delayed fluorescent immunoassays (DELFIA) may also prove to 
enhance the detection capabilities of these reagents.
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The BIAcore chip (CM5) used in this project has a carboxymethylated dextran 
surface to which the conjugate was immobilised. To establish the optimum pH for 
the immobilisation of the EE-CMO-BSA conjugate to the surface of the chip a 
preconcentration study was performed. Figure 4.24 shows the results of this 
experiment. A pH of 4.2 was chosen to perform the immobilisation. This was not 
the highest peak but as no peak between 4.2 and 4.6 was significantly better than 
another, a pH that suited the linking reagents was selected. Using this pH the 
conjugate was linked to the surface of the chip using a NHS-ester method. An 
example of the binding curve obtained with the immobilisation protocol is shown 
in Figure 4.25. The total amount of conjugate bound to the surface, in RU, is the 
change in values between the baseline before conjugate addition and the baseline 
after ethanolamine capping.
The ability of the antibodies to bind to this surface was evaluated. A number of 
solutions containing different amounts of antibody were passed across the surface 
until a response of approximately 500 units was seen. This concentration of 
antibody was used for all subsequent experiments using HBS as sample diluent, 
being 16 fig ml'1 for EEAbl and 15.2 fig ml"1 for EEAb2
The non-specific binding of the antibodies in this system were investigated. They 
were passed over an unmodified dextran surface, a BSA-immobilised surface and 
surface with the EE conjugate immobilised. The results (Figure 4.26) show that the 
antibody has negligible binding to either of the non-specific surfaces, but shows 
substantial binding to the conjugate-coated surface.
Each time the antibody binds to the surface of the chip it must be removed to allow 
another cycle to begin. The solutions required to remove the antibody and yet not 
denature the binding surface of the chip must be determined. A number of solutions 
were investigated including HC1 and NaOH (lO-lOOmM), alone and in 
combination, NaOH supplemented with 5-20% (v/v) acetonitrile and 1M 
ethanolamine, pH 13.6. Regeneration studies were carried out by determining the 
reproducibility of antibody binding to the surface over a course of antibody 
binding/regeneration cycles. If the amount of antibody binding remained relatively 
stable over a substantial number of regeneration cycles the regeneration protocol 
was taken to be sufficient. Figures 4.27 and 4.28 show the regeneration profile of 
the two antibodies using 1M ethanolamine pH 13.6 for EEAbl and 30mM HC1
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followed by 30mM NaC)H/10% (v/v) acetonitrile for EEAb2. Both regeneration 
protocols require the surface to be equilibrated before any assay is performed and 
this is achieved by passing a number of regeneration cycles across the surface. This 
ensures that any loosely immobilised conjugate is removed and the regeneration is 
only disrupting the antibody to surface binding.
The regeneration curve in Figure 4.28 shows the typical regeneration profile of 
most conjugate-bound surfaces. A slight drop is seen across the extent of the study. 
It has been proposed that once the surface loses no more than 20% of its original 
binding over the course of an assay then it can be deemed within tolerances (Wong 
et al., 1997). The profile seen in Figure 4.27 for the regeneration of EEAbl shows 
a different trend. This seems to have more binding after repeated regeneration 
cycles. This is not actually the case and it is purely an effect of the ethanolamine on 
the surface matrix. The same trend is seen if ethanolamine is passed over an 
immobilised surface without any antibody binding at all, (data not shown). The 
regeneration solution may cause a stretching or deformation of the dextran matrix 
that results in this slight increase in the amount of binding measured over time. 
Even though this is an unusual effect it would still lie within the 20% variation that 
has been proposed as agreeable.
Assays were carried out using the antibodies and EE spiked into HBS/2% (v/v) 
EtOH. The antibody solution in HBS was mixed in equal volumes with the EE 
samples and incubated for lh  at 37°C. The samples were then passed over an 
immobilised surface for the required time in triplicate and in random order. The 
random order is to facilitate the removal of any machine or assay bias that may 
occur if the samples are run consecutively.
For these assays, like the previous ELISAs, the reproducibility and accuracy of the 
assay was investigated. Each assay was run in triplicate and repeated three times. 
This lead to intra- and inter-day precisions being calculated along with the standard 
curves for the assays, Figures 4.30 - 4.33 and Tables 4.19 - 4.22. Table 4.29 below 
gives the ranges of the percentage coefficients of variation for the assays. The 
antibody response curves for the BIAcore assays also followed the 4-parameter 
model and this was used to fit the standard curve and calculate the percentage 
accuracy of it.
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Table 4.29 : CV ranges o f the inhibitive BIAcore assays for the detection of free 
EE in HBS/ 2% (v/v) EtOH and in bovine bile.
MBS/ 2% (v/v) EtOH Bovine Bile
Intra-assay Inter-assay Intra-assay Inter-assav ■
EEAbl 0.51 - 2.94% 1.05 - 8.08% 0.28 - 11.01% 0.58 - 19.70%
EEAb2 0.21 - 10.13% 1.81 -20.74% 0.42- 6.17% 2.35 -13.41%
The majority o f  the % CV ranges for the BIAcore assays are higher than those o f  
the corresponding ELISAs but that fact is deceptive as most o f the figures are at the 
lower end o f these ranges allowing them better overall precision. The accuracies 
are also closer to the value o f a 20% deviation of normal. Again there are some 
inaccuracies at the extremes o f the assay where it is approaching the asymptotes of 
the fit. These outliers may be removed to provide a more accurate assay system. 
The suggested ranges for the detection of free EE in HBS/ 2% (v/v) EtOH are
■ EEAbl BIAcore Inhibitive 97 - 25,000 ng ml'1
■ EEAb2 BIAcore Inhibitive 97 - 50,000 ng ml'1
After developing the working BIAcore assay the chosen matrix, bile, was tested in 
the system. The assays again look like they have higher % CV values than the 
corresponding ELISAs, (Table 4.29) but again the majority o f  the CVs are at the 
lower end of the range. Each o f the BIAcore assays in the bile matrix show greater 
inaccuracies at the lower range of the assay. This leads to a loss in sensitivity and 
reliability o f the assay in this region. As before the assay ranges given below show 
the most accurate range for the BIAcore assays.
■ EEAbl BIAcore Inhibitive 48 - 100,000 ng ml'1
■ EEAb2 BIAcore Inhibitive 1,563 - 100,000 ng ml'1
These detection ranges for EE represent assays that have accuracies close to the 
less stringent 75 - 125% limits that have been proposed for immunoassays. Some 
refinement o f the pre-incubation procedure may increase the accuracy although 
assays that did not use the pre-incubation and instead used a lOmin incubation
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within the machine for each sample did not show any great improvement in 
accuracy.
Previously, a BIAcore assay for the detection of EE has been described (Johansson 
and Hellenas, 2001). This assay showed a standard curve between 0.1 - 3 ng ml'1 
allowing the detection of EE below the action limits of 0.5 - 2 ng ml'1 depending on 
the matrix. The major advantage of this assay was the direct immobilisation of the 
steroid to the sensorchip surface. This gave the chip greater regeneration stability 
and the ability to be used for hundreds or even thousands of assays. This will make 
the assay very cost effective. The assays described in this study do not have 
unlimited regeneration capability because the proteins through which the steroids 
are linked to the surface are prone to degradation during regeneration protocols. 
Further work must be carried to investigate whether the immunoreagents developed 
in this study could be used directly immobilised to the chip and in this way produce 
a more sensitive and longer lasting assay (Gillis et al„ 2002).
Using EEAbl the competitive ELISA format showed a slightly lower assay range 
in both the model assay and the assay when bile was used as a sample matrix than 
that seen for the inhibitive format. The ranges in both EEAbl ELIS As are 
substantially better than those seen with the second antibody, EEAb2. Unlike the 
first antibody, EEAb2 gives a more sensitive assay using the inhibitive ELISA 
format, but it is still at least 8-fold less sensitive than the corresponding assay using 
EEAbl. This trend was also found in the BIAcore assay results. The two assays 
show similar detection ranges for the model biosensor assay but EEAbl shows 
substantially better detection for free EE than EEAb2 when the bile sample matrix 
is used.
The ELISA assays can be carried out quickly and simply with minimal amounts of 
equipment. They can screen many samples simultaneously and they would be 
ideally used where large numbers of animals were to be tested. The use of bile as 
the sample matrix lends the assay to the detection of bile in slaughter houses where 
this matrix is readily accessible. It will provide results within a couple of hours and 
at that stage carcasses can be held for further confirmatory testing.
The BIAcore assay could also be used in this manner and it would provide results 
as each sample is analysed and not in a batch fashion as the ELISA system. This
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would provide an even faster response to residue containing meat. The BIAcore 
assay can take anything between 5-10 mins to complete the analysis of each sample 
and so depending on the numbers of samples to be tested the ELISA may actually 
provide analysis of more samples in a day than the BIAcore assay.
In summary, EE-6-CMO was used to produce protein conjugates as both 
immunogens and assay reagents. These conjugates were used to produce anti-EE 
polyclonal antibodies. These antibodies were isolated from the rabbit serum and 
used to develop competitive and inhibitive ELISAs along with a BIAcore-based 
immunoassay to detect nanogram amounts of free EE in samples. Analysis of these 
assays shows both to be reproducible and accurate. These assay systems were then 
tested using bovine bile, a complex sample matrix. The results show that the 
antibodies and the systems developed can be used to detect free EE in bile with 
close to the same sensitivity as the model assay. The assays are not sensitive 
enough to provide screening at the recommended levels of 2ppb but further work 
such as the use of chemiluminescent substrates may increase the sensitivity of the 
assays to this required level (Kohen et al., 1983; Adamczyk et al., 2000). The 
studies on the cross-reactivities of these antibodies show that EEAbl has a high 
specificity for EE, but EEAb2 exhibits much higher interference from related 
compounds.
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C h a p t e r  5
D e v e l o p m e n t  o f  a  R a p id  E L IS A  M e t h o d  
u s in g  a  P o r t a b l e  A u t o m a t e d  D e v ic e
5.1 Introduction
5.1.1 Rapid Assays
Until recently the predominant usage of immunoassay methods had been 
confined to laboratories with the correct equipment and trained personnel (Paek 
et al., 2000). However, immuno-analysis has evolved from this starting position 
to one where it can be used in a variety of surroundings by relatively untrained 
operators. The current trends in the development of such on-site testing systems 
are moving towards the use of two technologies, the immunochromatographic 
test strip or lateral flow immunoassay and the immunosensor (Choi et a l, 1999). 
The theory behind these assay formats is described in section 1.4. The 
automation of existing immunoassays is also being investigated for use in areas 
outside the lab environment.
Lateral flow immunoassays can be used to detect a wide range of analytes, e.g. 
digoxin (Choi et al., 1999), cannabinoids (Wennig et. al., 1998) and 
trinitrotoluene (TNT, Heiss et al., 1999), using the formats described in section 
1.4.5. A dipstick dye immunoassay for schistosomiasis diagnosis has also been 
developed which would be of great benefit in the areas where this disease is 
prevalent (Zhu et a l, 2002). The lateral flow immunoassay can also be improved 
by the addition of extra steps within the test strip. A lateral flow immunoassay 
has recently been described that separates isoforms of proteins before analysis, 
all on a single assay strip (Lonnberg and Carlsson, 2000). In this form, the 
sample is first subjected to an anion exchange membrane, which will retard the 
flow of the unwanted protein isoforms and let the active isoform to proceed 
along the strip. The fraction containing the target isoform will continue along the 
strip and bind at the immobilised capture antibody. A second labelled antibody is 
then added to the base of the strip (post-anion exchange section) and will bind to 
any immobilised protein caught by the capture antibody. The label can then be 
visualised and the amount of protein determined. This system could be used in 
many different applications where samples may need to be separated before 
analysis. By altering the primary exchange system from an anion to a cation 
exchange, size exclusion or affinity system the strip could be used to separate 
many different types of analytes to provide more accurate and specific test strips.
Chapter 5: Development oi a rapid ELISA
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Portable imraunosensors may also be developed in the near future in formats that 
can be readily transported and used at different sites. Examples of this type of 
technology would be the BIAprobe (Figure 5.1) and the Texas Instruments 
Spreeta device (Figure 5.2). Both of these systems contain a sensing surface to 
which one half of a binding couple is immobilised. The BIAprobe can be 
immersed in the sample and any binding occurring will be detected through the 
same SPR phenomenon used for the BIAcore systems (section 4.1.5). The bound 
molecules can then be stripped and the probe used again. It may also be possible 
to mass-produce the sensing tips of the probe and so provide a disposable sensing 
platform that can be changed after each determination. It would also be possible 
to provide probes with different specificities to make this a universally useful 
assay system.
The Spreeta device works more like a miniature version of the BIAcore system. 
It utilises a flow system to bring the sample into contact with the sensing surface 
to allow binding and also to remove the bound molecules for the re-use of the 
surface. Both of these systems can be connected to a laptop computer for data 
acquisition and analysis outside the laboratory. With the correct immunoreagents 
these systems can be used in many areas to provide fast and accurate 
determinations of the presence or absence of numerous analytes that require 
monitoring.
A reduction in the time needed to perform an assay is also of interest. If these 
assays can be carried out in shorter times they become candidates for use in the 
field. Some workers have looked at the application of enzyme immunoassays to 
detect analytes in less than 30min (Yolken and Leister, 1981; Claycomb el a l, 
1998). There are numerous automated immunoassay systems on the market but 
most of them are designed for use in a laboratory environment (Wild, 1994). 
Many of these systems will become very useful as the trend towards home and 
bedside testing continues in the health sector (Lehmann, 2002).
The enzyme immunoassay device used in this work was designed to be easy to 
use and portable. It is small and can be mounted in the boot of a car or even on 
the dashboard (Figure 5.1). This device combines the shortening of the 
immunoassay procedure with a portable automatic system to provide a useful 
analytical device for use in the field. This device is explained in detail in the 
section 5.1.3.
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Figure 5.2 : The BIAprobe. A small thin fibre optic that has had one end coated 
with a gold layer. This is the sensing end of the probe. It is immersed and the 
signal is passed from the probe to a data acquisition device. Binding is detected 
using a combination of the light passed through the fibre optic and SPR
Surface Plasmon 
Layer
Reflecting 0ptlca, P|ast|C 
MfTor Substrate
\\Light Emitting \ 1 Temperature Photodlode 
Diode Polarizer Sensor Array
Figure 5.1 : Picture of the Spreeta biosensor from Texas Instruments. This 
device uses SPR to detect the required change in the sensing environment. The 
entire assembly is small and fits  easily into the palm of a hand The components 
o f the device are shown in the schematic above.
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Rapid assays, developed for the detection of steroids in less than 30min, are 
useful because of the conditions under which many of these analyses would be 
carried out, i.e. in slaughterhouses and on farms. Test strips, rapid enzyme 
immunoassays and an antibody-based electrodes have all been used as 
approaches to measure steroid concentration.
Ploum et al. (1991) described the development of prototype test strip 
immunoassays for the detection of nortestosterone and clenbuterol. For this 
format the drug-specific antibody was dried onto a nitrocellulose strip and the 
strip was then blocked with BSA and dried. The strip was held in a glass test tube 
and 1 ml of sample was added to the tube along with 15 [il of the drug-HRP 
conjugate. The strip was washed in water after a 45-60 min incubation period. 
The strip was transferred to a tube holding 0.8 ml of substrate and the colour 
reaction proceeded for lmin. The strip was washed and the presence of colour 
indicated a negative result and a clear strip indicated a positive result. This assay 
could take almost an hour to complete and it requires the use of multiple tubes 
containing different solutions and the strip requires washing between steps. The 
strip tests were sensitive enough to detect 1-2 ng ml'1 of nortestosterone and 10 
ng ml"1 of clenbuterol in urine.
A rapid plate-based enzyme immunoassay for the detection of progesterone has 
been described (Claycomb et al., 1998). This assay is similar to the competitive 
ELISA described in Chapters 3 and 4 except for the time it lakes to run the assay. 
This assay immobilises a monoclonal antibody on hydrazine-activated 
immunoplates. After the wells were washed and blocked, 50 pi of sample is 
added to wells in combination with 50 fil of a progesterone-HRP conjugate. The 
plate is incubated for 5min at room temperature with agitation. The plate is 
washed and the substrate is added and read every 10s for 3min. This assay had a 
dynamic range of 0.2-20 ng ml'1 for this steroid in milk.
The development of an antibody-based electrode that could be used to measure 
corticosteroids in animals was reported in Nature Bioterchnology (Cook, 1997). 
Antibodies specific for this group of steroids are immobilised on a platinum 
electrode. This is small probe encased in a membrane that separates the electrode 
environment from the sampling one. The electrode measures the peroxidase
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5.1.2 Use of Rapid Assay Systems for the Detection of Steroids
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activity of the corticosteroid-HRP conjugate. When the electrode is immersed in 
a solution containing the steroid, it competes for binding to the electrode. The 
more endogenous steroid present the lower the signal measured by the sensor. 
The whole assembly is small (350fim) and can be implanted to allow for 'real­
time' measurements within the circulating system of an animal. This particular 
electrode is viable for 200-400 sequential measurements and can detect between 
0.2-0.6 fig of cortisol or corticosterone per 100 ml. It is not very sensitive but it 
does show the possibility of creating small implantable sensors to monitor many 
compounds of biological significance.
5.1.3 The Prototype Rapid ELISA Device
This device has the ability to automate the steps involved in a competitive 
ELISA. The machine used a standard competitive ELISA protocol, where sample 
and conjugate are in competition for the binding positions of the immobilised 
antibody. The reagents are all prepared in advance, the coated wells, the blank 
wells, the conjugate solution and substrate. The operator of the machine needs 
only to put the wells and eppendorfs with their solutions in the correct position 
and press start. The machine aliquots the sample, mixes it with the conjugate and 
then transfers it to the reaction wells. It shakes the wells during all the incubation 
steps to ensure even binding and washes the wells after the reaction has occurred. 
It then adds the substrate to the wells and the operator reads the result. The 
device requires no further input from the operator after the initial set-up.
The protocol used in this device is described in detail in section 2.4.8.3. Briefly, 
it has antibody-coated wells into which it adds a mixture of the sample and a 
drug-HRP conjugate. After a short incubation period, (4min at 35°C with rapid 
shaking) the machine washes the wells and tetramethylbenzidine (TMB) 
substrate is added. The device reads the transmission of the substrate just after it 
is added to the wells and again after a 5min incubation. These two values are 
compared to give the percentage transmission result for each well. Figure 5.2 
gives the layout of the wells and the eppendorf tubes on the reaction wheel of the 
machine.
The machine takes 20min to complete each analysis, including the arrangement 
of all the wells and solutions. Initially all the coated wells contained antibody of
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the same specificity. This resulted in an assay that performed each analysis in 
quadruplicate and a single blank control well. The blank well can be used to 
relate different runs to each other. The 4 values for the sample are averaged and 
are then divided by the ratio for the blank well. This gives the analytical result 
for that particular sample. Each run was analysed in the same manner. To give 
these results meaning a blank sample (buffer) is analysed. Any sample that gives 
a value above that calculated for the zero concentration sample is considered 
positive.
If reaction wells coated with a number of specific antibodies are used the 
usefulness of this machine can be extended. The relevant conjugate solution can 
be used and the same sample can be analysed for up to five different substances. 
This format does not allow for a blank well and so the assay must be optimised 
and validated precisely. To show the principle of multianalyte testing using this 
machine an assay for the co-analysis of two steroids within a single sample was 
developed.
197
Chapter 5: Development of a rapid ELISA
F ig u r e  5 . 1  : The prototype rapid ELISA device. The buffer and waste reservoirs 
are located at the front o f the device under the reagent wheel. The placement of 
the wells on the reagent wheel is described in Figure 5 .2 .
1: 70pil Sample2: lml TMB3: Empty
4-8:  lODfj.1 s t e r o i d - H U P  9-12:13: Non-coated wel
F ig u r e  5 .2  : Layout o f the wells as they are positioned on the wheel o f the rapid 
ELISA device.
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The use of the rapid assay device is quite limited if it only detects the presence of 
a single residue. Multi-analyte testing would allow users to reduce the amount of 
time spent in testing and increase the amount of information produced from each 
assay run.
The assay format developed in this chapter aims to detect both trenbolone and 
diethylstilbestrol residues in a sample in a single assay. To achieve this wells 
were coated with anti-DES and others with anti-TR antibodies. The blank well 
was retained to allow for comparison between runs.
The conjugate solution was also altered. In the single analyte assay the same 
conjugate solution is added to all five mixing wells (4-8). This ensures that all 
reaction wells including the blank well receive the same amount of steroid-HRP 
conjugate. To maintain a homogeneous conjugate solution in the multi-analyte 
assay a mixture of the appropriate concentration of the two HRP-conjugates was 
used. The use of this mixture is only possible if neither of the antibodies show 
any cross-reaction with the other steroid being analysed or its HRP-conjugate. 
Any such cross-reaction would cause large errors and no differentiation between 
the concentrations of the two steroids as separate species would be possible.
5.1.4 The Co-analysis of Two Steroids using the Rapid Assay Device
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F ig u r e  5.3 : Development o f rapid ELISA andprototype assay for device.
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Polyclonal antibodies against two steroids were used in the development of the 
rapid ELISA protocol that shortens both the reaction and substrate development 
incubation times to assay their suitability for use with the rapid ELISA device. 
The production and characterisation of the anti-trenbolone antibodies is 
described in Chapter 3. Polyclonal antibodies were also raised against mono- 
carboxypropyl DES coupled to OVA (DES-CP-OVA) as described in section 
2.4.4.1. This immunogen was produced as per section 2.4.1.2 and 2.4.2.2 and the 
confirmatory mass spectrometry results arc contained in appendix B. They were 
purified by saturated ammonium sulphate precipitation and Protein G affinity 
chromatography and the purity of the resulting antibody-containing solutions 
were tested in SDS-PAGE (Figure 5.4).
5.2 Results
5.2.1 Antibodies used in rapid assay development
2 0 1
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F ig u r e  5 .4  : Coomassie stained SDS-PAGE gel with protein markers in lane 1 
and 8. Lane 2: serum from rabbit 1; lane 3: dialysed SAS cut o f rabbit 1 serum; 
lane 4 :  protein G affinity-purified IgG fraction (DESAbl); lane 5: serum from 
rabbit 2 ;  lane dialysed SAS cut of rabbit 2  serum and lane : protein G
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5.2.2 Development of Competitive and Inhibitive ELISA for the detection of 
DES using DESAbl Antibody
The optimisation of the ELIS As was caried out as described in chapters 3 and 4. 
Table 5.1 lists the concentrations of conjugates and antibody that were used in 
the standard length competitive and inhibitive ELISA formats.
Table 5.1 : Optimal coating and competing concentrations used in for the competitive and inhibitive standard length ELISA using DESAbl as the specific antibody.
Asay Coating Solution Competing Solution 1Inhibitive 1.38 fig ml'1 DES-CP- BSA 6.75 fig ml"1 DESAblCompetitive 0.68 fig ml"1 DESAbl 0.31 fig ml'1 DES-CP- HRP
A range of standards of DES was prepared as described in section 2.4.7.1. In the 
inhibitive format the standards were aded to a DES-CP-BSA-coated plate at 
50 |xl per wel together with DESAbl at the required concentration. After the 
incubation and washing steps had ben completed HRP-labeled anti-rabit pab 
was aded to the plates. In the competitive ELISA format the standards and the 
apropriate DES-CP-HRP dilution were aded to a DESAbl-coated plate. After 
washing, the bound HRP conjugate was detected in both asays as specified 
previously, (section 2.4.7).
For intra-day asay variation studies each concentration standard was asayed 5 
times on a single day and the mean absorbance was ploted against the DES 
concentration. Figures 5.5 and 5.7 show the intra-day asay results for the two 
asay formats. The acompanying tables 5.2 and 5.4 show the means, the 
standard deviations, the coeficients of variation (C.V.'s) and the percentage 
acuracy of the standard curve using 4-parameter curve fiting.
The inter-day asay variation was determined by carying out the asay over 5 
separate days. The absorbance of each of the standards was normalised by 
dividing the mean absorbance value for each DES concentration by the mean 
value for the day's zero concentration value, (A/Ao). The A/Ao value was 
compared acros the 5 days. Figures 5.6 and 5.8 show the inter-day asays for 
both asay formats. The acompanying tables 5.4 and 5.6 show the means, the
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standard deviations, the coefficients of variation (C.V.'s) and the percentage 
accuracy of the standard curve using 4-parameter curve fitting.
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DES Cone, (pg ml'1)
Figure 5.5 : Intra-day studies on inhibitive ELISAs using the anti-DES Pab, 
DESAbl for the detection of free DES in PBS/2% (v/v) EtOH. The inhibition 
assay uses DES-CP-BSA conjugate coated at 1.38 pg m t1 and the antibody at a 
concentration o f 6.75 pg  m t1.
Table 5.2 : Intra-day CV's and acuracies for DESAbl inhibition ELISA in PBS/2% (v/v) EtOH. Five sets of twelve standards were analysed on the same day and the CV’s were calculated. A four-parameter equation was used to fit a curve to the data using BIAevaluation software and its percentage acuracy was calculated.
DES Calculated MeanCoeficients ofAcuracy,Concentration I-SD, variation (%)(pg nil1) (Abs) (CV’s), (%)5000.0 0.083±0.01 13.50 129.412500.0 0.092±0.010 1.01 13.2612500.0 0.13±0.06 4.93 102.316250.0 0.143±0.014 9.64 90.0631250.0 0.189±0.014 7.36 76.2815625.0 0.20±0.017 7.86 97.617812.50 0.253±0.018 7.04 126.703906.25 0.313±0.021 6.80 120.071953.13 0.393±0.025 6.40 81.94976.56 0.438±0.030 6.86 73.8948.28 0.45±0.023 5.0 9.5624.14 0.46±0.028 5.91 145.65
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F ig u r e  5 .6  : Inter-day studies on inhibitive ELISAs using the anti-DES Pab, 
DESAbl for the detection of free DES in PBS/2% (v/v) EtOH. The inhibition 
assay uses DES-CP-BSA conjugate coated at 1.38 pg m t1 and the antibody at a 
concentration of 6.75 fjg m t 1.
Table 5.3 : Inter-day CV's and acuracies for DESAbl inhibitive ELISA in PBS/2% (v/v) EtOH. Five sets of twelve standards were analysed over five diferent days and the CVs were calculated. A four-parameter equation was used to fit a curve to the data using BIAevaluation software and its percentage acuracy was calculated.
DES Calculated MeanCoeficients ofAcuracy,Concentration SD, variation (%)(pg ml') ( VAi) (CV’s), (%)5000.0 0.242±0.065 26.97 85.402500.0 0.252±0.050 19.92 11.9112500.0 0.275±0.032 1.65 19.46250.0 0.33±0.043 12.98 97.7431250.0 0.423±0.050] 1.71 86.4615625.0 0.49±0.089 17.7 103.077812.50 0.618±0.065 10.49 101.03906.25 0.714±0.094] 13.19 12.821953.13 0.82±0.091 1.03 9.48976.56 0.909±0.104 1.39 65.0948.28 0.937±0.082 8.73 63.4624.14 0.917±0.103 1.25 23.15
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F ig u r e  5 . 7  : Intra-day studies on competitive ELISAs using the anti-DES Fob, 
DESAbl for the detection of free DES in PBS/2% (v/v) EtOH. The plates were 
coated with 0.68 pg  m t1 solution of DESAbl and the conjugate DES-CP-HRP 
was used at 0.31 pg m t1.
Table 5.4 : Intra-day CV's and acuracies for DESAbl competition ELISA in PBS/2% (v/v) EtOH. Five sets of thirten standards were analysed on the same day and the CVs were calculated. A four-parameter equation was used to fit a curve to the data using BIAevaluation software and its percentage acuracy was calculated.
DES Calculated MeanCoeficients ofAcuracy,Concentration SD variation (%)(Pi ml1) (Abs) (CV's), (%)390625.0 0.107±0.010 9.0 17.58195312.50 0.129±0.06 4.68 75.8697656.25 0.136±0.017 12.70 17.584828.13 0.168±0.013 7.54 104.622414.06 0.209±0,01 5.37 97.621207.03 0.256±0.01 0.5 92.486103.52 0.289±0.05 1.82 10.683051.76 0.340±0.019 5.53 86.121525.8 0.349±0.028 8.10 142.25762.94 0.391±0.023 5.94 67.47381.47 0.398±0.052 12.9 89.1295.37 0.407±0.010 2.54 156.89
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Figure 5.8 : Inter-day studies on competitive ELISAs using the anti-DES Pab, 
DESAbl for the detection of free DES in PBS/2% (v/v) EtOH. . The plates were 
coated with 0.68 fig m l1 solution o f DESAbl and the conjugate DES-CP-HRP 
was used at 0.31 jug m t1.
Table 5.5 : Inter-day CV's and acuracies for DESAbl inhibitive ELISA in PBS/2% (v/v) EtOH. Five sets of twelve standards were analysed over five diferent days and the CVs were calculated. A four-parameter equation was used to fit a curve to the data using BIAevaluation software and its percentage acuracy was calculated.
DES Calculated MeanCoeficients ofAcuracy,Concentration ¿SD variation (%)(pg ml'1) (A/A,) (CV's), (%)390625.0 0.189±0.018 9.27 86.26195312.50 0.203±0.032 15.54 97,197656.25 0.25±0.031 13.8 10.474828.13 0.251±0.05 21.96 13.672414.06 0.29±0.058 19.29 10.681207.03 0.348±0.094 26.98 103.926103.52 0.408±0.105 25.76 9.953051.76 0.471±0.121 25.72 93.401525.8 0.532±0.141 26.49 80.76762.94 0.549±0.127 23.14 123.36381.47 0.589±0.149 25.3 15.34190.73 0.620±0.160 25.84 98.0695,37 0.619±0.152 24.58 205.7047.68 0.69±0.168 25.15 0.36
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The antibody was tested for its ability to recognise other related steroid 
compounds. The asays were caried out as described in section 2.4.7.8. Table 
5.6 shows the percentage cros reactivities that were found. DESAbl shows very 
low levels of cros-reaction with the related compounds tested.
5.2.3. Cross Reactivities o f D E SA bl A ntibody
Table 5.6 : Cros reactivity of the polyclonal antisera to DES and other structuraly related steroid hormones and cros-reacting compounds in inhibition ELISAs. Percentage cros reactivity was calculated as (ICjo[DES]/ICjo[test compound])* 10.
Compounds Tested DESAbl 
% Cross Reactivity1DES 10.0Ethynyl estradiol <0.05Diethyl stilbestrol <0.05a-Estradiol <0.05ß-Estradiol <0.05Estrone <0.05Norgestrol <0.0519-Nortestosterone <0.05Methyl Testosterone <0.05Zeranol <0.05Norethisterone <0.05
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The assay format was first developed on 96 well immunoassay plates to test the 
rapid ELISA system. The format used was identical to that of the competitive 
assay described in section 3.1.4. The differences arise in the length of the 
incubation steps. The coating and blocking stages of the assay were carried out 
with either overnight incubation at 4°C or for one hour at 37°C. The drug-HRP 
conjugate and the standards are left in the wells for approximately lOmin before 
washing. This simulates the reaction time allowed in the prototype rapid assay 
device. The OPD substrate is then added and the absorbance is determined after 5 
and 2 0 min.
Two different coating procedures were assessed. The first used an anti-rabbit IgG 
antibody coated onto the plate, which acted as a capture antibody for the specific 
antibody. The specific antibody was then added and allowed to bind to the 
immobilised capture antibody. The second system involved the direct coating of 
the specific antibody onto the surface of the wells as seen in the competitive 
assays described in chapter 3 and 4. Various amounts of anti-rabbit IgG (from 
1/500 to 1/16,000) were coated onto the plate. The anti-TR antibody (TRAbl) 
was added to the plate at various concentrations. The TRAbl was also absorbed 
onto wells that had not been coated with the capture antibody. The results from 
this assay are graphed in Figure 5.9 and little difference is observed between 
wells that used the capture antibody and those that did not. The coating method 
that did not use the capture antibody was used in all subsequent assays. With this 
method less time was required to prepare the plates and fewer reagents were 
used.
5.2.4 Optim isation o f coating for rapid ELISA in a 96 well format
?.:{()
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Figure 5. 9 : Effects in signal detected with different coating concentrations and 
procedures. The plates were coated with dilutions of anti-rabbit IgG antibody 
from 1/500 to 1/16,000. The specific anti-TR antibody, TRAbI, was added at 
dilutions between 1/100 to 1/6,400 to each of the pre-coated wells and uncoated 
wells. The TR-HRP conjugate was used at 0.5 jug m l1 and left for lOmins on the 
wells. The substrate was added and the absorbance was determined at 405nm.
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5.2.5 Optimisation of the coating and labeled drug concentrations for the TR and DES rapid ELISA asay
A checkerboard ELISA was carried out to determine the optimum concentrations 
of both the antibody and the HRP conjugates. The method for this assay is 
described in detail in Section 2.4.7.3.
From the results (Figure 5.10) the optimum coating concentration for the 
antibody was 1/100 or 47.6 |i.g ml' 1 of TRAbl and 1/10,000 or 0.5 pig ml"1 of the 
TR-HRP conjugate. Similar experiments were carried out using DES-HRP and 
DESAbl (Figure 5.11). 3.4 pig ml"1 (1/400) was chosen as the optimal DESAbl 
coating concentration and the DES-HRP was used at a dilution of 1/10,000 or 
0.5 |ig ml'1.
2 1 2
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Dilution of TR-HRP (1/x)
Figure 5.10 : Non-competitive checkerboard ELISA to determine optimal TRAbl 
antibody coating concentrations and TR-HRP dilution. From this assay the 
optimal coating concentration was determined to be 1/100 (47.6 jug m tl)  of 
TRAbl and the optimal TR-HRP dilution was 100 /jl of 1/10,000, (0.5 /jg m t1).
DESAbl Dilutions
Dilution of DBS-HRP (1/x)
Figure 5.11 : Non-competitive checkerboard ELISA to determine the optimal 
DESAbl cmtibody-coating concentration and DES-HRP dilution. From this 
assay the optimal coating concentration of DESAbl was determined to be 1/400 
(3.4 p g m t1)  and the optimal DES-HRP dilution was 100 p i o f 1/10,000, (0.5 jug 
mT1).
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The ability of the rapid ELISA formal to detect free amounts of steroids was 
evaluated using the optimised conditions. Each of the assays was run with a 
broad range of standards, 039 - 100,000 ng ml'1, prepared in PBS/2% (v/v) 
EtOH. Figure 5.12 shows the dose response curves obtained from these assays. 
They show quite clearly that the rapid protocol can be used to detect low 
concentrations of free drugs in buffer.
5.2.6 Com petitive assay with a rapid ELISA format
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Steroid Concentration (ng ml'1)
F ig u r e  5 . 1 2  : Dose response curves for the detection offree T R  using T R A b l and 
free D E S  using DESAbl employing the rapid 96 well E L I S A  format. Both 
antibodies show a competitive assay with the ability to distinguish varying 
amounts o f free steroid in a buffer matrix.
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5.2.7.1 Stability Testing of Components for use with the rapid assay device
The next step was to determine if the reagents were compatible for use with the 
rapid assay device. The format and protocol for this assay are described in detail 
in section 5.1.3 and 2.4.8.3. The reaction in the wells is similar to that 
encountered in the competitive ELISAs already investigated (Chapter 3 & 4). 
The stability of the assay system was investigated by running a blank sample in 
the device at various times throughout a single day. It was expected that the 
results for the zero concentration would remain constant over the period but this 
was not the case (Figure 5.13). The machine reads the transmission values of 
each well and, over time, less colour is being developed using the same sample 
and reagents leading to an increase in the normalised transmission readings. To 
eliminate the source of this assay drift the stability of two assay components 
were enhanced, the conjugate solution and the coating on the wells.
There is an absolute requirement for the stability of the conjugate solution 
throughout the time the assay is running and it must also be stable in storage if 
the assay is to have any practical use. A commercial stabilising diluent was 
obtained, (Pierce Guardian Peroxidase Diluent) and used as the diluent for the 
conjugate and compared with results obtained when the conjugate was diluted 
with PBS. A slight improvement was seen but the increase in normalised 
transmission (decrease in amount of colour developed) was still evident (Figure 
5.14).
The stability of the coating on the wells was then investigated. A number of 
wells were coated and blocked using the standard protocol. Half of the wells 
were stored dry and at room temperature while PBS was added to the other half 
and they were kept at 4°C in an attempt to maintain the activity of the antibody 
coated onto the surface of the well. The cold, wet wells were allowed to come to 
room temperature before use in the machine. The results clearly show that the 
wells are more stable when stored cold and wet with very little difference in the 
normalised transmission value over time (Figure 5.15).
5.2.7 O ptim isation o f the assay using the prototype rapid assay device
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Figure 5.13 : Increase in the value of the normalised transmission (average 
transmission reading for the four coated wells divided by the transmission 
recorded in the blank well) for the zero concentration standard (PBS/2% (v/v) 
EtOH) over time. The wells were stored dry and at room temperature until 
needed and the conjugate was diluted in PBS. The normalised transmission value 
increases over time.
0 2.5 5
Elapsed time between assays (hours)
Figure 5.14 : Increase in the value of the normalised transmission for the zero 
concentration standard (PBS/2% (v/v) EtOH) over time. The wells were stored 
dry and at room temperature until needed and the conjugate was diluted in either 
PBS or peroxidase stabilising diluent. The stabilising diluent did not eliminate 
the drift on the zero concentration value over time.
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Figure 5.15 : The value of normalised transmission for the zero concentration 
standard (PBS/2% (v/v) EtOH) over time. The wells were stored dry at room 
temperature (RT) or wet at 4X1 until needed and the conjugate was diluted in 
peroxidase stabilising diluent. The dry, RT. wells showed the increase in 
transmission values over the period of the experiment, whereas the cold, wet 
wells showed consistent results. This indicates the use of the cold, wet wells in 
future assays.
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Using the optimised conditions (conjugate diluted in stabilising diluent and 
coated wells stored in PBS at 4°C) a competitive assay was run on the rapid assay 
device. Each sample was run in quadruplicate (four antibody-coated wells) with a 
fifth uncoated well as a control. The results for each of the wells are given as a 
ratio of the transmission before the 5min incubation and the transmission after it. 
The results are averaged and normalised by dividing them by the ratio for the 
blank welL The results for the assays are given in Figures 5.16 and 5.17. The 
dose response curves are not smooth but a clear trend can be seen and the assay 
is able to distinguish between 0 and 1 ng ml' 1 of free TR. The DES assay is not 
as sensitive and is only able to detect levels of drug greater than 50 ng ml'1.
5.2.8 C om petitive assay using the prototype device
m
Chapter 5: Development of a rapid ELISA
TR Concentration (ng ml'1)
Figure 5.16: Dose response curve for the detection of free TR in PBS/2% (v/v) 
EtOH using the rapid assay device, TRAbl-coated wells (47.6 pg  m^ )  aru  ^TR- 
HRP conjugate (0.5 pg  m t1). The normalised transmission for the zero 
concentration was 0.25 and the cut-off was chosen as 0.3 (red dotted line). 
Everything above this indicates the presence of free drug and below this the 
results are negative.
DES concentration (ng ml'1)
Figure 5.17 : Dose response curve for the detection of fre DES in PBS/2% (v/v) EtOH using the rapid asay device, DESAbl coated wels (3.4 pig ml"1) and DES- HRP conjugate (0.5 pig ml'1). The normalised transmision for the zero concentration was 0.2 and the cut-of was chosen as 0.25 (red doted line), Everything above this indicates the presence of fre drug and below this the results are negative,
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The rapid assay device is capable of detecting low nanogram quantities of the 
steroid hormones in a buffer matrix. To increase the usefulness of this system, 
the design was altered slightly to allow the co-analysis of samples for the 
presence of two steroids. Five wells were still used, two coated with specific 
antibody against TR, TRAbl and two coated with DESAbl. No antibody was 
absorbed onto the surface of the fifth well. The conjugate solution contained the 
correct dilution of both HRP conjugates, 1 fig ml' 1 of TR-HRP and 1 ftg ml' 1 of 
DES-HRP.
The results in Figure 5.18 show the dose response curves for the co-analysis of 
both TR and DES. The assay is able to detect TR when on its own and in a 
mixture with DES. The magnitude of the response is similar for both single and 
the mixed samples. In both cases, where it is measured on its own and in 
combination with DES, the assay gives a clear distinction between the zero value 
(normalised transmission of 1) and a 10 ng ml"1 sample. The results for the DES 
detection are not as clear. They show little, if any recognition of the free DES in 
solution.
Neither antibody shows any recognition of the other drug conjugate. The lack of 
cross reactivity between these antibodies and the co-analysed steroid gives the 
rapid assay device the ability to use a mixture of DES-HRP and TR-HRP 
conjugates to provide the competing conjugate molecules of the assay.
5.2.9 Co-analysis o f  two steroids using the rapid ELISA device
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TR Concentration (ng ml"1) DES Concentration (ng ml'1)
TR and DES concentration (ng ml"1)
Figure 5.18 : Dose response curves for the detection of both TR and DES 
containing samples on TR- and DES-coated wells. Each line represents the 
response seen for the one set of coated wells with a particular steroid standard. 
Part A of the figure indicates the responses for both the coated wells when the 
TR standard is run. Part B shows the results for the wells with the DES standard 
and Part C shows the response o f the wells when samples containing both TR 
and DES are used. All results have been normalised so that the zero 
concentration for each set o f results has a value of 1. Values above 1 are 
considered positive and those below are negative.
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An anti-DES polyclonal antibody was produced, purified and characterised. It 
recognised free DES molecules in buffer solution and a very sensitive ELISA for 
DES was developed, which was able to detect less then lOOpg ml' 1 of DES. The 
antibody, termed DESAbl, did not show cross-reactivity with the related 
molecules tested, some of which may be found in biological samples, as shown 
in Table 5.6. This antibody preparation and TRAbl were used as the antibody 
reagents for the investigation of the utility of the rapid ELISA device.
The number of wells for use on the prototype device were limited so the majority 
of the optimisation work for this assay was carried out on 96 well immunoplates. 
The wells were specially developed for use with this device and were 
manufactured by Nunc. Nunc were unable to supply the wells for a substantial 
period due to plant and machinery problems.
Two coating procedures for these wells were investigated. The first used an anti­
rabbit IgG antibody coated onto the well followed by the specific antibody, while 
in the other system the antibodies were coated directly onto the plate. Figure 5.9 
represents the results obtained. The difference in signal observed between the 
different amounts of anti-rabbit IgG coated onto the plate and the direct 
adsorption method was minimal. The direct method uses fewer reagents (one 
antibody instead of two) and it takes less time (single incubation) so this protocol 
was used for all subsequent assays. It has also been shown that reproducible 
ELISAs can be achieved using this method of well coating (Chapters 3 and 4). 
The reaction incubation time on the prototype device is 4min at 35°C with a 
constant fast vibration to allow for a faster reaction. The assay will only be viable 
if the kinetics of the antibodies allow them to react sufficiently in the short 
incubation period available. The rapid ELISA cannot reproduce these conditions 
exactly. The plates are incubated at 37°C but no method was available to shake 
the immunoplates while in this incubator. To aid the reaction the plates were 
shaken by hand for 10s on 3 occasions during the reaction incubation. The plates 
were washed as normal and OPD substrate was used. The device uses a different 
chromogen tetramethylbenzidine, TMB, as it turns blue and this is the 
wavelength interrogated by the optical system in the device. OPD produces a 
yellow/orange colour. The colour developed on the plates was recorded after
5.3. Discussion
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5min incubation at 37°C using a plate reader. The colour intensity at 5min was 
usualy adequate for the analysis of the plate but a further reading may have ben 
taken at lOmin if further colour development was required. The plate readers 
available detected the absorbance of the substrate, whereas the device measures 
transmision. As transmision and absorbance are related the absorbance was 
used directly without any alteration.
The rapid ELISA was caried out in a non-competitive format to optimise the 
coating concentration of the antibodies and the amount of competing HRP- 
labeled drug to be used in the asay. The plates were coated with varying 
concentrations of antibody and blocked as described (section 2.4.8.1) and 
varying concentrations of the steroid-HRP conjugate were aded. The results in 
Figures 5.10 and 5.1 show that with both asays the signal increases as the 
amount of tracer present decreases at the higher concentrations of the steroid- 
HRP conjugate.
This is not an expected result but it is sen with the asay systems for both TR 
and DES. It may be an efect sen when a high antibody concentration is coated 
onto the wel and the binding sites of the antibodies are at close to ful ocupancy 
with the steroid-HRP conjugates. Ordinarily, the curve would be expected to 
show saturation and not a fal in absorbance signal. This implies that some aspect 
of the high concentration of coating antibody and the high concentration of the 
steroid-HRP conjugate is interfering with the ability of the HRP to act on the 
substrate. As the tracer concentration is reduced the response curve returns to a 
more normal exponential decay patern. From these graphs an antibody coating 
concentration that gave reasonable signals was chosen along with a steroid-HRP 
concentration that fel on the downward slope of the response curve, (Table 5.7). 
This ensured that the amount of antibody coated onto the surface of the wel was 
the limiting factor for the asay not the conjugate concentration
Table 5.7 : The optimal coating and competing concentrations for use in the 96 wel format rapid ELISA.
Asay for Antibody Coating Cone, (fig ml1) Steroid-HRP Cone, (|ig ml1) Aprox. Detection Range (ng ini *)TR 47.6 TRAbl 0.5 0.38 - 1,00
DES 3.4 DESAbl 0.5 48 - 10,00
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Using the optimised conditions the competitive assays were carried out on the 96 
well plates. These used the rapid ELISA protocol and the samples were diluted in 
PBS/2% (v/v) EtOH. A wide range of standards was run to determine the 
detection range of the assays, Figure 5.12. Both assays show competition with 
free steroids. Using these parameters the TR assay is far more sensitive than the 
DES assay. Attempts were made to lower the limit of detection for the DES 
assay by altering both the antibody-coating concentration and/or the competing 
HRP-conjugate. An increase in the sensitivity of the assay was not achieved. This 
implies that the kinetics of this antibody-antigen interaction are not as suitable to 
deliver a sensitive assay with this rapid assay format as the TRAbl antibody is. 
Once the assays were proven as viable using the 96 well format they were then 
transferred to the prototype device. The success of the rapid ELISA indicates that 
the reagents can be used in an assay that uses shorter reaction times than a 
normal assay. The TR antibody has a more sensitive response in this rapid format 
than DESAbl. This implies that it has faster reaction kinetics allowing it to reach 
equilibrium quickly during the short incubation time used in the rapid ELISA. 
The DESAbl antibody may require a slightly longer incubation for detection 
levels similar to those shown with the standard length ELISAs.
With the rapid ELISA format each of the reagents are used at the same time, 
none of them are prepared and used over the course of a day. This avoids any 
problem of instability of the components if they have to be stored and this allows 
the solutions or solid phase to provide consistent results and show no bias with 
respect to any instability problems. The rapid assay device, however, runs assays 
sequentially and so reagents and components must be stored until needed. This 
can lead to problems if the reagent solutions are not stable or the antibody-coated 
wells lose activity over time.
A drift in the percentage transmission value was noticed with the device when 
zero concentrations were run throughout an assay procedure. The values for the 
normalised transmission in the coated wells were increasing over time, that is 
less colour was being produced in these wells. The standard itself (PBS/2% (v/v) 
EtOH) is stable at room temperature over many weeks and has shown the same 
results in previous ELISA studies. Other components that may have been 
unstable were the conjugate and the antibody-coated wells.
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To counter the possible instability of the conjugate solution a commercial 
stabilising diluent was obtained. The conjugate was diluted in both the stabilising 
diluent and PBS and the results were compared. The drift was not removed by 
using the improved diluent and the normalised transmission values continued to 
increase after a number of hours (Figure 5.14).
The wells for the device, up until this point, had been stored dry at room 
temperature after they were blocked until they were required. All wells were 
used on the same day that they were blocked. To assess the stability of the wells 
they were coated and blocked as normal and divided in two lots, the first group 
were left dry, at room temperature, while the second set were filled with 2 0 0  (0.1 
of PBS and kept at 4°C. Antibodies are stored at 4°C to maintain their activity 
and 200 |il of PBS was added to each well to avoid the loss of activity when the 
antibodies are allowed to dry out on the surface of the well. An alternative 
solution to the effect of drying on the antibody-coated wells would be to add a 
layer of a sugar, trehalose, over the antibody coating. The trehalose maintains 
some moisture in the wells and prevents the loss of activity of the antibodies if 
the wells are dried. The cold wells were emptied and allowed to come to room 
temperature before use in the machine.
The results show clearly that the cold, wet wells are more stable and produce 
more reproducible results for the zero concentration standard (Figure 5.15). After 
21hr of storage the result for the dry, R.T. wells had risen considerably with 
respect to the initial reading implying that the coated antibody had lost activity 
and was no longer binding the same amount of the steroid-HRP conjugate. This 
would lead to large inaccuracies in the assay. The cold, wet wells, however, had 
maintained their response and therefore their binding capacity after the 2 1 h of 
storage.
Once the drift had been eliminated the competitive assays were applied to the 
device. Figure 5.16 and 5.17 show the results obtained for each of the assays for 
the detection of TR and DES. Again it can be seen that the TR assay is more 
sensitive than the DES assay. The dose response curves are not smooth and 
become unreliable at low concentrations and this may lead to inconsistencies in 
results. The DES assay shows variations in the results obtained for the lower 
standard concentrations. In this case it would be prudent to set the detection limit
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of this assay at above 0.25 to avoid false positive readings. By adding 0.05 onto 
the negative value for the EE assay would also limit the number of false positives 
in this assay leaving only concentrations above 1 ng ml' 1 to give a positive result. 
Further validation of these assays is required before they could be used as 
screening tools. Unfortunately the supply of wells for the machine was extremely 
limited and the work here could not be continued.
This system has limited usefulness if it assays one sample for the presence of one 
steroid in a 20min period, (time taken to run each sample). The measuring of the 
sample in quadruplicate is not required for an initial screening test and so a 
system was developed whereby the presence of two drugs could be detected. 
Two wells coated with the TRAbl, two wells coated with DESAbl and an 
uncoated well were used. The conjugate solution contained the correct 
concentration of both the TR-HRP and the DES-HRP conjugates. The cross 
reactivities of these antibodies, Tables 5.6 and 3.10, show that neither antibody 
has any specificity for the other drug and so the conjugate solution can be used in 
both wells without interference.
The results of this co-analysis assay are shown in Figures 5.18 and 5.19. The TR 
assay seems to work quite well with the assay being able to measure free TR 
when in buffer on its own and in combination with DES. The DES-coated wells 
did not show any recognition of the TR steroid. The DES assay, however, did not 
produce the expected results. Most of the responses seen to DES were below that 
of the zero concentration standard. When the DES standard is run the assay 
seems to begin to detect the presence of the steroid at 1000 ng ml'1. This is far 
too high for use as a screening tool but a different antibody or even a change in 
the assay format may lower this detection limit to one that could be useful. The 
response of the wells when samples containing both TR and DES shows the 
assay easily detects the presence of TR but again the DES assay shows large 
inconsistencies that can not be explained by the assay itself and may be due to 
the device or the plastic in the wells. This implies that the assay is not optimised 
fully.
This experiment does show the potential of this device for the co-analysis of two 
steroids. With further optimisation it may be possible to use this device to screen 
for up to 4 different compounds in the one assay. Again the lack of availability of
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the special wells required to use the rapid ELISA device has curtailed the work 
into this area.
In conclusion, 96 well rapid ELISA was developed to mirror the assay protocol 
of the prototype device. Using this assay system the parameters for the 
development of the rapid assay were investigated. The range of detection for 
these assays was defined. The assay was applied to the rapid assay device and a 
drift was seen in the results. This was corrected by stabilising the coating of the 
wells while being stored. The assays showed the ability to detect nanogram 
quantities of free steroids. The assay for TR showed a clear measurable 
difference between 0 and 1 ng ml' 1 and DES could be distinguished at 50 ng ml'1. 
The system was then altered to detect two steroids in the same sample. The 
principle of this assay is shown and with some further work the assay would 
become a viable screening method.
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6.1 Introduction
6.1.1 Recombinant antibodies
The three main methods of antibody production are laid out in section 1.2. 
Polyclonal antibodies are the oldest and probably most widely used antibody 
type although monoclonal antibodies are also very popular due to their inherent 
advantages. It is thought that it soon may be possible to replace both these 
antibodies with recombinant antibodies that would retain or mimic many of the 
positive assets of these antibody types (Chiswell and McCafferty, 1992). Even 
though some library-isolated scFv can be extremely sensitive and specific, many 
isolated are, at best, only as sensitive as their polyclonal and monoclonal
counterparts. Phage display does, however, offer a cheaper and more rapid
production of antibody fragments (McElhiney et a l, 2000).
Recombinant antibodies are the resulting proteins when antibody genes have
been cloned and expressed in culture. They are monoclonal in nature in that a 
single antibody producing clone can be isolated and grown to produce a mono- 
specific antibody or antibody fragment. Recombinant antibodies can be produced 
as either full antibodies or as antibody fragments, such as single chain variable 
fragments (scFv) or antibody binding fragments (Fab) (Le Calvez et a l, 1995). 
With this technique the genetic sequence of the antibody has been cloned into a 
vector and so the manipulation of the antibody fragment is facilitated (Krebs et 
al., 2 0 0 1 ).
6.1.2. Phage Display Technology
The production of recombinant antibodies using phage display technology is 
presently the most popular technique and it is sometimes considered a superior 
method to monoclonal antibody production using hybridoma technology 
(Berdichevsky et al., 1999; Li et a l, 2000). This technique is described in detail 
in section 1.2.4 and it allows a fragment of the antibody, containing it's binding 
site, to be displayed on the surface of a bacteriophage, which can then be used to 
select the required affinities from a large number of antibody sequences. Once 
the antibody fragment is expressed on the surface of the phage it facilitates 
selection and screening of the clones (Andris-Windhopf et al., 2000; McElhiney 
et a l, 2000). This selection can be carried in a number of ways, using
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immunotubes, immunoplates and biosensors. It is also very simple and cost- 
effective to amplify these phage particles (Casey et al, 1995).
6.1.3. The Kreber Phage Display Library System
The method used in this library production is described by Krebber et a l  (1997). 
This method allows for the amplification of a vast number of murine antibody 
variable fragments, both heavy and light, once they are present in the initial 
mRNA sample. It involves the use of 23 primers for the light chain variable 
regions and another 23 for the heavy chains. This large number of primers is 
required so that the greatest number of variable fragments will be amplified and 
hence amplifying the sequences of interest.
The primers listed (section 2.4.10.3.1) cover all the primers sets from previous 
studies (Kettleborough et al, 1993; 0rum et a l, 1993 and Zhou et al, 1994) and 
they also cover the sequences contained in Kabat database (Kabat et al., 1991). 
Thus these primers are capable of amplifying all the expressed murine antibody 
sequences. This holds true regardless of whether or not the mouse has been 
exposed to antigen. These primers can be used to create a naive library, a pre­
immunised library or a library from the genes of a hybridoma cell line. A naive 
library is one which is non-specific and contains a large number of binders with 
different specificities. With this type of library it is hoped that antibody-binding 
fragments can be selected against numerous different antigens. A pre-immunised 
library primes the immune system of the animal involved with the antigen of 
interest to increase the number of B-cells producing antigen-specific antibodies. 
These cells are extracted and the mRNA isolated. In theory, this library will have 
a higher proportion of binding fragments directed against the antigen of interest. 
Once the heavy and light chains have been amplified this system then permits the 
combination of the two pieces in one reaction using splice by overlap extension 
PCR (Horton et a l, 1989). The Vh and the Vl fragments recombine through the 
sequence homology of the linker region that was built onto the 3' end of VL and 
the 5' end of the Vh sequences by the primers used in the amplification steps. The 
overlap is 15bp long and it codes for one repeat of the (Gly4 Ser)4  linker section. 
The sequence is repeated twice on the end of the Vh fragment and three times at 
the start of the Vl fragment. The linker region does not use the same codons to 
code for the glycine and serine residues in each of the repeats. By altering the
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codons in the repeats on either side of the zone of homology it is possible to 
prevent incorrect overlapping during the assembly PCR. The linker region in this 
construct is 20 amino acids long. This is longer than the frequently used 15aa 
linker, and it will reduce the tendency of the scFv fragments to aggregate.
The primers used in this step also introduce a FLAG tag onto the N-terminus of 
the Vl chain. FLAG is a 4 amino acid peptide sequence that can be bound by
commercially available antibodies, allowing for one simple method of detection
and purification of the final antibody fragments. At the end of this step the 
sequences have combined to form 800bp Vhl fragments that contain many 
different specificities. These will eventually be expressed as functional scFv.
A single rare cutting restriction enzyme is used for the directional cloning of this 
fragment into the phagemid vector. The enzyme, Sfi 1, has a recognition site of 
4bp located on either side of a non-recognised sequence of 5 nucleotide bases. It 
is within these 5 unrecognised bases that the enzyme cuts.
T
5' GGCC NNNN N GGCC 3'
3' CCGG N NNNN CCGG 5’
▲
The enzyme is used to cut the Vhl fragment at either end using the sites that have 
been engineered into the sequence. The site at the start of the construct was 
introduced in the heavy forward primers and the site at the end was added within 
the SOE-PCR back primer. The non-recognised bases have been designed so that 
they are not homologous and this ensures that the fragment will not self-ligate. 
CCCGA at one end of the sequence will not ligate with CAGCC at the opposite 
end. The phagemid vector, pAKlOO, contains two Sfi I sites to allow for the 
ligation of the construct. The vector contains the complementary sequences to 
allow the directional ligation of the construct into the vector.
This is a simple system as opposed to some methods which use 2 or even 4 
enzymes to clone the gene fragments. These systems have a higher chance of 
cutting within the antibody sequences so providing incorrect sequences for 
cloning.
The design of the pAKlOO phagemid vector also includes a number of 
improvements from previous systems. This vector contains a truncated form of
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the gill surface protein to which the scFv is fused. The particular truncated form, 
(residues 250-406) eliminates a Gly/Ser linker stretch and an unpaired Cys 
residue that are included in the protein used in some systems. This increases the 
stability and the folding yield of the fusion protein.
A terminator sequence is included between the lacl gene and the lac promoter 
region and this, along with the glucose repression of the lac promoter, removes 
the background expression of the scFv-glll fusion protein before induction. Even 
a small amount of this background expression can confer immunity from super­
infection with helper phage to the cell, which is vital for the production of the 
phage particles carrying the altered surface protein.
One other great advantage with the Krebber system is the series of compatible 
vectors that are available. Each vector has different characteristics, which allows 
for great flexibility and ultimate usefulness for the selected scFv gene (Krebber 
e ta l, 1997).
• pAKlOO is used to display, select and possibly express the scFv protein
• pAK200 is used for producing greater amounts of protein displayed on the
surface of the phage, although it may have a selective disadvantage compared 
to the lower level expression in pAKlOO
• pAK300 adds a hexa-histidine tag to the scFv allowing for detection and 
IMAC purification
• pAK400 retains the his tag from pAK300 but also includes a promoter with a 
stronger Shine Dalgarno sequence to enhance the level of expression
• pAK500 contains helices to allow for the dimerisation of the scFv
• pAK600 fuses the scFv to an alkaline phosphatase enzyme allowing for
direct detection. It also produces dimers.
In this chapter the use of this system to construct libraries from the antibody 
repertoires of immunised mice is described. These libraries were then panned to 
select antibody fragments that bound to the drugs under study, namely EE, DES 
and TR.
A previously constructed library was also panned against the steroid hormones. 
This library was constructed from the spleens of naive mice. In theory, this 
library contained a wide variety of antibody specificities and can be used to 
select antibody fragments for a number of different compounds.
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The construction of this library is described by Vaughan et al. in 1996. The 
rationale behind the construction of this library was to produce a resource from 
which a great many scFv's can be isolated against a number of different 
compounds. The library is derived from 43 non-immunised human donors and 
has a reported size of 1.4 x 1010 scFv fragments. This is a very large library and it 
should contain sequences specific for many compounds.
The donors provided peripheral blood lymphocytes, tonsil B-cells and bone 
marrow B-cells and from these mRNA was isolated and reverse transcribed to 
cDNA. The heavy chains were amplified separately from each of the sources of 
cDNA and they were re-amplified with tagged primers containing the restriction 
sites, Sfi 1 and Xho 1. The segments were then pooled, restricted and ligated into 
the pCANTAB 6  vector. The vector was transformed into E. coli TGI cells 
giving a Vh repertoire of 1 x 1 0 8 individual recombinants.
The Vl kappa and lambda sequences were amplified separately from the tonsil 
B-cell samples only. These were re-amplified and restriction sites, ApalA and 
Notl, were introduced. Two pools of light chains (VK and V\) were produced. 
Both pools were restricted and ligated into the phagemid vector, pCANTAB 
3his. They were electroporated into E. coli TGI cells and the resulting repertoires 
were calculated to be 1.1 x 105 VK and 1.7 x 106 Vx. To produce the library itself' 
the VK and Vx pools were combined and ligated to an upstream dummy Vh 
sequence and a gly/ser linker. This construct was electroporated into E. coli TGI 
cells and a repertoire of 2  x 1 0 7 V l recombinants with an upstream linker 
sequence was developed.
To construct the library both the Vh and the linker-VL fragments were amplified 
and assembled on the Jh region. The constructs were digested with Sfi I and Not 1 
and inserted into pCANTAB 6  giving a final repertoire of 1.4 x 1010 individual 
recombinants (Vaughan et al., 1996).
This study will attempt to select scFv clones that recognise each of the 3 steroid 
drugs, EE, DES and TR.
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6.1.4 Human Naive Library
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Once a library has been produced, regardless of its method of construction, the 
next step is to isolate a functional binder from it. This usually takes the form of 
selection as opposed to screening, which would be the usual method in 
hybridoma technology. If, for example, the Vaughan library of 1.4 x 1010 clones 
was to be screened it would take a vast amount of time and expense. If, on the 
other hand, the specific binders could be selected and enriched within the library, 
screening would become a much easier task (Wind et ah, 1997).
Panning can be defined as the selection of fusion proteins that bind to a specific 
ligand (Choudary et ah, 1995). There are a number of methods of panning using 
various forms of immunotechnology. Immunoplates, petri dishes, polystyrene 
and magnetic beads and immunotubes can all be used as solid matrices to recover 
selectively bound phage. Selection can be driven by competitive elution, 
differential panning or adjusting the conditions to allow panning with antigens 
that are otherwise unstable under physiological conditions (Krebs et al„ 2001).
In this study immunotubes were employed as the method of choice in the 
panning procedure for the selection of specific binders. This method requires the 
linking or absorbing of a ligand to the plastic surface of an immunotube by 
incubating a solution of the ligand or hapten-conjugate in the tube. The proteins 
are passively absorbed to the surface of the tube. The haptens are usually too 
small to be absorbed so use is made of a protein conjugate. Once the protein is 
absorbed the remaining areas on the plastic must be filled or blocked with a non­
specific protein. The reasons for this are similar to the reasons for the same step 
in ELISA procedures (section 3.1.4).
There is a significant problem with the use of blocking proteins and carrier 
proteins during panning steps. Once they are present in the selection process any 
antibody fragments specific for them will bind in the immunotube along with 
those specific for the target (Lu and Sloan, 1999). If a non-specific method of 
elution is used then all binders will be eluted and amplified. To minimise the 
amount of interference this may cause to the actual selection of specific binders, 
some simple steps may be undertaken. To prevent the binding of recombinant 
antibodies to the blocking protein it may be included in the diluent used. In this 
way the antibodies will tend to bind to the saturating concentration of the protein
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in solution and not to the surface of the tube. The solution-bound fragments will 
be removed by simply washing the tube. This may also help for the carrier 
proteins.
It is also possible to select for particular epitopes on a target antigen (Parsons et 
al., 1996). By pre-incubating a phage repertoire with a cross-reacting protein or 
hapten the clones that recognise these common epitopes can be eliminated. In 
this way antibody fragments can be isolated that only recognise epitopes specific 
for the target and are not present on similar molecules.
Another suggested approach for the elimination of the carrier-specific binders is 
the use of different carrier molecules or even different selection methods in 
alternate rounds of panning (Lu and Sloan, 1999). This may limit the carryover 
of contaminating protein-specific binders from round to round. Phage that are 
specific for the carrier used in the first round will have no target in the second 
round if the carrier protein has been changed and will, therefore, be removed 
from the selection process. A non-protein carrier, such as dextran, may also be 
used. This is a repeating sugar molecule and has resisted attempts to produce 
recombinant antibody specific for it (Xiao et al, 1995). Using this as the carrier 
far fewer carrier-specific binders may be amplified and carried through to the 
next panning stage.
The method of elution can be optimised to allow for greater specificity in the 
binders that are selected. One of the most common procedures for the elution of 
the bound particles is the use of low pH (Krcbber et a l, 1997). This disrupts the 
binding between the immobilised target and the antibody fragment, releasing the 
fragment into the solution where it can be retrieved. This is a highly non-specific 
method as it releases all the bound particles regardless of their target. Other 
methods include the use of competing antigen to release the binders from the 
tube, the use of a monoclonal antibody recognising the target epitope, passive 
elution using male bacteria or the use of dithiothreitol (Wind et al., 1997). Some 
of these methods are quite mild and some are specific but not all can be used 
with each constructed library. The choice of elution method must be made 
carefully and be compatible with the scFv system.
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The libraries are to be screened against three compounds with steroidal 
properties, EE, DES and TR. For more information on EE see section 4.1.1 and 
for TR, section 3.1.1. This section will deal with the synthetic estrogenic 
compound diethylstilbestrol, M.W. 268 (DES). DES has structural features at 
either end of the molecule that mimics the A-ring of estrogens, (Figure 6.1).
DES is a pharmaceutical estrogen with a molecular weight of 268.34 and it was 
administered to pregnant women in the 1950's and 1960's to prevent spontaneous 
abortion. It was later seen that children of the treated women suffered from 
reproductive organ dysfunction (Berg et al., 1999; Strohsnitter et a l, 2001). The 
use of DES in both medicine and as a growth promoter has been phased out due 
to its numerous side effects and its use in livestock was banned completely in the 
late 1970's (Sawaya et a l, 1998b). It is now used only as a drug in certain cases 
of prostatic and breast cancer and some postmenopausal vaginal disorders 
(Marselos and Tomatis, 1993). Pharmaceutical estrogens have also been 
associated with increases in breast and vaginal cancer, endometriosis, testicular 
and prostate cancers and lower sperm counts (Folmar et al., 2000). There is also 
evidence that the administration of DES to pregnant women can have detrimental 
health effects lasting into the third generation (Economou et al., 1990)
In a study of numerous natural and synthetic estrogens, phytoestogens and 
industrial chemicals, EE and DES were shown to be most potent and usually 
have a higher estrogenic activity than 17(3-estradiol (Gutendorf and Westendorf, 
2001). Other studies using different testing criteria have concluded that DES is 
less estrogenic than 17f}-estradiol but all studies have shown the ability of DES 
to act as a strong estrogen (Berg et al, 1999; Folmar et al, 2000).
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OH
Figure 6.1 : Structure of diethylstilbestrol, DES. This compound is a synthetic estrogen although it does not have a classical steroidal structure.
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6.1.7 Antibody Fragments Specific for Steroids
To test the utility of a naive human library described in Vaughan et al. (1996) 
antibodies against a number of compounds were isolated, including fluorescein, 
diethylenetriamine pentaacetic acid (DTPA), doxorubicin and estradiol. Using a 
single estradiol conjugate (estradiol -BSA) they were able to isolate a scFv with a 
Kd of 3.7nM after 2 rounds of panning (Vaughan et al., 1996).
Pope et al. (1996) isolated a scFv recognising estradiol from a human naive 
library. This had a high affinity (3.7nM) and was very specific for estradiol when 
compared to other steroids. The screening procedures used were designed to 
allow the selection of clones that bound favourably to free steroid. This antibody 
fragment was also able to detect differences in both ends of the estradiol 
molecule showing that it did not have the 'blind-spot' usually associated with 
monoclonal or polyclonal antibodies.
The availability of the genetic sequence of a scFv clone makes it possible to alter 
the specificity of the scFv to improve its affinity or even change its specificity. 
Chames and Baty (1998) have shown that it is possible to take a monoclonal 
antibody specific for cortisol and through antibody engineering and phage 
display create an antibody that binds estradiol. This exemplifies the usefulness 
and power of the recombinant antibody techniques.
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The conjugates used in this study for E and TR are described in chapters 3 and
4.
To produce conjugates of DES it was necesary to derivatise it to mono-carboxy 
propyl-DES, M.W. 354 (Figure 6.2), as described in section 2.4.1.2. The suces 
of the reaction was judged from analysis of the mas spectrums of the compound 
produced, (Apendix B). This derivative provided the chemical handle through 
which carier molecules could be linked. BSA, OVA THY, and DEX conjugates 
were al produced using either the mixed anhydride or NHS ester chemistry 
(section 2.4.2).
6.2 Results
6.2.1 Conjugates used in this study
Figure 6.2 : Structure of monocarboxypropyl-diethylstilbestrol, used to link carriers to diethylstilbestrol.
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6.2.2 Pre-immunised Library Production
6.2.2.1 mRNA extraction
Mice were imunised using the procedure described in section 2 A A3. The mice 
were sacrificed and the splen was removed asepticaly. The splen was 
homogenised and subjected to a procedure to extract the mRNA present. The 
resulting mRNA was investigated spectrophotometricaly at both 260 and 280 
nm. The ratio betwen these two readings should be greater than 1.65 to alow 
for a god quality preparation with litle protein contamination. Table 6.1 shows 
the results obtained for the preparations.
Table 6.1 : Purity and concentration estimations for splen extracted mouse mRNA.
ImunogenOD (â). 260nmOD (a). 280I1IU260nm 280nin Estimated Cone, (nig ml1)E 1.034 0,616 1.68 8.27DES 0.729 0.428 1.70 5.83TR 0.858 0.540 1.6 3.43
The values for the 260/280nm ratio are al above 1.65 giving them suficient 
purity to continue with the library production. The concentration values are 
estimated from a standard reading of 1 absorbance unit at 260nm equating to 40 
fxg ml'1. The absorbance values in Table 6.1 are for a 1/20 dilution of both E 
and DES and a 1/10 dilution of TR.
6.2.2.2 cDNA synthesis
The synthesis of cDNA from the extracted mRNA was caried out as described 
in section 2.4.10.2. 8 (ig of mRNA was used in each reaction. When synthesis 
ocurs sucesfuly thre bands are visible within the cDNA smear when it is run 
on an agarose gel. These thre bands corespond to the amplification of 
ribosomal RNA present in the RNA sample. These bands wil only be sen after 
mRNA has ben reverse transcribed into cDNA (Figure 6.3).
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Figure 6.3 : Synthesis o f cDNA from mRNA template. Lane 1 is a Ikbp marker; 
Lanes 2-5 are results o f the synthesis. The ribosome bands are clearly visible in 
the lanes.
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The procedure for amplifying the variable heavy and light chain fragments 
contained in the cDNA is laid out in section 2.4.10.3. This procedure uses many 
different primers to amplify the majority of the individual chains. This is a very 
complex multiplex PCR and each component of the PCR must be optimised. A 
number of different buffers were used to select the right conditions for the 
amplification of the variable fragments. In these buffers the MgCk concentration 
and the pH varied. By testing the reaction in a number of these buffers the 
optimal MgCb concentration and pH could be determined (Figure 6.4). A MgClz 
concentration of 2.5mM was used in subsequent heavy chain amplifications 
along with a buffer pH of 9.0.
The optimal amount of Taq enzyme and of each primer was also found by a 
simple concentration titration. The optimal amount of Taq was chosen to be 5 
units per reaction, though results did not change significantly between 2  to 6  
units. The primer concentration was titred to determine the optimum 
concentration for use in the reaction. Concentrations between O.lnmol to 
0.0125nmol of each primer per reaction were tested (Figure 6.5). The optimum 
primer concentration was found to be 0.025nmol per reaction.
The reactions were then run to prepare stocks of both the heavy (V h) and light 
chain (VL) variable fragments for each of the three drugs. These chains ran at 
approximately 400bp on an agarose gel and from this they were purified and 
their concentration was estimated.
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6.22.3 Heavy and Light Chain Amplification
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Lane 2: 1.5mM MgCl2, pH9.0
Lane 3 & 12: 2.5niM MgCl2, pH9.0 Lane 4: 3.5mM MgCl2, pH9.0 
Lane 5: 1.5mM M gC k pH9.5 Lane 6: 2.5mM MgCl2, pH9.5 
Lane 7: 3.5mM MgCl2. pH9.5 Lane 8: 1.5mM MgCl2, pHlO.O 
Lane 9: 2.5mM MgCl2, pH 10.0 Lane 10: 3.5mM MgCl2, pHlO.O 
Lane 11: 2.5mM MgCl2. pH8.5
Figure 6 .4: Effect o f different MgCh concentrations and pH  on amplification of 
heavy and light chain variable fragments. Lane 1: lOObp marker, Lane 2-10: 
heavy chain amplification with various buffers, Lane 11-12: Light chain 
amplification with 2 buffers.
1 2 3 4 5 6 7 8 9 10 11 12
123456789
Lane 1 & 6: 0. lnmol of each primer 
Lane 2 & 7: 0.05nmol of each primer 
Lane 3 & 8: 0.025nmol of each primer 
Lane 4 & 9: 0.0125nmol of each primer
Figure 6.5 : Effect o f different primers concentration on the multiplex PCR for 
the amplification o f variable heavy chains. Lanes 1-4: heavy chains primers with 
cDNA for EE library, Lane 5: lOObp marker, Lane 6-10: heavy chain primers 
with cDNA for DES library. Lanes 8 and 9 have faint bands at 400bp but they 
have not reproduced well. The optimal concentration was taken to be 0.025nmol 
per primer per reaction.
40bp
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6.2.2.4 Splice-by-Overlap Extension PCR
This technique allows the joining of the heavy and light chains together in one 
reaction. Each chain has an identical overlap that was introduced by the primers 
in the amplification stage. This allows the two chains to associate and so be 
amplified as one chain with a linker in the middle. The two 400bp fragments 
become an 800bp fragment after this step containing both the Vh and Vl chains. 
This reaction must be optimised as described previously for the multiplex PCR. 
The array of buffers was used to determine the optimum MgCk concentration 
and pH. A reaction without the bands at 650bp and 1 lOObp, as seen in figure 6 .6 , 
would be the optimum reaction, but an amount of these bands were seen with all 
buffers. The optimum was found to be 2.5mM MgCl2, pH 9.0. This was used to 
run all the SOE-PCR as it gave the least amount of contaminating bands.
6.2.2.5 Sfi/ Digestion
Sites for the rare cutting enzyme, Sfi 1, have been engineered at either end of the 
800bp fragment. This allows the insert 800bp and the phagemid vector to be cut 
only using this enzyme. This restriction enzyme recognises 4bp either side of a 
random sequence of 5bp. This fact ensures that neither the insert nor the vector 
will self-ligate giving only intact phagemid containing the insert following 
ligation. The difference in size between the restricted and unrestricted insert is 
very slight with only a few base pairs being removed from the sequence. Figure
6.7 show both unrestricted and restricted inserts while Figure 6 . 8  shows the 
restriction of the pAKlOO phagemid.
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1 2 3 4 5 6 7
80bp
l ip
Figure 6.6: SOE-PCR on heavy and light chains for EE, DES and TR libraries. Lane 1: lOObp marker, Lane 2-3: EE, Lane 4-5: DES, Lane 6-7: TR
1 2 3 4 5 6 7 8
80bp
Figure 6.7 : Sfi7 digestion of Vhl fragments. Lane 1: lOObp marker, Lane 2: unrestricted purified Vhl fragment, Lane 3-4: restricted EE Vhl fragment, Lane 5-6: restricted DES Vhl fragment. Lane 7-8: restricted TR Vhl fragment.
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linearised vector (~6.5kb) 
doubly restricted vector (~4kb)
restricted Tet gene (~2kb)
Figure 6.8 : Restriction of pAKlOO phagemid using Sfi7 restriction enzyme. 
Lane 1: lOObp marker, Lane 2: Unrestricted pAKlOO, Lane 3-4: Restricted 
pAKlOO.
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The ligation is described in section 2.4.10.9. The formula below was used to 
calculate the amount of DNA to add to each reaction. The concentrations were 
estimated using a quantifiable marker on an agarose gel.
6.2.2.6 Ligation o f insert into phagemid vector
Using the ratio of 1 . 5  vectors for each insert increased the chances of each V h l  
construct being incorporated into a vector. The 5  |il of the ligation mixture was 
visualised on an agarose gel to ensure that ligation had occurred before 
proceeding to the transformation step.
6.2.2.7 Transformation of Supercompetant XLl-Blue E. coli cels with ligated vector
The cells were transformed as per the manufacturers instructions and the 
resulting colonies were titred. The cells were either screened immediately or they 
were panned and then screened by phage ELISA depending on the size of the 
library. The sizes of the libraries constructed using this method are listed in Table
6.2. A number of different libraries were constructed. Not all of them were large 
enough to pan and some did not produce sufficient colonies to screen (Table 6.3). 
Figure 6.9 shows the results from a screening ELISA. The positives are fairly 
weak but they were all tested to see if they had specificity for the drug in 
question.
Testing was carried out on all positive clones from the non-competitive ELISA. 
All results showed that the results seen in the non-competitive ELISA were non­
specific and the clones did not contain the genes for a scFv coding for the 
required drug specificity.
amount of insert (ng) = amount of vector (ng) xsize of insert (kb) 
size of vcetor (kb)
x required ratio of insert
vector
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Table 6.2 : Number of colony forming units (cfu) in each of the constructed libraries produced using the Kreber method.
Library Size Library 1 Library 2 Library 3 Library 4E 2 x 104 cfu 1.4 x 10Jcfu 0 cfu 4 x 103 cfuDES 6.6 x 103 cfu 3 x 10* cfu 2 x 103cfu 7 x 103 cfuTR 5 x 103 cfu 3 x 102 cfu 6 x 102 cfu 4 x 102 cfu
Table 6.3 : Paning and screning conjugates for each of the sets of constructed libraries
Library Round P u n n i i i f ira mg Screning1 __ Conjugate ConjugateLibrary 1 1 THY BSA2 BSA BSA3 DEX BSA4 OVA BSALibrary 2 1 BSA No binders elutedLibrary 3 No pan BSALibrary 4 1 DEX BSA2 THY BSA3 DEX BSA4 DEX BSA
Figure 6.9 : Absorbance values obtained after screening 95 clones in a non­
competitive ELISA after pan 3 against EE with library 4. Four clones were tested 
further for EE specificity, HI, F3, G 7 and C8. The negative control was HI 2. 
None of the clones tested showed competition in further analysis.
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This library was created from the spleens of naive mice that had not been 
exposed to any immunisation. In theory they will have the entire antibody 
repertoire present for amplification. In creating this library the diversity is the 
most important issue. It must be as diverse as possible as it will be used to isolate 
scFv's for many different antigens. In this study a naive library, Manning 1, was 
panned against two of the drugs under investigation, EE and DES (Table 6.4). 
Phage from rounds 2 and 3 were grown up in 96 well format for a phage ELISA. 
Round 2 was screened against BSA conjugates and did not produce any clones 
that gave a significant reaction in the phage ELISA. Round 3 was screened 
against DEX conjugates and some weak positives were detected. Figure 6.10 
shows the results from the phage ELISA for the third round screening of the EE 
library.
These positives were grown up using different scale-up procedures and each was 
tested against conjugates, carrier proteins and blocking solutions. Figure 6.11 
shows the results using one of the clones from the DES library. The only 
significant response was seen against THY. Clones chosen from the EE library 
gave comparable results. No clone from either the DES or EE libraries showed 
specificity for or competition with the required drug.
6.2.3 Naive Krebber Library
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Table 6.4 : Results from the paning of a naive library, Maningl, against E and DES.
Paning Round Piage E Selection DES SelectionRound 1 Input 1 x IO10 1 x 10lüConi.: OVA Output 8.48 x 10* 1.06 x IO3Round 2 Input 1 x 10lü 1 x 10lüConj.: DEX Output 3.4 x 104 1.04 x IO4Round 3 Input 1.23 x 101 1.41 x IO1Conj.: THY Output 1.29 x IO4 4.92 x IO2
n
8
8n
<
Figure 6.10: Absorbance values obtained from the screening o f 95 clones after 
the third pan against EE. Three o f the clones were chosen for further testing, F2, 
D12, E9. Clone D6 was grown and used as a negative control in further 
experiments. H12 was a blank well that was not inoculated with a clone from the 
library.
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DEX BSA THY
Plate coating
Figure 6.11 : Specificity o f anti-DES clone A6, as both a phage bound and 
soluble scFv, against a number o f conjugates and hapten carriers. The clones did  
not recognise any o f the conjugates or proteins apart from THY. The clone did 
not show any response to the DES steroid
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The Vaughan library is a naive human library with a repertoire of 1.4 x 1010 
scFv's displayed on the surface of phage (Vaughan et al., 1996). This library was 
panned against EE, DES and TR (Figure 6.5).
The selected phage from rounds 3 and 4 were grown up in 96-well format for 
screening by phage ELISA. Both rounds showed positives in these ELISAs and it 
was decided to continue work with the positives from round 4, Figure 6 .12.
6.2.4 Selection of scFv from the Vaughan naive library
Table 6.5 : Results from the panning of a naive library, Vaughan, against EE, 
DES and TR.
PanningRound Phage E SelectionDES SelectionTR Selection
Round 1 Input 2 . 1  x 1 0 u 2.1 x lO 11 2.1 x lO 11
Conj.: BSA Output 1.7 x 10b 4.9 x 106 2 . 2  x 1 0 b
Round 2 Input 2 . 6  x 1 0 y 4.0 x 10y 5.5 xlO 9
Conj.: DEX Output 2.4 x 10" 8.4 x 103 9.0 x 102
Round 3 Input 2.4 x 1010 2 . 1  x 1 0 lu 2 . 8  x 1 0 1U
Conj.: OVA Output 1.3 x 1 0 6 3.7 x 103 2.9 x 107
Round 4 Input 1 . 8  x 1 0 10 3.4 x 1010 3.4 x lO 10
Conj.: BSA Output 4.2 x 107 2.5 x 106 7.3 x 106
Clones were grown up as phage particles, soluble scFv and as periplasmic 
extracts. They were tested for their ability to recognise bound conjugate and for 
their ability to recognise competing drug. None of the clones tested showed any 
significant amount of recognition of the steroid over carriers or blocking solution 
(Figure 6.13).
In many cases the response seen in the ELISA analysis was due to the 
recognition of the blocking proteins by the phage or the soluble scFv's.
One clone was grown and scFv was expressed into the periplasm. This was 
purified using IMAC and analysed by SDS-PAGE, (Figure 6.14). The resulting 
fraction had a molecular weight of approximately 31kDa, the expected weight of 
a scFv protein. It did not, however, recognise the drug on which it was selected.
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Figure 6.12 : Results from phage ELISA after the 4th round of panning of the 
Vaughan library. H12 contains a negative control on each plate. Varying 
amounts of reaction are seen to the coated antigen and a number of these clones 
were tested further.
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Dilution o f Phage supernatant (1/x)
Figure 6.13 : Response of phage particles from clone, A4, from the 4th round 
screening o f the Vaughan library against TR conjugates and their carriers. There 
is no significant difference seen in response between the conjugates, the carriers 
and the blocked plastic. The other clones tested showed similar results.
Figure 6.14 : SDS-PAGE of scFv purification by IMAC. Lane 1 & 7: Molecular 
weight marker, Lane 2: Growth media supernatant after cells were removed, 
Lane 3: Periplasmic lysate, Lane 4: Non-binding fraction on IMAC column, 
Lane 5: IMAC-purified scFv fraction. Lane 6 contains some overflow from the 
marker in lane 7.
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The pre-immunised libraries that were produced were quite small with only one 
library containing more than 10,000 clones. This is a very small library system 
when libraries containing 1010 clones are possible. The reason for continuing 
work with these small libraries was the fact that they were constructed from 
mRNA extracted from a pre-immunised mouse. This mouse had been immunised 
with a drug conjugate previously and had been sacrificed following the 
appearance of a suitable antibody response from its serum. Once it was clear that 
the mouse was producing antibodies for this steroid it is assumed that the number 
of antibody producing cells with specificity for this drug would be increased. The 
spleen was removed and the mRNA, representing the template for protein 
production, was isolated. This had to be done quickly so as to avoid degradation 
of the mRNA by the naturally present RNAses. Using a smaller library derived 
from this template is feasible as much of the antibody mRNA present codes for 
binding sites specific for the immunogen, in this case the steroids, EE, DES and 
TR.
Using this mRNA as a template, cDNA was produced and used as the starting 
material for the library construction. The extensive lists of primers that are used 
in this system were developed by Krebber et al. in 1997. They use a set of 
primers that cover all mouse Vh, Vx and VK sequences found in the Kabat 
database and other previously described primer sets. Using this extensive set of 
primers it is proposed that the widest range of sequences possible will be 
amplified.
Each amplification is performed a number of times and the resulting chains are 
purified and combined. By amplifying the chains on a number of occasions the 
greatest diversity of sequences can be achieved. This also occurs for the SOE- 
PCR. This stage can be enhanced by repeated the PCR more than once and 
combining the results so increasing the amount of different V hl constructs 
created.
The restriction in this particular library construction is quite ingenious as it only 
requires a single enzyme and yet still allows for directional cloning. The Sfi 1 
restriction enzyme is a cutting enzyme that recognises a sequence of 4 nucleotide
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6.3 Discussion
6.3.1 Pre-immunised Libraries
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bases on either side of a random, non-recognised 5bp sequence. The insert itself 
can be ligated in the correct orientation by engineering this random sequence to 
be different on either side of the insertion point of the vector.
A commercially available preparation of supercompetent XLl-Blue E. coli cells 
was used to maximise the number of transformants. These cells enhanced the 
chances of all ligated phagemid vectors being incorporated into a host cell. It is 
possible to estimate the size (no. of phagemid clones) of the constructed library 
by calculating the number of cells containing the phagemid after transformation. 
The constructed libraries were then tested to determine if they contained any 
clones that recognised the haptens of interest. The clones from libraries 1 and 4 
were subjected to bio-panning before they were screened. In theory this step 
would enrich the clonal population to one that contained mainly Vhl sequences 
that would bind to the specific targets. Repeating this step a number of times and 
altering the selection conjugates should isolate specific antibody fragments. The 
scFv proteins displayed on the surface of phage were panned against a number of 
hormone conjugates including THY, BSA, DEX and OVA. One of the 
advantages of using DEX is that it has proven very difficult to raise scFv's 
against it. This makes it an ideal choice as a conjugate carrier as few, if any 
scFv's specific for it will be selected. This is borne out in the low amount of 
phage that are eluted after a DEX panning in contrast to the amounts seen with 
protein carriers as shown in Table 6.5.
Usually a phage ELISA was carried out on clones after the third or fourth rounds 
of panning. The second and third libraries were tested directly on phage ELISA 
due to their small size. A positive result was taken as any absorbance value that 
is significantly higher, 150%, than the background or negative control on the 
plate. The phage ELISAs were mostly carried out using a steroid-BSA conjugate- 
coated plate to which the phage supernatant was added. The bound phage was 
detected by an anti-fd bacteriophage polyclonal antibody followed by a HRP 
conjugated anti-rabbit IgG. This does not test for total specificity to the steroid 
but it is a useful guide as to which clones may bind to the target molecule.
Clones that showed a response on the phage ELISA were subjected to further 
testing, for example competitive ELISAs and soluble expression of the scFv. 
Competitive ELISAs using the phage particles or soluble scFv proteins were 
carried out. The clones tested were shown not to be competitive, that is specific
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for the steroid molecules. The clones were grown in small culture volumes, 5-15 
ml, and induced to produce phage or soluble scFv. These particles were tested in 
ELISA for their ability to bind to both an immobilised conjugate and to free 
steroid. In all cases this competition was not seen. This indicates that the 
response seen on the ELISA was due to non-specific binding of either the phage 
particles or one of the detection antibodies and not due to a specific recognition 
of the target molecule.
In addition, the clones did not produce absorbance readings much greater than 
the background absorbance of the plate in the original screening ELISA. Clones 
were considered to be positive if they had an absorbance of over 0 . 1 2  when the 
negative control was 0.08. It could be argued that these results were not due to 
specific interactions. It was decided to investigate the clones further to determine 
if the low signals seen were due to low phage concentrations or lack of 
specificity.
In our laboratory the Krebber method has been used successfully to produce scFv 
libraries containing specific clones for aflatoxins and morphine (Daly, 2002; 
Dillon, 2002). The size of the constructed libraries was reported to be 5xl03 
clones and 5xl03, respectively. Both libraries have produced scFv and they have 
been expressed using a number of the pAK vectors. One of these vectors fuses 
the scFv fragment to an alkaline phosphatase enzyme. This has been used in 
ELISAs to produce assays that can be run quickly and without the need for any 
further enzyme labelling (Brennan, 2002).
Both the aflatoxin and morphine molecules are small and as such required 
conjugation before immunisation. They have also been shown to be very 
immunogenic in this form and useful polyclonal antibodies have been raised 
against these conjugates. This can also be said for the target molecules used here 
with specific and sensitive polyclonal antibodies having been produced using 
conjugates of TR (Chapter 3), EE (Chapter 4) and DES (Chapter 5). The lack of 
success in raising recombinant antibodies could be due to the loss of diversity in 
the initial stages of the library construction. If at this stage all the primers were 
not acting optimally, this could result in the loss of some diversity in the 
constructed library. One method of maximising the diversity may be to limit the 
number of primers used in each amplification reaction and then pool the results.
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By limiting the number of primers each primer set may have a better chance of 
amplifying a sequence and so creating a larger genetic repertoire.
6.3.2 Naive Murine Library (Manningl)
A naive library was constructed previously using the same technique as that 
described for the production of a pre-immunised library. This was done using 
spleenomic mRNA from mice that had not been exposed to any antigens and 
therefore had the largest undifferentiated B-cell population. With this large 
population it should be possible to isolate all the possible variable sequences and 
amplify them to produce a large, broad scFv library. The advantages to this 
approach are outlined in section 1.2.4.
The Manningl library was panned against two of the steroids under study, EE 
and DES. This library failed to provide scFv fragments specific for either drug. 
Both libraries showed weak positives on phage ELISA (Figure 6.10) but none of 
these showed competition or specificity for the steroids in further testing. Figure 
6.11 shows the responses seen when one of the anti-DES clones was grown both 
as phage particles and as soluble phage. The clone does show a response but it is 
to THY, a carrier protein.
One of the rationales of panning with a number of different conjugates is to 
eliminate the number of clones that are specific to carrier proteins being selected. 
In this study an OVA pan was followed by a DEX pan and finally a THY pan. 
With this protocol the phage that may have bound to the OVA in the first round 
will have no target in the immunotube during the second round panning. In this 
way they should not be selected and only those phage that react with the 
elements common to both the first and the second round of panning, i.e. the 
steroid, should be amplified.
The results from these libraries show that the phage selected in rounds 1 and 2 
contained many non-specific clones. The clones giving positive results on the 
phage ELISA after round 3 were shown to be specific for THY, the carrier used 
in the third pan. It was expected that some of the positive clones from the phage 
ELISA would have directed towards the steroid. The fact that only THY-specific 
clones were isolated implies that no specific clones were being selected 
throughout the panning procedure.
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If  it is the panning procedure itself that w as inadequate a number o f  strategies 
can be applied to increase the likelihood o f  success. A n  alternative panning 
strategy or different elution methods could be utilised to increase the 
effectiveness o f  the panning procedure.
This library has been used previously to screen for scFv's against aflatoxins, 
morphine, chlorpyrifos, and Listeria monocytogenes. N one o f  these studies were 
successful in producing specific clones. This evidence, coupled w ith the inability 
to select scF v capable o f  binding either o f  the two steroids tested, leads to the 
conclusion that this library does not contain enough diversity to be used to 
develop numerous binding specificities.
6.3 .3  N aive H um an Library
The Vaughan library is a naive human scF v library with a reported diversity o f
1.4 x  1010 clones (Vaughan et al., 1996). This library w as panned against three 
different steroid hormones, EE, D E S and T R  with a sequence o f  B S A , D EX , 
O V A  and B S A  conjugates. This approach w as designed to elim inate non-specific 
protein binders from  being selected and passed from round to round.
One hapten for each o f  the steroids w as used to produce all the conjugates 
required for his w ork, TR-17-hem isuccinate, E E -6 -carboxym ethyloxim e and 
DES-m onocarboxypropyl. This meant that throughout the panning process the 
phage w ere exposed to the same linker region along w ith the steroid structure 
itself. During the selection process phage specific for these linker or bridge 
regions could be am plified. T o avoid the use o f  these clones careful examination 
o f  positive clones is required. A  clone recognising the linker region w ould bind 
to a conjugate specifically  but would not show competition for the free steroid. 
This pattern o f  binding w as not shown with any positive clone tested from  any o f  
the library methods.
The number o f  phage that were eluted follow ing the D E X  panning step was quite 
low  in relation to the amounts eluted when proteins were used. Dextran is a long 
repeating sugar and it has proved difficult to raise scF v against it, as mentioned 
previously. W ith the use o f  dextran conjugates it is usual to assume that a greater 
proportion o f  eluted phage are directed against the drugs in question.
A fter the third and the fourth round o f  panning phage E L IS A s w ere carried out 
on 95 clones eluted from the immunotubes. The results from  the fourth round are
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shown in Figure 6.12. The negative control on these plates w as contained in H 12 
and as can be seen the majority o f  the clones w ere positive, to different extents, 
against the drug in question. This result seemed promising as the number o f  
clones seemed to suggest that the selection strategy had worked and there w ere a 
number o f  different clones recognising one o f  the components im m obilised on 
the surface o f  the plate.
1 2  positive and 1 negative clones in total from each library w ere tested for 
specificity. The clones w ere grown as phage particles, soluble scF v released into 
the supernatant and soluble scF v retained in the periplasm. Each o f  these 
preparations w as tested for their ability to recognise the steroid, both in the 
im m obilised and free forms. Figure 6 .13  shows the response o f  one such clone to 
a number o f  conjugates and proteins. The clone seems to recognise each o f  the 
presented coatings just as much as any o f  the others including uncoated wells. 
This im plies that the clones are recognising the only proteins that are common to 
all the w ells, w hich  is the milk blocking solution.
It is difficult to reconcile this conclusion with the procedures used. The phage 
used in the panning procedure were pre-blocked in a solution containing large 
amounts o f  the blocking agent (2%  (w/v) marvel m ilk powder). In this w a y  it 
w as hoped that any m ilk-binding phage would be kept in solution and not bind to 
the blocked immunotubes during the panning. This does not seem to have 
w orked in this instance. Another factor that supports this conclusion w as the 
reduction in signals obtained when m ilk w as used in the diluent for the phage or 
scFv. A  further E L IS A  was carried out eliminating the use o f  m ilk m arvel as the 
blocking solution. The plates were blocked with 1%  (v/v) foetal ca lf  serum but 
this did not rem ove the absorbance signal (data not shown). Responses were seen 
with FC S-coated wells. This im plies that the clones isolated are polyreactive and 
are not recognising any one epitope in particular.
T o ensure that a scFv w as actually being expressed, S D S -P A G E  analysis was 
carried out on the purified fraction from  one o f  the periplasmic expressed clones. 
Figure 6 .14  shows the resulting fraction using the IM A C  purification method. A  
single strong band is seen at approxim ately 31kD a, the estimated size for a scFv. 
A  protein o f  approxim ately 3 1k D a  w ith an affinity for a metal chelating column 
w as produced in the periplasm o f  the cells. It is not specific for the steroids and it 
m ay suggest that an alternative panning strategy would be worth investigating.
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T o use the same biopanning procedure with a different blocking protein m ay not 
cause any change in the reactivity o f  the binders produced. A  new method for 
preventing the non-specific binding o f  the phage particles to the uncoatcd sites o f  
the plastic immunotubes may be required. An alternative method o f  eluting the 
sp ecifically  bound phage may also prove useful. A  strategy that uses a form o f 
specific elution, possibly with com peting steroids, m ay provide a more efficient 
w a y  o f  selecting the correct phage (W ind et al., 1997).
This library w as subjected to panning, in our laboratory, against xilpaterol, a fj- 
agonist used as a bovine growth promoter (Dillon, 2002). The results from this 
study w ere similar to those found here. The clones giving positive results in the 
phage E L IS A  w ere tested further and they proved to bind non-specifically  to all 
proteins they w ere tested against. This included proteins that had not been a part 
o f  the panning process. From this evidence it seems that this particular method o f  
clone isolation m ay not be the optimal process. The library has been used to 
isolate a scF v specific for estradiol (Vaughan et al., 1996) showing that scF v for 
steroids are present in this library. A n  alternative panning and selection strategy 
m ay provide a greater return o f  specific scF v from this library.
A  scF v sp ecific for halofugine has been isolated from this library (D uffy, 2002). 
It has shown to be com petitive and specific. The library w as also panned against 
a number o f  other compounds but non-specific poly-reactive clones w ere again 
isolated. This implies that the library has a high proportion o f  these poly-reactive 
clones and they are preferentially isolated with the selection process used.
6.3 .4  Sum m ary
Three different approaches to the selection o f  steroid-specific scF v proteins have 
been attempted. A  number o f  pre-immunised libraries have been constructed and 
panned for the presence o f  specific steroid binders. This strategy did not produce 
any antibody fragments that were able to bind to the target m olecules. A  naive 
m ouse scF v library w as panned. This strategy provided phage and soluble scFv 
that recognised T H Y , the protein carrier used at the third round o f  panning, 
above other proteins and m olecules tested. N one o f  the clones tested showed any 
specificity  tow ards the hormone o f  interest. Lastly, a naive human antibody 
fragm ent library w as selected against the three drugs. This library also failed to
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produce clones sp ecific for the drugs under study. The clones that showed 
positively on the phage E L ISA  proved to be non-specific in further testing.
Il seems that these strategies, as applied in this study, are not able to select for the 
specificity that is required. An approach that may be useful in altering the 
outcomc o f  this study could be the application o f  alternative selection or panning 
strategies.
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Steroid drugs can be used to enhance the growth characteristics o f  animals 
destined for the food chain. The drugs increase the feed-to-m uscle ratio o f  the 
animal resulting in greater amounts o f  leaner meat produced per animal. The use 
o f  these drugs is illegal within the European Union and, as such, testing systems 
must be in place to ensure that animal products tainted with steroid residues are 
not permitted to enter the food chain.
The use o f  im m unochem ical methods o f  analysis is one approach to the 
screening o f  animals for the presence o f  these compounds. The testing systems 
must be very sensitive and be able to detect as little as 2  ng ml' 1 o f  these drugs in 
a sample. U sing specific antibodies as reagents confers the advantages o f  a 
specific recognition system  and a strong non-covalent binding onto any 
analytical system.
One steroid analogue used extensively as a growth promoter before the European 
w ide ban, w hich is still legal in both the U S and Canada, is trenbolone acetate. 
This compound is readily metabolised into 17P-O H  trenbolone, the active form 
o f this drug. The use o f  this steroid must be monitored, not only in meat 
produced in Europe, but also in meal imported from  elsewhere.
A  hapten o f  T R  w as constructed by converting the hydroxyl group at the 17 
position to a hemisuccinate. This introduced a chem ical group (C O O H ) that 
could be easily linked to carriers for both immunisations and analytical methods. 
T w o anti-TR -17-H S antibodies w ere raised in rabbits, purified and characterised. 
These antibodies w ere applied to two com petitive E L IS A  formats (designated 
'com petitive' for direct com petitive assays and 'inhibitive' for indirect inhibitive 
assays). The assays show ed excellent sensitivity and precision for the detection 
o f  free T R  in both buffer and bile. The com petitive assays show ed the greatest 
sensitivity and w ere the more robust o f  the two E L IS A  formats. The best 
com petitive assay used T R A b l and it w as able to detect less than 2 ng ml' o f  
free T R  in a bile sample. This is the recommended cu t-off or action limit for the 
residue level o f  this compound. The precision and accuracy levels o f  this assay 
w ere w ell within the limits for an ELISA -based assay.
These E L IS A s have a number o f  advantages over previously described assays by 
com bining low  levels o f  cross-reactivity to related compounds, minimal sample
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pre-treatment, the use o f  enzym atic labels and taking hours instead o f  days to 
perform. W ith these attributes these assays could be useful in large scale 
screening program mes to avoid the incorporation o f  tainted meat into the food 
chain.
T w o polyclonal antibodies were raised in rabbits against the constructed 
conjugate E E -6-C M O -O V A . The antibodies were purified and their ability to 
recognise free EE  w as established. These antibodies were applied to both 
com petitive and inhibitive E L IS A  formats and a biosensor assay. The precision 
and accuracy o f  the assays was investigated and each assay was w ell within the 
tolerances for an assay o f  this type. The assays w ere then adapted to detect free 
E E  in bile samples. The precision and accuracy o f  the assays w as again 
determined and w hile being slightly less precise and accurate than the 
corresponding assays for the detection o f  free E E  in buffer, they are still with 
acceptable limits (± 2 0 % ).
The com petitive E L IS A  using E E A b l w as capable o f  detecting 12 ng ml' 1 o f  free 
E E  in bovine bile. The assays to detect E E  have sim ilar advantages over previous 
analytical system s as the T R  assays. T hey com bine a specific recognition system  
with a simple pre-treatment step, easy to detect enzym e labels, a high throughput 
system  and a short assay time. The B IA core assays are not as sensitive as the 
corresponding E L IS A s but m ay find a use in on-line rapid screening o f  single 
samples.
The sensitivity o f  both assays systems must be im proved to low er their detection 
limit so that they w ould be able to detect the low  residual amounts o f  EE 
required by the 2 ng ml"1 action limit that would lead to the rem oval o f  meat from 
the food chain.
W ith the E L IS A  assays described, although being quick and simple to perform, 
there is a presumption that they w ould be carried out in a laboratory 
environment. A  test system like this m ay benefit from the ability to be portable 
and even more rapid. T o  this end the reduction o f  the incubation times o f  the 
com petitive E L IS A s w ere investigated. It w as shown that the T R A b l antibody 
could produce a result in less than 20min. The D E S antibodies w ere also tested 
and, whereas, they w ere not as sensitive as the T R  antibodies they could also 
detect nanogram levels o f  free D ES in buffer.
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These antibodies w ere then applied to a rapid E L IS A  machine. This machine 
uses the same reagents as for a com petitive E L IS A  but it carries out the steps 
required for the assay without the intervention o f  an operator. The device 
autom atically aliqouts the sample, m ixes it with the enzym e-conjugate solution, 
incubates the w ells, w ashes them and, finally, detects the bound enzym e. Assays 
using both the D E S A b l and T R A b l antibodies w ere adapted for use with this 
machine. An assay system  that detected the presence o f  either o f  the two steroids, 
T R  and D E S, in a single sample was also developed. This system could 
distinguish and measure low  nanogram amounts o f  T R  in a single or mixed 
sample but due to the slow er kinetics o f  the D E S antibody it was not able to 
detect nanogram amounts o f  D E S. I f  more w ells had been available for this 
device this w ork could have been extended and com pleted to give a simple, user 
friendly and portable assay system  for the detection o f  a number o f  steroid 
hormones in a single sample.
W hile polyclonal antibodies have been shown to be specific reagents and useful 
in the developm ent o f  assays system s, they do have drawbacks. Polyclonal 
antibodies by their very nature have numerous specificities contained within their 
solutions and these m ay cause large problems in assays due to cross-reactivity 
with related or even unrelated compounds. There is also a finite supply o f  this 
reagent. Once a particular antibody has been consum ed the assay based on it 
must be re-optimised for any other polyclonal antibody that m ay be substituted. 
T o alleviate this problem the developm ent o f recom binant antibodies with 
specificities for 3 steroid hormones w as attempted. This w ould result in an 
infinite antibody source that was monoclonal in nature. Three approaches were 
tried for the construction and isolation o f  scF v antibody fragments. A  naive 
murine library and a naive human library were panned against the three drugs in 
question, EE, D E S and TR. ScF v specific for the hormones were not isolated 
from these libraries. It is proposed that the murine library m ay have been too 
limited to contain the scF v required. This library had been panned on previous 
occasions against other sm all haptens and proteins and no specific antibody 
fragments have been isolated from it.
The naive human library w as a large library system with greater than 1010 
individual clones and one o f  the compounds used to test the utility o f  the library 
was a steroid hormone. It w as hoped that this library w ould contain the required
2.67
Chap«« 7: Cottchtsions
scF v clones. The hbrary w as panned against the three steroid drugs and the 
clones isolated were all non-specific. T hey each recognised a number o f  different 
proteins, some used in the panning procedure and some that w ere not. None o f  
the clones tested showed any sp ecificity  for the drugs being studied.
The third approach consisted o f  pre-immunising a m ouse w ith the hapten o f 
interest so that the number o f  B -cells producing specific antibodies w ould be 
maximised. Libraries were then constructed from the m R N A  isolated from the 
spleen o f  the immunised mice. These libraries should have contained a greater 
number o f  clones sp ecific for the original immunogen. The libraries w ere all 
panned and tested for their ability to recognise both conjugate and free drug, but 
no specific clones w ere isolated.
This research has successfully  generated a number o f  different working 
immunoassays for the detection o f  three steroid hormones, used as illegal growth 
promoters in meat.
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A p p e n d i x  A
G lossary o f  term s and defin itions com m only em ployed  in  b ioanalytical 
validation  procedures
The terms listed below  were referred to for validation purposes o f  certain 
procedures carried out in this thesis. The criteria w hich they can be defined under 
have been review ed elsewhere (Findlay et al., 2000).
M ean
y > i  xDescribes the average o f  replicate (x) measurements, (i.e. — ---- — )
x
Precision
Is defined as the closeness o f agreement, or variance between independent test 
results o f  multiple measurements o f  the same sample obtained under a set o f 
specified analytical test conditions. It is norm ally expressed in terms o f  the 
relative standard deviation (% R .S.D .), or the coefficient o f  variation (% C .V .) o f 
the determined concentration o f  a replicate number o f  assays. The degree o f 
precision assessed between replicates (i.e. %  C .V .) performed during a single 
assay batch, is com m only referred to as the intra-assay variation (also referred to 
as repeatability). The term inter-assay variation is (also referred to as 
reproducibility) is used to describe the precision betw een assays when related to 
multiple batches.
L im it o f  D etection  (L .O .D )
Defines the low est analyte concentration that the analytical technique can 
differentiate from  background signals and is usually determined as background 
noise ± 3 standard deviations.
R obustness
Is a term used to describe the ability o f  an analytical techique to withstand 
fluctuations in the described analytical test conditions. For immunoassay
1
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procedures the term could be used to describe changes in the ionic strength o f  the 
sample matrix, as w ell as pH and temperature changes.
Standard C urve
This describes the relationship between the measured analyte response (i.e. 
absorbance, response units) and the analyte concentration.
N on-Specific  B ind ing
This describes matrix effects w hich affect the degree o f  binding o f  the 
antibody:antigen interaction, and can occur as a result o f  increased protein 
concentration and sam ple viscosity  in the sample matrix (e.g. grain matrix), and 
also as a result o f  altered ionic com position (e.g. bile) o f  the sam ple matrix.
C oefficient o f  V ariation
A  quantitive measure o f  the precision o f  an analytical measurement expressed as 
a percent function o f  the mean value, also referred to as the Relative Standard 
D eviation (%  R .S.D .)
% C V = ^ ^ - x lO O
M e a n
P recision  Profile
A  quantitive measure o f  the variation between measurements, usually the 
coefficient o f  variation versus the nominal concentration o f  analyte in the 
sample.
N orm alised  A b sorban ce V alues
The absorbance recorded (A U ) at each particular antigen concentration divided
by the absorbance recorded in the presence o f  zero antigen.
, Absorbance measured at particular antigen concentration
Normalised Absorbance = --------------------------------- ----------------- ----------------------
Absorbance measured at zero antigen concentration
2
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Appendix B 
Mass spectrometry analysis of steroid derivatives
Figure 1: Nominal Mass Spectroscopy analysis o f  Trenbolone (MW 270).
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Figure 2: Nominal Mass Spectroscopy analysis o f  Trenbolone-17-hemisuccinate 
(alkalinated, M W 368)
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Figure 3: Nominal Mass Spectroscopy analysis o f  Diethylstilbestrol (M W 268)
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Figure 4: Nominal Mass Spectroscopy analysis o f  Mono-carboxypropyl 
Diethylstilbestrol (M W 354)
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